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Abstract 
The organism is a complex system composed with different organs and various types 
of cells. It has become more and more evident that diseases, although originally 
raised from restrict region, normally lead to a global impact affecting multiple parts of 
the body. This indicates that the organisms should be regarded as an interconnected 
system, both physiological and pathological alterations should be studied in an 
unbiased way. Recent tissue clearing methods start to play an important role in 
systems biology studies since it enables the screening of the transparent tissue with 
its entirety. However, because of the light scattering as well as autofluorescence for 
deep tissue imaging and the limited sample size that can be imaged by a light-sheet 
microscope, it remains challenging to scan and analyze large samples such as an 
entire rodent body. 
 
Here, we developed uDISCO and vDISCO whole-body tissue clearing methods which 
enables the complete scanning of adult rodent bodies with standard light-sheet 
microscopy. As an organic solvent based tissue clearing method, uDISCO 
overcomes the fast quenching of fluorescent proteins and preserves the GFP signal 
over months. Combining with a high pressure transcardial circulating system to 
deliver the nanobody, vDISCO achieved whole-body immunolabeling and imaging 
through the intact transparent bone and skin. Applying uDISCO to biological studies, 
we evaluated the bio-distribution of bone marrow-derived stem cells with intravenous 
transplantation. By using vDISCO, we studied the global inflammation after acute 
central nervous system injury and revealed the short connections between skull bone 
marrow and brain meninges as novel additional immune cells infiltration route. 
Combining with a deep learning based algorithm, vDISCO enables the automated 
mapping of cancer metastasis and therapeutic drug distribution through the entire 
mouse bodies with cellular level resolution.  
 
Taken together, uDISCO and vDISCO whole-body tissue clearing methods provide a 
powerful platform for unbiased screening and systemic analysis of entire rodent 
bodies. As practical and efficient techniques, they can be readily used for various 
biological and biomedical researches. 
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1. Introduction 
The great success of Human Genome Project (HGP) from 1990s has led life science 
research to a productive ‘genomic era’ to present days (Poliakov et al., 2015). As 
declared by former President of the Sanger Center, John Sulston, “Think of the 
human genome as the Book of Life. We are about to read the first chapter, as 
important an accomplishment as discovering the Earth goes round the sun or that we 
are descended from apes” (Cooper, 2001; Perbal, 2015). 
 
Regarding the “Book of life”, deciphering individual molecule’s structure/function and 
resolving the related cellular signaling pathways is like reading each page of the 
book, which is extremely important, yet insufficient to provide the key information how 
an organ or organism is assembled and functioning as a complex biological system. 
To answer this question, in early twenty-first century, the concept of ‘systems biology’ 
was raised aiming to understand how the individual components and different tissue 
are structurally connected and dynamically interacted at whole organ or even whole 
organism level (Kitano, 2002). Although the discoveries in research field of molecular 
biology and cellular biology were blooming in last two decades, the “organism-level 
systems biology” is restricted due to the lack of technical approaches despite its 
importance in life science and biomedical research. Therefore, an advanced 
methodology which enables the fast screening of an entire organism (e.g. an intact 
mouse or rat body) at cellular level resolution will provide a powerful platform for  
systems biology studies and will facilitate various biomedical research fields (Susaki 
and Ueda, 2016). 
 
Nowadays, the widely used whole rodent body imaging techniques include 
bioluminescence imaging (Vick et al., 2015; von Neubeck et al., 2018), PET and MRI 
(Dall'Ara et al., 2016; Schoder and Gonen, 2007). Although scientists can get 
preliminary metabolism or structure information by using these techniques, the 
millimeter-level resolution can only provide bulk signals which is impossible to resolve 
single cells from the whole-body scale. On the other hand, combining tissue 
sectioning, histological staining and microscopy achieved micrometer-level resolution 
and became a standard protocol for life science research. However, to section, stain 
and image the whole-body of an adult mouse will take weeks to months. Although 
whole-body sectioning method has been used to study T cell distribution by analyzing 
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representative sections (Odoardi et al., 2012; Reinhardt et al., 2001), it is nearly 
impossible to achieve the whole-body reconstruction for volumetric analysis. 
Furthermore, tissue sectioning is not suitable to neuroscience research as it could 
only provide partial or fragmented information of neuronal projections covering 
millimeter to centimeter distance (Erturk and Bradke, 2013). Therefore, to 
systemically study the bio-distribution of specific cell subtypes or drugs and to 
investigate the neuronal network in health or disease requires a novel methodology 
which enables the mapping of intact organism at cellular level resolution with its 
entirety.  
 
As discussed above, ideally the biological samples should be imaged without 
sectioning. However, because of the different refractive indices (RI) between the lipid 
based cellular membranes and water-based interstitial fluid or cytoplasm, imaging 
light is obstructed by light absorption, scattering and aberrations (Tuchin, 2015; Zhu 
et al., 2013). As a result, the imaging depth of a standard confocal microscopy is 
limited to 150 μm and 2-photon microscopy to 500–800 μm underneath the tissue 
surface (Clendenon et al., 2011; Theer and Denk, 2006), which is far from 
overcoming the intact whole organs, not to mention the entire mouse bodies. 
 
The development of various tissue clearing methods in recent years provides a 
potential technical pathway to overcome these bottlenecks and holds the promise to 
image the organism without sectioning. Tissue clearing aims to match the refractive 
index within the biological samples and thereby achieves the homogeneity of the 
refractive index (Richardson and Lichtman, 2015). As a result, the samples become 
optically transparent and the imaging light can illuminate through the biological 
samples without severe scattering or aberration. Another technical approach is the 
development of light-sheet fluorescent microscopy (LSFM). Differently from the 
traditional confocal or 2-photon microscope, light-sheet microscope generates a thin 
laser to illuminate the specimen at the focal plane and the emission signal from the 
entire panel will be collected by a vertically integrated objective (Dodt et al., 2007). 
Combining with various transgenic or immune-fluorescent labeling strategies, tissue 
clearing enables the fast optical sectioning of the intact biological samples with their 
entirety.  
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Although several tissue clearing methods before our approaches (uDISCO and 
vDISCO) achieved some degree of whole-body clearing, which are PARS and 
CUBIC, they mainly cleared the whole body of a mouse and dissect the organs of 
interest for imaging due to the lack of transparency. In my PhD study, I developed 
uDISCO and vDISCO methods with colleagues which achieved the whole-body 
tissue clearing and complete imaging at cellular level resolution (Cai et al., 2019; Pan 
et al., 2016). These two advanced whole-body clearing and imaging methodologies, 
as the best tools for systems biology studies, will significantly contribute to the a 
variety of life science and biomedical research fields. 
 
In the introduction section, I will firstly present the overview of tissue clearing field 
and will focus on the development of u/vDISCO technologies by comparing existing 
whole-body tissue clearing methods. Secondly, I will present the applications of 
u/vDISCO methods in diverse biological studies such as stem cell transplantation, 
global neuroinflammation after CNS injury, cancer metastasis and therapeutic drug 
bio-distribution, which led to novel biological discoveries in the related fields. 
 
1.1 Optical Tissue clearing 
As previously mentioned that imaging light scatters because of the mismatching of RI 
within biological samples. Biological tissue normally contains 70–80% water with low 
RI (n = 1.33), ׽10% lipids with high RI (n > 1.45) and ׽10% proteins with high RI (n > 
1.44) (Richardson and Lichtman, 2015). Since the proteins are the major functional 
carriers of cellular events and attract most of the research interests, tissue clearing 
mainly aims to preserve the protein content and match the RI of protein by using 
high-RI medium. Depends on different technical approaches to achieve high RI 
matching, the tissue clearing field can be classified into three categories, 1) water-
reagent based clearing, 2) hydrogel based clearing, and 3) organic solvent based 
clearing.  
  
1.1.1 Water-reagent based clearing 
Since sugar based chemicals are highly soluble and are able to increase the RI of 
water, high concentration sugar solutions are considered as promising high-RI 
matching medium. SeeDB protocol uses gradient fructose solutions up to 115 wt% to 
reach the RI around 1.49. It successfully preserved the morphology of samples both 
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in macro and in micro scale (Ke et al., 2013). However, Since the clearing process 
depends on the passive diffusion of high concentration viscous sugar solution, it can 
only clear highly permeabilized tissue such as mouse embryo, neonatal mouse brain 
(P3) or 1.5 mm thin sections of adult mouse brain. 
 
In addition, urea is also widely used in tissue clearing as it has the strong 
hyperhydration abilities and can improve the molecular influx (Tainaka et al., 2016). 
FRUIT combined fructose and urea solutions, which was less viscous and achieved 
better clearing efficiency than SeeDB. Since no harsh delipidation reagent was used, 
both SeeDB and FRUIT  preserve the cellular membrane and therefore are 
compatible with DiI labeling (Hou et al., 2015). However, FRUIT is still insufficient to 
clear and image the intact adult mouse organs. 
 
Alcohol based chemicals which have a high RI are also considered as candidates in 
tissue clearing field. Scale A2 and ScaleS clearing protocols utilized sorbital and urea 
as the major components. Combining with detergents such as triton-X 100 and 
chemicals which can loosen the texture of the tissue (methyl-β-cyclodextrin and N-
acetyl-L-hydroxyproline), ScaleS further improved the clearing efficiency (Hama et al., 
2015; Hama et al., 2011). In addition, it preserves the ultrastructure of the biological 
samples, allowing high resolution 2-photon microscopy or even electron microscopy 
of the cleared samples. Although it achieved proper transparency for an entire brain 
from a Thy1-YFPH line transgenic mouse, it took 15 months to clear the whole brain 
which does not match the normal experimental timeline schedule for most of the 
laboratories. 
 
The first practical whole-organ scale water-reagent based clearing is CUBIC (clear, 
unobstructed brain imaging cocktails and computational analysis). By using CUBIC 
reagent1 containing 25% urea, 25% N,N,N’,N’-tetrakis(2-hydroxypropyl) 
ethylenediamine and 15% Triton X-100 and followed by CUBIC-2 which is a mixture 
of 50 wt% sucrose, 25 wt% urea, 10 wt% 2,20,20’-nitrilotriethanol  and 0.1% (v/v) 
Triton X-100, the whole mouse brain can be cleared within two weeks. The 
involvement of N,N,N’,N’-tetrakis(2-hydroxypropyl) ethylenediamine successfully 
decolorizes the heme rich tissue by removing the heme chromophore from 
hemoglobin. As a result, CUBIC achieved sufficient organ transparency for 
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fluorescent light-sheet microscopy and is compatible with various fluorescent proteins 
and immunolabeling (Susaki et al., 2014). Furthermore, CUBIC also achieved whole-
body clearing with adult mice (Tainaka et al., 2014). The authors used this method to 
image the cancer metastases in whole mouse bodies from different cancer cell lines 
expressing fluorescent proteins and to quantify the cancer metastasis in specific 
organs such as lungs and brains (Kubota et al., 2017). However, the quantifications 
of metastasis were mainly conducted on individual organs after dissection which 
limited the advantageous usage of whole-body tissue clearing. On the other hand, 
the entire clearing process for a dissected organ takes more than ten days which is 
much longer than the organic solvent-based tissue clearing methods. 
 
1.1.2 Hydrogel based clearing 
Hydrogel based clearing aims to generate an extra acrylamide gel within the 
biological tissue to lock the endogenous proteins in situ. Then the following steps of 
delipidation by ionic detergent and the high-RI matching by sugar or alcohol based 
solutions will be conducted to achieve tissue transparency while the proteins of 
interest will be preserved in the hydrogel crosslink.  
 
The Deisseroth’s group developed CLARITY (clear lipid-exchanged acrylamide-
hybridized rigid imaging/immunostaining/in situ hybridization-compatible tissue-
hydrogel) which combined electrophoretic delipidation (Chung and Deisseroth, 2013; 
Chung et al., 2013). This method can clear a whole mouse brain within 10 days and 
achieved high permeability of the tissue which is valuable for whole mount 
immunohistochemistry analysis. However, the major risk is the integrity of the 
samples since the harsh treatment and the heat created by electroporation may 
damage the tissue (Tomer et al., 2014). To overcome this obstacle, PAssive 
CLARITY technique (PACT) was developed (Yang et al., 2014). It holds the same 
hydrogel embedding concept with CLARITY but the delipidation is conducted by 
passive shaking with 8-10% SDS solutions.  
 
Combining with additional treatments or different clearing techniques, other tissue 
clearing techniques were developed based on hydrogel embedding concept. For 
instance, complemented with decalcification by EDTA solutions, bone CLARITY was 
developed for investigating the bone structure and bone marrow cellular content with 
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their integrity (Greenbaum et al., 2017). Combining with CUBIC, ACT-PRESTO can 
clear various biological tissues from zebrafish to rodents (Lee et al., 2016). It is worth 
noting that by active transcardial perfusion of the delipidation solution, PARS 
(perfusion-assisted agent release in situ) also achieved whole-body clearing of adult 
mice (Treweek et al., 2015; Yang et al., 2014). Although PARS has been used to 
evaluate the bio-distribution of virus through the entire mouse body (Deverman et al., 
2016), the whole clearing process took more than 3 weeks and the organs were 
dissected for imaging. This brings the major drawbacks of Hydrogel based clearing, 1) 
it normally causes tissue swelling which makes the enlarged samples difficult to fit in 
the imaging system; 2) the hydrogel is quite fragile and not easy to handle.   
 
1.1.3 Organic solvent based clearing 
The history of organic solvent based tissue clearing methods can be traced back to 
early 1900s. Spatleholz used a mixture of organic solvents which reaches the RI of 
1.55 to clear large biological samples for anatomical studies (Richardson and 
Lichtman, 2015). At the beginning of 21st century, organic solvent based clearing was 
barely used for biological studies because the harsh treatment of dehydration quickly 
quenched the fluorescent proteins which are widely used for labelling. In 2007, Dodt’s 
group built the first modern light-sheet microscope for imaging cleared samples (Dodt 
et al., 2007). By using gradient ethanol as dehydration solutions and a mixture of 
benzyl alcohol/benzyl benzoate as RI matching solution, brain samples from adult 
Thy1-GFPM line mouse were cleared and the green fluorescent protein (GFP) 
sparsely labelled neurons were imaged. However, the GFP signal can only stay for a 
few hours which limits the general application in neuroscience studies.  
 
After screening the organic solvent library, GFP-friendly solvents such as 
tetrahydrofuran (THF) were selected as dehydration solution and dibenzyl ether (DBE) 
was chosen as RI matching solution (Becker et al., 2012; Erturk et al., 2011). This 
termed 3DISCO (3D imaging of solvent-cleared organs), a practical method for whole 
organ clearing which could render the whole mouse brain transparent within 2 days 
and preserves the GFP labelled neuronal structures (Erturk et al., 2012). In terms of 
time consuming, 3DISCO stands as the most efficient clearing methods comparing to 
water-reagent or hydrogel based clearing methods which usually take more than a 
week to clear dissected mouse organs. Nevertheless, the quenching of fluorescent 
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proteins is still the biggest challenge since the half life of GFP is only one to two days 
after clearing (Erturk et al., 2012). This not only means that the samples need to be 
imaged immediately after clearing but also implies that the fine structures such as 
dendritic spines are already not visible after 3DISCO clearing. To overcome this 
hurdle, Schwarz et al. suggested that 1-propanol and tert -butanol dehydration 
significantly improved the signal preservation comparing with 3DISCO, as the 
remaining fluorescence proteins comparing with the signal before clearing was 24.2% 
and 79.2% respectively (Schwarz et al., 2015).  
 
By using tert -butanol as a mild dehydration solution and by adding diphenyl ether 
(DPE) which has high RI (1.579) and is inert to further reactions, we developed 
uDISCO (ultimate DISCO) (Pan et al., 2016). As a robust tissue clearing method, 
uDISCO is able to clear whole bodies of adult mice within 3-4 days. Benefiting from 
the signal preservation, we resolved the dendritic spines from cortical neurons with 
Thy1-GFPM line mice. Among the organic solvent based clearing methods, uDISCO 
achieved such level of fluorescent protein preservation and subcellular resolution for 
the first time. For details please see Research Article 1. 
 
 
Table 1. Comparison of different tissue clearing methods 
The “time to clear” was measured by samples from 2 mm thick brain sections to whole brain. 
“—,” indicates that the clearing method itself would not improve the antibody penetration. 
However, the related protocols might still be compatible with immunostaining prior to the 
clearing process (Wan et al., 2018). 
 
           
Method
Clearing 
capability
Time to clear Size change
Fluorescence 
signal
Imaging 
depth
Chemical 
permeability
uDISCO Excellent One day-days Strong shrinkage Preserved Very deep —
3DISCO Excellent Hours-days Strong shrinkage Major loss Very deep —
SeeDB Medium Days Slight expansion Modest loss Shallow —
Scal eS Medium Days Slight expansion Preserved Deep 2 mm/4 daysc
Scal eSQ Weak Hours Strong expansion Modest loss Deep —
CUBIC Good Days-weeks Slight shrinkage Modest loss Very deep 3.2 mm/6 daysd
ClearT2 Weak Hours Slight shrinkage Modest loss Shallow —
PACT Excellent Days Strong expansion Modest loss Very deep 3 mm/7 days
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On the other hand, the widely used immunohistochemistry methods provided a 
promising strategy to further improve the imaging quality by applying bright dye 
conjugated antibodies. These synthetic dyes are normally stable in organic solvent 
which dispel the concerns of fluorescence quenching. In order to achieve complete 
whole mount staining, the permeability of biological samples needs to be increased to 
improve the penetration of antibodies. To reach this goal, Renier et al. combined 
graded methanol, dichlormethane (DCM) and H2O2 for dehydration/rehydration. After 
immunostaining, the tissue was then cleared by 3DISCO (Renier et al., 2014). The 
termed iDISCO/iDISCO+ protocols provide a powerful tool to map the 
physiology/pathology changes of mouse brains and have been used in various 
biomedical studies (Liebmann et al., 2016; Renier et al., 2016). Alternatively, by using 
a mixture of saponin and PBSGT as permeabilization solution, Chedotal’s group 
achieved the homogenous immunolabeling of the human embryos to study the 
development of the nervous system in health and disease (Belle et al., 2017).  
 
Apart from the conventional antibody, the heavy chain variant antibody, named as 
nanobody, emerged to be a promising candidate to achieve deep tissue 
immunolabeling. It is 10 times smaller in size (15 KD) comparing to conventional 
antibody (150 KD) and therefore holds much higher penetration rate (Muyldermans, 
2013). To further increase the permeability of the tissue, we used a mixture of 
methyl-β-cyclodextrin, trans-1-acetyl-4-hydroxy-l-proline and Triton. Combining 
decolorization and decalcification with bright Atto dye conjugated nanobodies anti 
GFP or RFP, we developed vDISCO whole-body immunolabeling method which 
achieved the homogenous labelling of adult rodent for the first time (Cai et al., 2019). 
With nanobodies conjugated with Atto dyes (Atto N647 or 594) excited at far red 
spectrum, the imaging quality of vDISCO increased more than 100 times comparing 
with imaging the original GFP signal from green/blue spectrum in which the tissue 
emits severe autofluorecence. This allows the cellular level light-sheet microscopy 
through intact skin and bone tissue. Applying vDISCO to various lines of transgenic 
mice, we resolved the first whole-body neuronal connectivity map and discovered 
novel functional anatomic structure in the intact skull. For details please see 
Research Article 2. 
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1.2 Applications of u/vDISCO in diverse biological research fields 
As a novel technical revolution, whole-body tissue clearing and cellular level imaging 
bridged the gap for fast and high resolution unbiased screening of the intact 
organisms. Applying u/vDISCO to various transgenic rodent lines or disease models, 
we evaluated the bio-distribution of stem cells after systemic transplantation, 
revealed novel anatomical structures involved in neuroinflammation and developed a 
deep learning based mapping tool to study the whole-body cancer metastasis and 
drug distribution at cellular level. In this section, I will summarize the current status of 
the related research fields. 
 
1.2.1 Bio-distribution of bone marrow–derived mesenchymal stem cells  
Bone marrow–derived mesenchymal stem cells (BMSCs) transplantation has long 
been used as an effective cell therapy strategy to cure a variety of diseases (D'Souza 
et al., 2015; Parekkadan and Milwid, 2010). Firstly, BMSCs were transplanted after 
bone marrow ablation to restore the hematopoiesis of cancer patients (Koc et al., 
2000). Later on, as a promising restorative therapy, BMSCs transplantation was 
explored as aid to structural and functional recovery of brain after stroke by 
enhancing neurogenesis and angiogenesis (Zhang and Chopp, 2009). Furthermore, 
other chronic or acute neurodegenerative diseases such as amyotrophic lateral 
sclerosis (ALS) (Vercelli et al., 2008), Parkinson’s disease (PD) (McCoy et al., 2008), 
Huntington’s disease (HD) (Lin et al., 2011) and spinal cord injury (SCI) (Gu et al., 
2010; Yang et al., 2008) also benefit from BMSCs therapy.  
 
As BMSCs transplantation is usually applied intravenously, visualizing and analyzing 
the systemic distribution of BMSCs in whole-body becomes extremely important. 
Various labeling and imaging techniques are available to study the distribution of 
BMSCs. For instance, traditional ﬂuorescent immunohistochemistry was used to 
study the BMSCs homing in specific organs (Kawada et al., 2004).  Radioactive 
labeling was applied to evaluate BMSCs whole-body distribution but with limited 
resolution to detect single stem cells (Barbash et al., 2003). Using these methods, 
researchers found that the transplanted BMSCs were majorly detected in lungs 
shortly after transplantation. A potential mechanism is that lung capillary is too narrow 
for BMSCs and obstructive effects will occur during the lung passage (Leibacher and 
Henschler, 2016). However, a more time and sensitivity efficient methodology is 
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required for BMSCs study which enables the cellular detection of sparsely located 
BMSCs and it will contribute to explore the novel and unexpected homing tissue of 
BMSCs by unbiased whole-body screening. 
 
Applying uDISCO to the mice intravenously (IV) or intraperitoneally (IP) injected with 
BMSCs labeled by quantum dots, we found that the majority of BMSCs were 
accumulated in lungs and livers, which is in line with the previous findings. In addition, 
we also detected BMSCs in bone marrow and intestine 3 hours after injection. 
Comparing with IP injection, IV injection provides significantly higher BMSCs delivery 
efficiency (Pan et al., 2016). Overall, as a valid methodology which enables the 
unbiased screening of whole mouse bodies with cellular level resolution, uDISCO 
setup a powerful platform for BMSCs related studies. For details please see 
Research Article 1. 
 
1.2.2 Immune cell infiltration upon acute damage in central nervous system 
(CNS) 
Acute CNS injuries including stroke and brain trauma have become one of the 
leading cause of death and disability through the whole world (Langlois et al., 2006; 
Mendis, 2013). Despite the initial neuron death and tissue damage, the subsequent 
inflammatory response involving local microglia activation and peripheral immune 
cells infiltration plays an important role in neuronal survival, dead cell debris 
clearance and tissue regeneration (Gadani et al., 2015; Kyritsis et al., 2014). 
 
As a sophisticated system, the neuronal network is monitored constantly by immune 
system to react with pathogens and to maintain the microenvironment for neuronal 
function (Russo and McGavern, 2015). Due to the selectively permeable blood-brain 
barrier (BBB), peripheral immune cells are inhibited from passing into the health brain 
freely (Habgood et al., 2007; Muldoon et al., 2013). However, a variety of immune 
cells are located in the brain meninges and conducting the immune surveillance of 
the nervous system (Derecki et al., 2010). Furthermore, Kipnis’ group recently 
described lymphatic vessels in the sagittal sinuses which are connected to the 
cervical lymph nodes functioning as a standard drainage system of the brain, 
indicating that the CNS is closely connected with global immune system (Da 
Mesquita et al., 2018; Louveau et al., 2018; Louveau et al., 2015).  
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When the CNS injuries occur, the mechanical impact as well as the microglia 
activation responding to alarmin release increases the permeability of BBB and lead 
to infiltration of peripheral immune cells (Finsen and Owens, 2011). Hours after injury, 
neutrophils arrive and start to produce anti-microbial products to fight pathogens 
(Amulic et al., 2012; Trivedi et al., 2006). However, it has been proved that these 
effects are harmful to neuronal cells. Prohibiting the neutrophils infiltration improved 
the neuronal survival and functional recovery post injury (Gorio et al., 2007; Semple 
et al., 2010). In the following hours to days, monocytes, macrophages and 
lymphocytes are recruited and generally considered as a contributor to the scar 
formation and angiogenesis which promotes the recovery of CNS (Brancato and 
Albina, 2011; Koh and DiPietro, 2011).  
 
Apart from the disrupted BBB, the alternative infiltration route of circulating immune 
cells were recently reviewed (Benakis et al., 2018). Louveau et al. discovered that 
ablation of lymphatic vessels in the meninges suppressed the activation of T cells 
upon multiple sclerosis, suggesting that meningeal lymphatic vessels is potentially a 
recruiting gateway for immune cell infiltration (Louveau et al., 2018). Llovera et al. 
found that peripheral T leukocytes accumulated in the choroid plexus (ChP) and 
invaded the peri-infarct cortex after stroke (Llovera et al., 2017). More intriguing, both 
Nahrendorf’s group (Herisson et al., 2018) and we discovered the short vascular 
connections (SMCs) between skull bone marrow and brain meninges (Cai et al., 
2019) which indicates the interaction of bone marrow and CNS. Furthermore, we 
found that cell number of Lysm+ neutrophils in these connections increased upon 
stroke, suggesting that SMCs could be a novel alternative infiltration route in addition 
to meningeal lymphatic vessels and ChP . For details please see Research Article 2. 
 
1.2.3 Breast cancer metastasis and antibody-based therapeutic approaches 
In 2018, about 8.2 million cancer cases among women were newly diagnosed, from 
which one fourth of these cases were breast cancer. As the most frequently 
diagnosed cancer in women, breast cancer led to ~630 thousand cancer deaths last 
year (Bray et al., 2018). In general, about 90% of cancer-associated deaths was 
caused by metastatic disease distally from the primary tumors (Lambert et al., 2017). 
Therefore, breast cancer is more and more treated as a systemic disease (Redig and 
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McAllister, 2013) and understanding the mechanisms of metastasis as well as the 
therapeutic approaches blocking the metastasize pathology has great value for 
breast cancer therapy.  
 
Breast cancer metastasis involves with several steps. Firstly, the cancer cells from 
the primary tumor conduct epithelial-mesenchymal transition (EMT) and obtain 
mesenchymal morphology which is more suitable to migrate and metastasize in 
distant organs (Scully et al., 2012). This proceed can be characterized as reduction 
of cell-to-cell adhesion mediated by down-regulation of E-cadherin, cytokeratin and 
up-regulation of N-cadherin, fibronectin and Vimentin (Wu et al., 2016). Then, the 
cancer cells with mesenchymal morphology will be released into blood or lymphatic 
vessels (Hunter et al., 2008) and circulated to remote tissue. Although the majority of 
these circulating tumor cells (CTCs) will be cleared by immune system, the survival 
cancer cells might invade into the organ parenchyma and form metastasis (Lambert 
et al., 2017). It is also worth noting the CTCs are regarded as a bio-marker for clinical 
diagnose since they are rarely found in healthy women (van de Stolpe et al., 2011). 
 
Therapeutic approaches for breast cancer can be categorized into two groups, 
standard chemotherapy and targeted therapy (Scully et al., 2012). In standard 
chemotherapy, cytotoxic chemicals are widely used and are notorious for developing 
drug resistance and severe side effect (Alvarez, 2010). In the targeted therapy, 
estrogen receptor (ER) has long been considered as a primary target to suppress 
breast tumor growth by using hormone therapy and ER inhibitors (e.g. tamoxifen) 
(Nicolini et al., 2006). The emerging immunotherapy involving monoclonal antibodies 
targeting specific cell surface receptors or enzymes holds great therapeutic potential 
to improve the survival rates and to reduce the systemic side effect for cancer 
patients (Nathan and Schmid, 2018). For instance, trastuzumab is an monoclonal 
antibody targeting the extracellular domain of human epidermal growth factor 
receptor 2 (HER-2). Binding to HER-2,  trastuzumab is able to block the proliferation 
of the tumor (Baselga et al., 1998). Furthermore, Gondi et al. developed a 
monoclonal antibody (6A10) blocking the function of carbonic anhydrases (CAs) XII 
which is producing bicarbonate to maintain pH homeostasis and providing a survival 
advantage for breast cancer metastasis (Gondi et al., 2013). Intravenous 
 14 
 
administration of 6A10 significantly improved the survival rate of the experimental 
mice and decreased the signal of primary tumor in bioluminescence imaging.  
 
Nevertheless, due to the limited resolution of bioluminescence imaging, Gondi et al. 
could not extract the information of distant metastasis. Later on, by collaborating with 
the same group, we combined 6A10 antibody based immunotherapy with doxorubicin 
(DOX) involved chemotherapy and applied uDISCO tissue clearing to evaluate the 
therapeutic effect on lung metastasis. With the cellular level resolution and volumetric 
quantification provided by tissue clearing and light-sheet microscopy, we found that 
the combined therapy approach nearly eliminated the metastasis in lungs comparing 
to untreated control or to mice only received DOX (von Neubeck et al., 2018). This 
result demonstrates that 6A10 antibody makes the breast cancer cells more sensitive 
to chemotherapy and less prone to metastasis. However, the global metastasis and 
bio-distribution of therapeutic antibody 6A10 through the entire mouse bodies 
remains unsolved. Applying vDISCO to cancer mice received 6A10 antibody therapy 
and by developing a deep learning based algorithm (DeepMACT) which provides 
automatic identification and quantification of metastasis, we systemically studied the 
whole-body metastasis and immunotherapeutic antibody targeting efficiency with 
cellular level resolution for the first time (Pan et al., 2019). The result shows that lung 
tissue is the primary target for breast cancer metastasis and overall 77% of 
metastasis are targeted by the 6A10 antibody. For details please see Research 
Article 3. 
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2. Research Articles 
2.1 Research Article 1: Shrinkage-mediated imaging of entire organs and 
organisms using uDISCO 
 
Tissue clearing techniques are widely used in neuroscience research field as they 
can provide the intact connectivity information of neuronal network. However, light 
scattering particularly in hydrogel based and water reagent based clearing methods 
pose obstacles for deep tissue imaging. In addition, the size or volume of biological 
samples treated with these two groups of methods usually increases after clearing 
which further hinders the standard light-sheet microscopy with limited working 
distance of objectives. On the other hand, while organic solvent based tissue clearing 
methods have high clearing efficiency and shrink the tissue, they are notorious to 
rapid reduction of fluorescent  protein signals which are widely used for cellular 
labeling.  
 
We developed ‘ultimate DISCO’ (uDISCO) clearing to bridge the gap of signal 
preservation and volumetric reduction in large sample imaging. uDISCO preserves 
fluorescent proteins over months and renders intact mouse organs transparent while 
decreasing their size up to 65%. Using uDISCO, we cleared and imaged a whole 
mouse body from Thy1-GFPM transgenic mouse line and studied the neuronal 
projections in the intact CNS over 7 cm. Furthermore, uDISCO enables the whole-
body clearing of adult rats, which is 4-5 times larger than mouse bodies in volume. 
We imaged the vasculature of the rat CNS over 13 cm with high resolution light-sheet 
microscopy. We also used uDISCO to study the bio-distribution of BMSCs after 
systemic application and found that the majority of BMSCs were accumulated in 
lungs and livers, while sparse BMSCs were detected in kidney, bone marrow and 
intestines. Overall, uDISCO provides a powerful platform to study the alterations 
under health and disease conditions of large organ systems throughout the entire 
organisms. 
 
Author contribution: developed the uDISCO protocol with Ruiyao Cai; collected and 
cleared whole-body samples from Thy1-GFPM line, rat, BMSCs transplantation and 
AAV virus tracing; wrote the manuscript with colleagues (please see section 7 for 
further details). 
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recent tissue-clearing approaches have become important 
alternatives to standard histology approaches. however, light 
scattering in thick tissues and the size restrictions on samples 
that can be imaged with standard light-sheet microscopy 
pose limitations for analyzing large samples such as an entire 
rodent body. We developed ‘ultimate disco’ (udisco) clearing 
to overcome these limitations in volumetric imaging. udisco 
preserves fluorescent proteins over months and renders intact 
organs and rodent bodies transparent while reducing their size 
up to 65%. We used udisco to image neuronal connections and 
vasculature from head to toe over 7 cm and to perform unbiased 
screening of transplanted stem cells within the entire body of 
adult mice. udisco is compatible with diverse labeling methods 
and archival human tissue, and it can readily be used in various 
biomedical applications to study organization of large organ 
systems throughout entire organisms. 
Until recently, histological techniques relied on sectioning 
to observe nonsuperficial cellular structures deep in tissues. 
However, investigation of complex cells with large projections, 
such as those in the nervous system, is best performed in intact 
tissue. While recently developed tissue-clearing methods have 
overcome obstacles imposed by light scattering1–10, the difficulties 
associated with specimen size remain to be addressed. Available 
clearing methods either increase or do not change the volume of 
tissues, with the exception of organic-solvent-based methods such 
as 3D imaging of solvent-cleared organs (3DISCO), which causes 
a substantial volumetric reduction instead5,6,11.
When combined with tissue clearing, light-sheet microscopy 
produces micrometer-resolution image volumes of large speci-
mens within minutes. However, several limitations still exist. 
Photons traveling through samples (cleared or uncleared) are 
absorbed or scattered by interaction with the tissue, resulting in 
attenuation of both excitation and emission light12,13. Relatively 
thick light sheets (thickness ≥ 4 µm) are used to image volumes 
larger than a few hundred micrometers14. These light sheets 
are generated by cylindrical lenses and have Gaussian profiles; 
shrinkage-mediated imaging of entire organs and 
organisms using udisco
Chenchen Pan1,2,6, Ruiyao Cai1,2,6, Francesca Paola Quacquarelli1,6, Alireza Ghasemigharagoz1,  
Athanasios Lourbopoulos1, Paweł Matryba1,5, Nikolaus Plesnila1–3, Martin Dichgans1–4, Farida Hellal1,3 & Ali Ertürk1–3
thinnest widths, which provide the best resolution, occur only at 
the beam waist. Thus, the volume of sample that can be imaged at 
the highest resolution is limited to the central region of the light 
sheet. Finally, both small imaging chambers and the short work-
ing distance (WD ≤8 mm) of high numerical aperture (NA ≥ 0.9) 
objectives pose additional challenges. Thus, 3D reconstruction 
of neuronal connections over 5–8 mm (the approximate size of a 
mouse brain) has remained a challenging task.
Organic-solvent-based clearing methods, such as 3DISCO, 
achieve the highest level of transparency and size reduction 
among all clearing approaches11,15. 3DISCO has been used to 
study immune cells16, stem cells17, cancer cells18, and transdiffer-
entiating lung cells19; and it has been combined with deep-tissue 
antibody labeling and automated activity mapping20–22. However, 
3DISCO quickly quenches endogenously expressed fluorescent 
proteins (with a half-life of a few days)6, which has limited the 
applicability of 3DISCO. Here, we developed uDISCO, a method 
that revealed and preserved the signal of endogenous fluores-
cence over months while retaining the advantageous size reduc-
tion. Thus, uDISCO allows subcellular imaging of 2× to 3× larger 
volumes in a single scan and avoids or reduces artifacts of physical 
sectioning and mosaic imaging. Using uDISCO, we imaged entire 
bodies of adult rodents to determine long-distance neuronal 
and vascular projections and spatial information on stem cell 
transplants (which have previously been difficult to study) at 
single-cell resolution.
results
udisco preserves endogenous signal and reduces volume 
by 65%
We reasoned that 3DISCO-induced shrinkage could be promising 
for imaging whole rodent bodies. However, 3DISCO resulted in 
a fast decline of endogenous fluorescence signal during whole-
body clearing, where longer treatments with clearing solutions 
are required (Supplementary Figs. 1 and 2). To overcome this, 
we searched for organic compounds that preserved fluores-
cence while providing a potent tissue-clearing effect. Our screen 
1Institute for Stroke and Dementia Research, Klinikum der Universität Mu¨nchen, Ludwig Maximilians University of Munich (LMU), Munich, Germany. 
2Graduate School of Systemic Neurosciences (GSN), Munich, Germany. 3Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. 4German Center 
for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany. 5Current address: Department of Molecular and Cellular Neurobiology, Nencki Institute of 
Experimental Biology of Polish Academy of Sciences, Warsaw, Poland. 6These authors contributed equally to this work. Correspondence should be addressed  
to A.E. (ali.ertuerk@med.uni-muenchen.de).
Received 1 MaRch; accepted 26 July; published online 22 august 2016; doi:10.1038/nMeth.3964
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resulted in a tissue-clearing method (uDISCO) based on diphe-
nyl ether (DPE), an organic solvent with a refractive index of 
1.579 (Supplementary Fig. 3). uDISCO reveals fluorescence 
notably better and maintains it several weeks longer within 
Thy1–GFP-M mouse brains (expressing GFP in a sparse neu-
ronal population23) compared with 3DISCO and water-based 
ScaleS protocols (Fig. 1a,b, Supplementary Figs. 4–6, and 
Supplementary Video 1). As DPE has a melting point of 26 °C, 
we mixed it with benzyl alcohol (−15 °C melting point) and benzyl 
benzoate (18 °C melting point) to obtain a mixture that is liquid 
at room temperature, which we named BABB-D (Supplementary 
Table 1 and Supplementary Protocol). Additionally, uDISCO 
utilizes both the antioxidant α-tocopherol (Vitamin E) to scav-
enge peroxides and tert-butanol24, a dehydrating reagent that is 
more stable than tetrahydrofuran (THF) used in 3DISCO. With 
the resulting protocol, the fine structures of labeled neurons in 
the lipid-dense brain and spinal cord can be detected over 
weeks to months.
uDISCO effectively cleared internal organs (Supplementary 
Fig. 7) and hard tissues, including calcified bones (Supplementary 
Figs. 8–10; Supplementary Videos 2 and 3), without any addi-
tional treatment, such as decalcification with EDTA25. Bones are 
heavily mineralized, allowing only minimal exchange of clearing 
solutions. Therefore, bone clearing requires clearing solutions 
with similar refractive index (RI) to reduce the clearing duration 
and light scattering. The RI of bones has been estimated as 1.555–
1.564 (refs. 26 and 27), which is very similar to the RI of BABB-D, 
the final clearing agent in uDISCO.
We measured the size-reduction capability of uDISCO com-
pared with existing whole-body clearing techniques. We found 
that whole-body clearing by uDISCO reduced the volume of mice 
(~42%), while both CUBIC (clear, unobstructed brain imaging 
cocktails and computational analysis) and PARS (perfusion-
assisted agent release in situ) whole-body clearing methods 
enlarged it (Fig. 1c and Supplementary Fig. 11). We also tested 
the size reduction on dissected organs and found that uDISCO 
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Figure 1 | Development and principles of uDISCO. (a) Preservation of GFP (Thy1–GFP-M brain) after uDISCO, assessed by light-sheet microscopy.  
(b) Fluorescence-level quantifications in the GFP-M brains after uDISCO, ScaleS, and 3DISCO over time (n = 3, 3, and 4 mice, respectively; a.u., arbitrary 
unit). (c) Volume changes of 4-month-old GFP-M mice after CUBIC, PARS, and uDISCO whole-body clearing (n = 5, 3, and 7 mice, respectively).  
(d) Volume changes of dissected brains from 6-month-old mice after CUBIC, PACT, and uDISCO passive clearing (n = 4, 4, and 3 mice, respectively).  
(e) Illustration of the advantages and disadvantages of tissue shrinkage versus expansion during imaging. (f) Mouse brains (GFP-M, 4 months old): 
uncleared (left), after uDISCO (middle), and after CUBIC (right) whole-body clearing. (g) Light-sheet microscopy imaging of cortical neurons in GFP-M 
brains with shrinkage (uDISCO) and expansion (PACT and CUBIC) after clearing. (h) Imaging depth quantifications on brains after CUBIC, PARS, and 
uDISCO whole-body clearing (n = 4, 4, and 3 mice, respectively). (i) Imaging depth quantifications on brains after CUBIC, PACT, and uDISCO passive 
clearing of dissected brains (n = 4, 3, and 3 mice (6 months old), respectively). All values are mean ± s.d.; statistical significance in b–d, h, and i  
(*, P < 0.05; **, P < 0.01; and ***, P < 0.001) was assessed by one-way ANOVA followed by Dunnett’s post hoc test.
np
g
© 
20
16
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
np
g
© 
20
16
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
nAture methods  |  VOL.13  NO.10  |  OCTOBER 2016  |  861
Articles
reduced the size of adult mouse brains up to 55%, in contrast to 
CUBIC and PACT (passive CLARITY technique), both of which 
enlarged mouse brains (Fig. 1d and Supplementary Fig. 11). This 
size reduction, together with uDISCO’s preservation of fluorescent 
proteins, resulted in a substantial advantage for imaging larger 
volumes compared with other tissue-clearing methods (Fig. 1e,f). 
Using light-sheet microscopy, we found that the maximum portion 
of a cleared tissue that can be imaged at once increased 2× to 4× with 
uDISCO compared with PARS or PACT and CUBIC (Fig. 1g–i). 
To test whether the shrinkage was isotropic, we compared images 
before and after clearing. We found that brain tissues such as the 
cortex and hippocampal layers shrank homogenously, ~30% in 
each dimension at macroscopic scale (Supplementary Fig. 12). 
In addition, the shrinkage of different cell types (neurons, glia, 
etc.) and vasculature in the same brain region was homogenous 
in all dimensions (Supplementary Fig. 13). Finally, we found that 
individual cell and vascular morphologies were preserved in brain 
tissue after uDISCO clearing (Supplementary Fig. 14).
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Figure 2 | Whole-body clearing and imaging of adult mouse with uDISCO. (a–c) Adult GFP-M mouse (3 months old) was transcardially perfused (a), 
cleared with uDISCO (b) and imaged by fluorescence stereomicroscope at cellular resolution (c). Insets show higher-magnification images of the brain 
(magenta rectangle), spinal cord (cyan rectangle), and sciatic nerve (yellow rectangle). (d) Whole-body light-sheet imaging of intact GFP-M mouse  
(4 weeks old). (e–g) High-magnification images of the boxed regions in d. Colored rectangles show high-magnification images from the indicated regions 
in the brain (e), spinal cord (f), and sciatic nerve (g). (h) 3D visualization of the intact head from Thy1–YFP-H mouse (4 months old) after whole-body 
uDISCO clearing, indicating the detailed structure of optic nerve (i) and nerves at the base of the whiskers (j). The arrowheads in i and j mark some of 
the individual axons. The composites in c, d, and h were obtained via tile imaging.
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udisco enables micrometer-resolution whole-body imaging
We used uDISCO on whole rodent bodies for system-level inter-
rogation. We cleared the whole body of an adult Thy1–GFP-M 
mouse within 3–4 d (Fig. 2a,b; 3-month-old mouse; the skin 
was removed before clearing). We first imaged the whole trans-
parent mouse with a standard fluorescence stereomicroscope 
(Fig. 2c; the skull and vertebra were removed for epifluorescence 
imaging). We readily identified the individual neurons and 
their extensions throughout the brain, spinal cord, and limbs 
in the intact mouse (Fig. 2c). To accommodate the entire trans-
parent mouse into the imaging chamber of a standard light-
sheet microscope, we constructed sample holders to keep the 
cleared specimens in place within the imaging chamber for 
automated tile scans without obstructing the excitation light 
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Figure 3 | Whole-body clearing and imaging of rats with uDISCO. (a–c) A young adult female rat (4 weeks old) was injected with Texas Red Dextran  
to label the vasculature. The rat was transcardially perfused (a), cleared with uDISCO (b) 20 min after the dextran injection, and imaged with a 
fluorescence stereomicroscope (c). (d–f) High-magnification images of the boxed regions in c, such as the brain (d), spinal cord (e), and hindlimb (f). 
(g–i) Adult rat (10 weeks old) CNS (brain and spinal cord) before (g) and after (h) uDISCO clearing. (i–l) 3D visualization of vasculature via light- 
sheet imaging throughout the entire CNS from the adult rat (i). The vasculature in the cortex (j) (yellow arrowhead shows the right middle cerebral 
artery), brainstem (k) (yellow arrowheads show the two vertebral arteries, and purple arrowhead shows the basilar artery), and lumbar spinal cord 
(l) (yellow arrowheads show the spinal vessels, and purple arrowheads show their small s ulcal branches) are shown. The composites in c and i were 
obtained via tile imaging.
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(Supplementary Figs. 15 and 16). Upon shrinkage, the width of 
the largest body region (torso) was reduced from 2.24 ± 0.052 cm 
to 2.0 ± 0.048 cm (mean ± s.e.m., n = 7 mice), allowing us to 
complete 10-mm depth scans from dorsal and ventral sides of 
the mouse (Supplementary Fig. 17). Subsequently, we imaged 
the entire transparent mouse using light-sheet microscopy to 
detect neuronal structures throughout the intact mouse body 
at ~0.5- to 2-µm lateral and ~4-µm axial resolution (Fig. 2d). 
Subcellular details of neuronal projections in the whole body 
were visible throughout the animal with light-sheet microscopy 
(Fig. 2e–g). In addition, large body regions such as the head, 
torso, and whole limbs could be studied in detail. For example, 
when we imaged the entire head from an adult Thy1–YFP-H 
mouse23, we observed the projections of optic nerves and inner-
vation of whiskers (Fig. 2h–j).
uDISCO is also applicable to larger rodents. Rats (Rattus nor-
vegicus) are valuable experimental models in toxicology and 
neurological studies because, compared with those of mice, 
rat physiology and behavior more closely resemble those of 
humans. uDISCO successfully cleared whole rats (Fig. 3a,b and 
Supplementary Fig. 18). We could observe the details of Texas 
Red–dextran-labeled vasculature in the brain, brainstem, and 
limbs using a standard fluorescence stereomicroscope in the 
intact 4-week-old rats (Fig. 3c–f). In addition, uDISCO achieved 
uniform clearing and over 60% tissue shrinkage of the intact cen-
tral nervous system (CNS) in adult rats (10 weeks old, n = 4 rats; 
Fig. 3g,h). Subsequently, we obtained light-sheet microscopy 
images of the vasculature in the intact CNS over 13 cm (Fig. 3i 
and Supplementary Video 4). We identified vascular structures 
such as the right middle cerebral artery (Fig. 3j); the two vertebral 
1 cm
10 µm
100 µm
100 µm
1 mm
1 cm
5 mm
100 µm
a
b c
d
e
f
g
f
d
e
Figure 4 | Projections throughout the entire adult mouse CNS (whole brain and spinal cord). (a) The intact CNS from a GFP-M mouse (4 months old) 
after uDISCO clearing and light-sheet microscopy imaging. (b) Image of the brain in a showing the transparency after uDISCO. (c) Details of neuronal 
structures in the entire brain in a. (d–f) High-magnification images of boxed regions in c, showing the neuronal structures at subcellular resolution in 
the cortex (d), in the hippocampus (e), and projecting to the midbrain (f). (g) After uDISCO, imaging of dendritic spines with light-sheet microscopy. 
The composites in a and c were obtained via tile imaging.
np
g
© 
20
16
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
np
g
© 
20
16
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
864  |  VOL.13  NO.10  |  OCTOBER 2016  |  nAture methods
Articles
arteries, which merge to form the basilar artery (Fig. 3k); and the 
spinal vessels and their small sulcal branches (Fig. 3l).
udisco allows tracing of the intact central nervous system
Since we could image the intact CNS of rodents with light-sheet 
microscopy at subcellular resolution, we used uDISCO to trace 
neuronal structures from head to toe in the entire CNS (brain 
and spinal cord) of 3- to 5-month-old Thy1–GFP-M adult mice. 
We could trace individual axons in the intact CNS over several 
centimeters in these scans (Fig. 4a; Supplementary Videos 5 
and 6). Focusing on the brain, we observed the details of neuronal 
structures in the cortex, the hippocampus, and fine axonal projec-
tions to the midbrain (Fig. 4b–f and Supplementary Video 7). 
PACT1 and CUBIC8 reported visualization of dendritic spines 
using confocal or two-photon microscopy. For the first time for 
an organic-solvent-based clearing method in intact adult mouse 
brain, uDISCO achieved dendritic-spine resolution using light-
sheet microscopy (Fig. 4g and Supplementary Video 8).
udisco allows interrogation of Bmscs in the entire mouse
Bone marrow stem cells (BMSCs) are widely used for neuropro-
tection, regeneration, immunomodulation, and localized drug 
delivery studies28,29. So far, assessment of their distribution and 
densities has relied on methods such as histology, biolumines-
cence, or radiolabeling30. These approaches are time consuming 
and lack the sensitivity to detect sparsely localized cells or unex-
pected sites of grafting31. We used uDISCO whole-body clearing 
for an unbiased screen of transplanted syngeneic mouse BMSCs 
in the entire body at single-cell resolution. We collected BMSCs 
from β-actin EGFP mice as described previously32 and labeled 
them with quantum dots (Qdots) (Supplementary Fig. 19). Cells 
easily incorporate Qdots, which do not interfere with cell func-
tionality or migration capacities and therefore Qdots are widely 
used for cell tracking33. Subsequently, we injected the cells either 
intravenously (IV) or intraperitoneally (IP) into host C57BL/6N 
mice (Fig. 5a). Control animals were injected with vehicle 
(PBS) only. At 3 h after injection, we euthanized the animals for 
whole-body clearing. We first imaged whole mouse bodies using 
a fluorescence stereomicroscope to determine sites of grafted 
BMSCs (Supplementary Fig. 20). Subsequently, we performed 
high-resolution light-sheet microscopy on body parts and organs 
that hosted BMSCs. As expected, the majority of BMSCs were 
trapped in the first-passage, low-flow organs such as the lungs, liver, 
and spleen after IV injection (Fig. 5b,c, Supplementary Figs. 20–22, 
and Supplementary Video 9)31,34. Moreover, we detected sparsely 
distributed BSMCs in organs such as kidneys, bone marrow, and 
intestines (Fig. 5b,c; Supplementary Figs. 21 and 22). The locali-
zations in bone marrow and intestines are of high interest because 
they were previously difficult to investigate despite their impor-
tance for hematopoietic cell populations or immune reactions31. 
As reported35, we did not observe any BMSCs in the intact healthy 
CNS (Fig. 5b,c). Overall, our data demonstrate that uDISCO 
whole-body clearing can be used to study density and distribution 
of fluorescently labeled transplanted cells throughout the entire 
host body at single-cell resolution in an unbiased way, combining 
both high speed and resolution for transplantation studies.
udisco is compatible with virus labeling and immunostaining
Most animal models used in the laboratory, as well as human 
clinical samples, do not express fluorescent proteins. Hence, we 
sought to test alternative methods to label tissues for uDISCO. To 
this end, we used adeno-associated virus (AVV) tracing to label 
neurons in the CNS of mice. We transduced the right motor cor-
tex of mice with AAV2–Syn–EGFP and the left motor cortex with 
AAV2–Syn–RFP (Fig. 6a). 4 weeks after transduction, we per-
formed whole-body uDISCO clearing. Fluorescence expression 
of the virally delivered proteins was detectable in the brain and 
throughout the intact spinal cord (Fig. 6b–f and Supplementary 
Fig. 23). The pyramidal decussation of descending motor axons 
was clearly visible (Fig. 6c). We detected both bundles of axons as 
well as individual axons in the brain and spinal cord over several 
centimeters (Fig. 6d–f).
Antibody staining is a valuable approach for labeling molecules 
of interest without the need for fluorescent tagging. Deep- 
tissue antibody-labeling methods20,21 were recently combined with 
3DISCO. To test these methods with uDISCO, we cut 1-mm-thick 
tissue sections of mouse brains and labeled them with antibodies 
against glial fibrillary acidic protein (GFAP) and ionized calcium 
binding adaptor molecule 1 (Iba1) as well as with a DNA-specific dye 
(Fig. 6g). After uDISCO, the slices shrank more than 60% in volume. 
We found that the signals from GFAP (astrocytes), Iba1 (micro-
glia and macrophages), and TO-PRO-3 (DNA dye) were visible 
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Figure 5 | Distribution of mouse BMSCs after transplantation. (a) Illustration of the experimental design. (b) Images of liver, lung, limb, and head 
(brain) from host mice in control, IP, and IV groups assessed by light-sheet imaging. The composites of individual organs were obtained via tile imaging. 
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throughout the tissue, indicating compatibility of uDISCO with 
deep-tissue labeling (Fig. 6h–l and Supplementary Fig. 24).
Human clinical tissue samples are typically stored in 4% forma-
lin over extended periods of time. To determine whether uDISCO 
could be applied to such specimens, we immunostained 1-mm-
thick human samples (archived for either 1 month or 14 months) for 
GFAP and TO-PRO-3 or Iba1 and TO-PRO-3. We measured shrink-
age of 52% and 46% in samples stored for 1 month or 14 months, 
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Figure 6 | uDISCO is compatible with AVV neuron tracing and immunolabeling. (a) Experimental design for AAV–Syn–RFP and AAV–Syn–GFP injections. 
(b,c) Maximum-intensity projections of the entire brain (b,c) and CNS (b) after whole-body uDISCO clearing. Arrowheads in c indicate decussation of 
the descending motor axons. (d–f) Details of neuronal extensions of boxed regions in (b): the thalamus and midbrain (d), cervical (e), and thoracic (f) 
spinal cord regions. Colored rectangles show the enlarged views from the respective images. (g) Immunolabeling workflow. (h–l) GFAP and TO-PRO-3 
labeling of coronal sections. 3D reconstructions show labeling of astrocytes (h) and cell nuclei (i) stained by GFAP antibody and TO-PRO-3, respectively. 
(j) Merged image of h and i. (k,l) Maximum-intensity projections of the z-positions marked by purple boxes in j; nuclei are shown in cyan and astrocytes 
in red. (m,n) 14-month fixed human tissue before (m) and after (n) uDISCO. (o–r) GFAP and TO-PRO-3 labeling of 14-month fixed human cortical tissue. 
Astrocytes (o) and nuclei (p) are labeled. (q) Merged image of o and p. (r) Maximum-intensity projection of the z-position marked by the purple box in q;  
nuclei are shown in cyan and astrocytes in red. All values are mean ± s.d. The composites in b and c were obtained via tile imaging.
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respectively (Fig. 6m,n). uDISCO allowed successful clearing, 
signal preservation, and imaging of human tissues stored in for-
malin more than a year (Fig. 6o–r and Supplementary Fig. 25), 
although the image quality was better for shorter storage periods 
(Supplementary Fig. 25i). Importantly, the combination of 
uDISCO and deep-tissue antibody labeling did not require addi-
tional antigen retrieval steps. Overall, these results demonstrate 
that uDISCO is a versatile method that can be used to clear and 
image different types of tissues with various labeling methods.
discussion
uDISCO achieved whole-body clearing and imaging because of 
sample-size reduction and preservation of fluorescent proteins. 
Another major advantage of organic-solvent-based clearing meth-
ods is the easy handling of cleared tissues; specimens become 
hard because of dehydration, yet are flexible enough for versatile 
positioning of long samples, such as the entire spinal cord of adult 
rats. In contrast, concentrated glycerol and sugar solutions used 
in various clearing methods are difficult to work with because of 
their high viscosity, the resulting gel-like texture of the cleared 
tissue, and the air bubbles generated during the refractive-index 
matching procedures and imaging11.
Recently, tissue expansion was used to obtain super-resolution 
images of small volumes (expansion microscopy)36–38. Treweek 
et al.25,39 used a similar concept (expansion (e) PACT) for high-
resolution imaging. While expansion provides more resolution, 
tissue shrinkage, in theory, decreases resolution (30% in one 
dimension for uDISCO). However, uDISCO resulted in high-
quality images (Supplementary Fig. 26), allowing the visu-
alization of dendritic spines and individual axons over several 
centimeters in the intact CNS of adult mice. This high image 
quality could result from a larger proportion of shrunken samples 
(compared with nonshrinking samples) fitting into the optimal 
imaging region of the light sheet. Hence, shrinkage allows imag-
ing of 2× to 3× larger volumes in the same setup without apparent 
loss of resolution. Importantly, uDISCO did not alter the struc-
tural integrity of the brain either at macroscopic (e.g., cortex and 
hippocampus structures) or microscopic scales (e.g., individual 
cells). However, isotropic shrinkage remains to be confirmed for 
other tissues such as muscle or fat. In addition, uDISCO can be 
combined with microscopy techniques that deliver even higher 
resolution and/or faster scanning, such as confocal, two-photon, 
and lattice light-sheet microscopy40. We demonstrated that high 
numerical aperture (NA), long working distance objectives such 
as Zeiss CLARITY 20× and Olympus 25× are compatible with 
uDISCO (Supplementary Fig. 27).
Acute injuries in the CNS might affect not only the injury site 
but also uninjured distal parts of the CNS41,42. Thus, repair strate-
gies after CNS traumas need to be evaluated throughout the entire 
CNS. The uDISCO approach enables the assessment of long-range 
axonal projections and individual cells throughout entire organisms. 
Hence, this approach can help to reduce (1) the bias of analyzing only 
selected organs; (2) the time needed to prepare and screen individual 
organs and body parts of a complete mouse43; and (3) by generating 
whole mouse atlases and databases it can reduce the resources and 
number of animals needed in experimental research.
Whole-body clearing of diverse tissues, and the compatibility of 
this method with different imaging techniques, may have broad 
applications in the biomedical sciences. Whole-body clearing 
approaches could facilitate the assessment of neurodegeneration 
in diseases that affect both the central and peripheral nerves such 
as in amyotrophic lateral sclerosis (ALS), inflammation that may 
extend from gut to brain, stem cell transplantation studies, or even 
3D mapping of the cellular structures in larger brain volumes, 
possibly even the whole human brain.
methods
Methods and any associated references are available in the online 
version of the paper.
 Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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A step-by-step protocol for uDISCO is available as Supplementary 
Protocol (and ref. 44).
Animals. We used the following animals in the study: 1- to 
6-months-old, mixed gender 27 (15 male and 12 female) C57BL/
6N (Charles Rivers Laboratories), 57 (28 male and 29 female) 
Thy1–GFP mice (line GFP-M), 5 (2 male and 3 female) Thy1–YFP 
mice (line YFP-H)23, 32 (13 male and 19 female) CX3CR1–GFP 
mice (B6.129P-Cx3cr1tm1Litt/J, Jackson Laboratory strain code: 
005582), 6 (3 male and 3 female) β-actin EGFP mice (C57BL/ 
6-Tg(CAG–EGFP); 131Osb/LeySopJ, Jackson Laboratory strain 
code: 006567), and four rats (4 female) (CD IGS Rat strain 001). 
Sample sizes were chosen based on preliminary experiments. 
Sample sizes are specified in figure legends. The animals used 
in this study were selected for each experiment based on their 
genetic background (wild type or fluorescent transgenes), and 
animals that resulted fluorescent-protein negative by genotyp-
ing were excluded from the study. Within each strain, animals 
were randomly selected; different stages of experiments (clearing, 
imaging, and data analysis) were carried out by different opera-
tors. Animals were housed in our animal facility under a 12/12 h 
light/dark cycle and were provided food and water ad libitum. 
Experiments were conducted according to institutional guidelines 
of the Ludwig Maximilian University of Munich after approval of 
the Ethical Review Board of the Government of Upper Bavaria 
(Regierung von Oberbayern, Munich, Germany). All data are 
reported according to the ARRIVE criteria45.
Human tissue. Human tissues used for this study were obtained 
from five donors of 64–89 years old (1 male and 4 females). 
Human tissue donors gave their informed and written consent to 
the donation of their bodies for teaching and research purposes 
regulated by the Saxonian Death and Funeral Act of 1994 (third 
section, paragraph 18 item 8).
Perfusion and tissue preparation. Animals were deeply anes-
thetized by intraperitoneal injection with the triple combination 
of midazolam/medetomidine/fentanyl (MMF) (1 ml per 100 g of 
body mass for mice) before intracardial perfusion. Subsequently, 
animals were perfused transcardially (100–125 mm Hg pressure on 
Leica perfusion one system) with heparinized 0.1 M PBS (10 U/ml 
of heparin, Ratiopharm) for 5–10 min at room temperature until 
the blood was washed out and with 4% paraformaldehyde in 
0.1 M PBS (pH 7.4; Morphisto, 11762.01000) for 20 min using 
100–125 mm Hg pressure. The dissected tissue samples (whole 
brain, spinal cord, whole brain with the spinal cord, and femurs) 
were postfixed in 4% paraformaldehyde for 1–2 d at 4 °C. Then, 
tissues were washed once in PBS for 5 min; meninges were 
removed; and bent samples, such as spinal cords, were kept 
straight for the clearing procedure.
For cut bone clearing, femurs dissected from CX3CR1–GFP 
mice were fixed in cold 4% PFA for 24 h. Afterwards, the bones 
were washed with PBS and incubated in 30% sucrose PBS solution 
overnight at 4 °C. For longitudinal dissection, a Leica cryostat 
(Leica, CM3050S) was used to cut the bones embedded in opti-
mum cutting temperature (O.C.T.) formulation (SAKURA, 4583). 
The section thickness was set at 30 µm, and the serial section-
ing was performed until the entire bone marrow appeared. The 
remaining intact half bones were collected and washed with PBS 
to remove OCT and then processed for immunostaining and 
respective clearing46.
For whole-body clearing, after the mouse body was well perfused 
and fixed, the skin was separated from the body while avoiding 
adhesion of pelage. The skull and vertebra were carefully opened, 
avoiding any damage such as puncturing and squeezing of the 
tissue. Whole-body tissue clearing was started immediately.
Immunostaining. The following antibodies and dyes were used in 
this study: Iba1 (Wako, 019-19741, dilution 1:350), GFAP (Dako, 
Z033401-2, dilution 1:350), Collagen 4 (SouthernBiotech, 1340-01, 
dilution 1:650), AlexaFluor 647 conjugated anti-GFP rabbit 
polyclonal antibody (Life Technology, A31852, dilution 1:500), 
TO-PRO-3 iodide (642/661) (Life Technologies, T3605, dilu-
tion 1:500), AlexaFluor 568 goat anti-rabbit IgG (H+L) (Life 
Technologies, A-11036, dilution 8 µg/mL), AlexaFluor 647 goat anti-
rabbit IgG (H+L) (Life Technologies, A-21245, dilution 8 µg/mL), 
and Cy3 AffiniPure donkey anti-goat IgG (H+L) (Jackson, 705-
165-147, dilution 1:300).
For immunostaining, the tissues (mouse brains or human tissue) 
were cut into 1 mm slices using a vibratome (Leica, VT1200S). 
Mouse sections were immunostained using iDISCO20 or Belle 
et al.21 protocols. We used the following iDISCO protocol. The 
sections were initially pretreated: first, they were washed in 0.1 M 
PBS for 50 min two times, then they were incubated in 50% and 
80% methanol (in 0.1 M PBS) for 50 min at each step and then in 
100% methanol for 1 h two times. Sections were bleached with 
ice-cold 5% H2O2 (Sigma, D216763) and 20% DMSO (Sigma 
D8418)/methanol (AppliChem, 141091.1211) at 4 °C overnight. 
After bleaching, sections were washed in methanol for 45 min 
three times; then in 20% DMSO/methanol for 45 min two times; 
then in 80% and 50% methanol for 45 min each step; then in 0.1 M 
PBS for 45 min two times; and finally in PBS/0.2% Triton X-100 
(Sigma, T8787) for 45 min two times. For the immunostaining 
step, pretreated sections were incubated in PBS–0.2% Triton 
X-100–20% DMSO–0.3 M glycine (Sigma, G8898) at 37 °C overnight, 
then blocked in PBS–0.2% Triton X-100–10% DMSO–6% goat 
serum at 37 °C for 1 d, washed in PBS–0.2% Tween-20 (Sigma, 
P9416) with 10 mg/ml heparin (PTwH) overnight and then incu-
bated with primary antibody dilutions in PTwH–5% DMSO–3% 
goat serum at 37 °C with gentle shaking on an oscillator for 6–8 d, 
refreshing the primary antibodies once after 3–4 d. Sections were 
then washed for 1 h with PTwH four times and then incubated 
with secondary antibodies diluted in PTwH–3% goat serum at 
37 C° with gentle shaking on an oscillator for 3–4 d, refreshing 
once after 2 d. Sections were finally washed in PTwH 30 min five 
times and incubated with TO-PRO-3 iodide (642w/661) (dilution 
1:750) in PTwH for 5 h at room temperature with gentle oscil-
lation, washed again for 1 h four times with PTwH, and stored 
at 4 °C in 0.1 M PBS until clearing.
Human sections were immunostained using a modification of 
the protocol from Belle et al.21; briefly, 1 mm thick brain sections 
were incubated on a rocker (IKA, 2D digital) at room tempera-
ture in PBSGT solution, which consists of 0.1 M PBS with 0.2% 
porcine skin gelatin (Sigma, G2500), 0.5% Triton X-100, and 
0.05% sodium azide (Sigma, 71290) for 24 h. Next, PBSGT was 
exchanged with PBSGT + 1% goat serum containing the primary 
antibodies and left in incubation at 37 °C with gentle shaking on 
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an oscillator (IKA, MS 3 basic) for 8–9 d. The primary antibod-
ies were refreshed once after 4–5 d. Then, samples were washed 
for 30 min with PBSGT five times at room temperature and incu-
bated with secondary antibodies, diluted in PBSGT + 1% goat 
serum at 37 °C with gentle shaking on an oscillator for 4–5 d. 
The secondary antibody was refreshed once after 2 d. Finally, 
samples were washed for 30 min three times with PBSGT, incu-
bated with TO-PRO-3 in PBSGT for 5 h at room temperature with 
gentle oscillation, washed again for 1 h four times with PBSGT 
and stored at 4 °C in 0.1 M PBS until clearing.
For cut bone immunostaining, collected half bones were pre-
treated with 5 d of PBSGT incubation at room temperature. Then, 
the tissue was incubated in PBSGT with 1% goat serum and 
AlexaFluor 647 conjugated anti-GFP antibody (dilution 1:500) 
at 37 °C for 10 d, refreshing once after 5 d, and finally washed five 
times with PBSGT for 10 min.
Preparation of uDISCO solutions. Dehydrating solutions were 
prepared by mixing tert-butanol (Sigma, 360538) and distilled 
water in the following concentrations: 30 vol% tert-butanol, 
50 vol% tert-butanol, 70 vol% tert-butanol, 80 vol% tert-butanol, 
90 vol% tert-butanol, 96 vol% tert-butanol. Pure (100%) tert- 
butanol has a melting point between 23 °C and 26 °C; therefore. we 
recommend keeping it above the melting temperature before use. 
Delipidation solution dichloromethane (DCM) (Sigma, 270997) 
was used as a pure solution. Three refractive index matching solu-
tions were used: BABB-D4, prepared by mixing BABB (benzyl 
alcohol + benzyl benzoate 1:2, Sigma, 24122 and W213802) with 
diphenyl ether (DPE) (Alfa Aesar, A15791) at a ratio of 4:1 and 
adding 0.4% vol DL-alpha-tocopherol (Vitamin E) (Alfa Aesar, 
A17039); BABB-D10, prepared by mixing BABB with DPE at a 
ratio of 10:1 and adding 0.4% vol vitamin E; BABB-D15, prepared 
by mixing BABB with DPE at a ratio of 15:1 and adding 0.4% vol 
vitamin E. In passive clearing, BABB-D4 preserved the fluores-
cence signal better, while BABB-D15 gave better transparency. 
BABB-D10 was used for whole-body tissue clearing. The ratio of 
DPE to BABB can be adjusted to achieve either better preservation 
of fluorescence or more tissue transparency.
uDISCO passive clearing procedure. All incubation steps were 
performed in a fume hood with gentle rotation or shaking using 
5 ml tubes (Eppendorf, 0030 119.401) for whole mouse brain or 
smaller samples, or steps were performed using glass chambers 
(Omnilab, 5163279) for bigger samples such as rat tissues or whole 
brain and spinal cord. The samples were covered with aluminum 
foil to keep them in dark.
The clearing consisted of serial incubations of the fixed samples 
in 5–80 ml of 30 vol%, 50 vol%, 70 vol%, 80 vol%, 90 vol%, 96 vol% 
and 100% tert-butanol at 34–35 °C to dehydrate the tissue, fol-
lowed by immersion in DCM for 45–60 min at room temperature 
to remove the lipids. Eventually, they were incubated in BABB-
D at room temperature for at least 2 h until samples became 
transparent. The requirement of DCM step and the incubation 
time of each step in tert-butanol solutions depended on sample 
size. For instance, small tissues such as mouse spinal cord or 
1-mm-thick coronal slices did not need DCM step and required 
short incubation times (2–4 h) per each tert-butanol step com-
pared with thicker or mineralized tissues such as whole brain 
and intact bones (12 h). Details of each protocol are showed in 
Supplementary Table 1. Samples could be stored in BABB-D 
at room temperature in dark for weeks.
All other clearing methods, including PACT, CUBIC, 3DISCO, 
1-propanol BABB, ScaleS, SeeDB and Murray’s clear (Fig. 1; 
Supplementary Figs. 5,6, and 9–11), the clearing protocols were 
performed following the original publications1,2,6,9,10,14,24,25,47.
uDISCO whole-body clearing procedure. We established a 
transcardial circulatory system comprised of a peristaltic pump 
(Gilson, Peristaltic Pump MINIPULS 3; Supplementary Fig. 28; 
see also the step-by-step protocol of uDISCO in Supplementary 
Protocol). In principle, two channels from the pump were 
required for circulation. The first channel pumped the clearing 
solution through the mouse body, and the second channel col-
lected the solution exiting the mouse body and recirculated it 
back to the original bottle. Since clearing solutions are corrosive, 
Viton reference tubing was chosen (Gilson, F1817745) because 
it is resistant to clearing chemicals. First, the reference tubing 
was set up following the instructions, and each end of the tubing 
was connected to a tubing connector (Omnilab, 5434482). Next, 
the tubing connectors were linked with additional PVC tubing 
(Omnilab, 5437920). For the outflow tubing of the first channel, 
which injected the solution into the heart, the head part cut from 
a 1 ml syringe (Braun, 9166017V) was inserted as the connec-
tor of the perfusion needle and fixed with a mouse transcardiac 
perfusion needle (Leica, 39471024). Meanwhile, the inflow tubing 
of the second channel, which recirculated solution, was fixed to 
the glass chamber containing the mouse body. Eventually, the 
inflow tubing of the first channel was kept below the surface of 
the solution, and the circulation was started until air bubbles were 
pushed out from the tubing system.
All clearing steps should be performed in a fume hood. First, 
the mouse body was put in a glass chamber, and the perfusion 
needle was set into the heart through the same pinhole made 
during tissue preparation in the perfusion setup. Next, the 
chamber was covered with aluminum foil, and the transcardial 
circulation was started. Each gradient of dehydration solution was 
circulated at 8–10 ml/min for 10–12 h. As the melting point of 
tert-butanol is 23 to 26 °C (close to room temperature), a heating 
plate with 35–40 °C was used for the two rounds of 100% tert-
butanol circulation to prevent the solution from solidification. 
The final step of tissue clearing could normally be achieved by 
circulating BABB-D10 with the same injection rate for 6–12 h. 
The transparency of the mouse body was checked by eye during 
clearing. Bubbles were carefully prevented from forming, 
especially in the first channel, at every step. For rat whole-body 
clearing, a thicker perfusion needle (Leica, 39471022) without 
rubber head was used, and each step of circulation was prolonged 
to 24 h with a flowing rate of 15–20 ml/min. A passive incubation 
step of DCM for 6–8 h with gentle shaking was included before 
performing BABB-D10 circulation. Supplementary Table 1 sum-
marizes the incubation times and temperatures of each clearing 
solution for whole-body clearing.
As a final note, the amount of solutions for circulation depends 
on the capacity of the clearing chamber. For mice whole-body 
clearing, if the maximum volume of the glass chamber is 400 ml, 
300 ml of volume of solution was used for circulation. For rat 
whole-body clearing, a 1,000 ml capacity glass chamber with 
800 ml working clearing solution would be sufficient.
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PARS and CUBIC whole-body clearing methods (Fig. 1  
and Supplementary Fig. 11) were performed following the 
original papers10,25.
Vasculature labeling with Texas Red Dextran. Texas Red Dextran 
(70,000 MW, Lysine Fixable, Invitrogen) was diluted in saline with 
a concentration of 15 mg/ml for mouse (0.1 ml per animal) and 
8 mg/ml for rat (1 ml per animal). A pulled tubing (nonsterile 
polythene tubing, ID 0.86 mm, OD 1.27 mm, Harvard Apparatus) 
was attached to the syringe needle to achieve sharp ending thinner 
than femoral vein. For dextran injection, animals were anesthe-
tized (MMF triple combination, 8 ml/kg, i.p.) and placed ventral 
side up. The right femoral vein was identified and exposed by 
surgical dissection in the inguinal region. The sharp ending of the 
tubing was inserted into the venous sinus of femoral vein, and the 
dextran was injected at a rate of 0.3–0.4 ml/min. After injection, 
the tubing was retreated and the wound was sealed by surgical 
suture. Then, the animals were placed in a warm cage for 15–20 min 
before proceeding with the standard perfusion and tissue prepara-
tion procedure. We experienced that skipping heparin in the pre-
washing step of the perfusion (and using only 0.1 M PBS instead) 
resulted in better labeling of the vasculature.
Neuronal tracing by AAV virus. AAVs expressed EGFP (AAV2–
Syn–EGFP) and RFP (AAV2–Syn–RFP) under the promoter of 
human Synapsin (Vector Core, University of North Carolina). 
The final titers were around 2×109 GC (Genome Copy) per µl. 
For the virus injection, 3- to 4-month-old female C57BL/6N mice 
were anesthetized (MMF triple combination, 8 ml/kg, i.p.) and 
placed in a stereotaxic frame. To expose the motor cortex targeted 
for tracing axons into spinal cords, two cranial windows on each 
side of the skull were created within the area: 1.0 mm and 2.0 mm 
lateral; 0.5 mm anterior and 1.5 mm posterior to bregma. AAVs 
were injected into the cortex using a custom-established injector 
fixed with a pulled glass pipette. First, ten independent injection 
sites were targeted with the following coordinates: 1.2 mm and 
1.8 mm lateral; 1.0 mm deep; 0.3 mm anterior to bregma, 0.1 mm, 
0.5 mm, 0.9 mm, and 1.3 mm posterior to bregma. Next, 400 nl 
virus was injected at a rate of approximately 200 nl/min for 
every injection site. The glass pipette was kept in situ for 1 min 
before moving to the next site. After finishing all the injections, 
the cranial windows were covered by absorbable gelatin sponge 
(GELITA-SPON, GS-110), and the incision was closed by wound 
clips (CellPoint Scientific, part no. 203-1000). The animal was 
placed in a warm cage for waking up and then transferred into a 
regular keeping room. Carprofen (0.2 ml per injection, 1 mg/ml, 
i.p.) was given 3 times per d for 3 d. The animal survived for 
4 weeks post virus injection before performing uDISCO.
Culture and characterization of mouse BMSCs. Mouse BMSCs 
were collected and cultured from β-actin EGFP mice as described 
previously32,48. Briefly, femur and tibia from 8- to 12-week-old 
mice (4–5 mice per culture) were removed under sterile condi-
tions, and bone marrow was flushed out using a 20 gauge needle 
syringe. After mechanical dissociation with repeated flow of the 
bone marrow through needles of progressively smaller diameter, 
the cell suspension was filtered through a sterile 40 µm nylon 
cell strainer mesh. Cells were resuspended in a final density 
of 20 × 106 cells per ml of medium and were plated in T25 
flasks (5 ml per flask) at 37 °C with 5% CO2. Culture medium 
was composed of aMEM, 10% lot-selected mesenchymal- 
stem-cell-qualified fetal bovine serum (FBS), 1% L-glutamine, 
1% penicillin–streptomycin, and medium was stored at 4 °C for 
1–3 weeks until usage. The medium was changed on day 2 (half 
of medium) and day 7 (complete change), followed by a complete 
change of medium every 3–5 d. Cells were passaged for the first 
time when 70–80% confluent using 0.05% trypsin–EDTA, and 
they were split at a 1:3 ratio.
Characterization of mix BMSCs was done with flow cytometry 
(FACS) and differentiation assays on passage 3. For FACS analysis 
the following primary antibodies were used in two different 
staining panels: CD11b-eFluor450 (eBiosciences 48-0112, clone 
M1/70, dilution 1:400), CD45.2-PE (eBiosciences 12-0454, clone 
104, dilution 1:400), CD34-eFluor450 (eBiosciences 48-0341, 
clone RAM34, dilution 1:100), Sca1-APC (eBiosciences 17-5981, 
clone D7, dilution 1:200), CD29-PE (eBiosciences 12-0291, clone 
HMb1-1, dilution 1:200), and CD44-APC (eBiosciences 17-0441, 
clone IM7, dilution 1:200). Briefly, cells were harvested by trypsini-
zation with 0.05% trypsin, washed with ice-cold PBS, centrifuged 
at 1,500 r.p.m. for 8 min at 4 °C, resuspended at a concentration 
of 1–5 × 106 cells/ml, and stained with the primary antibodies for 
45 min at 4 °C in the dark. Following washing with ice-cold PBS 
three times, cells were immediately read at a flow cytometer (BD 
Biosciences, FACS Verse). Unstained cells and cells stained with 
the corresponding isotypic controls were used as negative controls 
for FSC, SSC, and autofluorescence adjustments.
Osteogenic and adipogenic differentiation capacity of BMSCs 
was tested on cells of passage 3 as previously detailed47. Bone min-
eralization and fat droplets after osteo- and adipo-differentiation 
were detected using alizarin red and oil red O staining assays, 
respectively, according to standard protocols. Chondrogenic dif-
ferentiation capacity of mBMSCs was studied using the StemPro 
chondrogenesis differentiation kit (Gibco A10071-01) accord-
ing to manufacturer instructions; proteoglycans produced 
by chondrocytes were stained with 1% alcian blue solution 
according to a standard protocol. Characterization of the trans-
planted EGFP+ mBMSCs is shown in Supplementary Fig. 19. 
Approximately 30% of the transplanted cells were EGFP+, and 
60% were loaded with quantum dots.
Labeling of cells with Qdots. The EGFP+ BMSCs were cultured 
for 30–45 d until reaching passage 4 or 5. 1 d before transplantation, 
EGFP+ BMSCs were labeled with fluorescent carboxyl quantum 
dot nanoparticles (Qtracker Qdots, Invitrogen, emission at 655 
nm or 800 nm). The nanoparticles were aseptically reconstituted 
according to manufacturer’s instructions (20 µl of component A 
and 20 µl of B), allowed to sit at room temperature for 5 min, 
vortexed for 30 s, mixed with full BMSC medium up to a volume 
of 400 µl, and then added to the flasks (200 µl per 1 T75 flask with 
confluent BMSCs). Labeling of the EGFP+ BMSCs with Qdots 655 
was checked 24 h later with microscopy and FACS analysis before 
transplantation. The efficiency of the labeling and the presence of 
any remaining free Qdots was also checked by sequential transfer-
ring of the Qdots-containing medium to a new flask with BMSCs, 
which did not produce any further cell labeling.
Transplantation procedures. Transplantation of the EGFP+ 
BMSCs, EGFP+/Qdot-labeled BMSCs, or vehicle (PBS) was 
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performed via tail vein intravenous (IV) or intraperitoneal (IP) 
injections. The injections were performed in C57BL/6N mice. All 
animals were food-starved overnight before the transplantation 
to clear the intestines for visualization.
For IV transplantation, animals were shortly anesthetized with 
2% isoflurane. To achieve maximum vein dilation for successful 
infusion, the tail was shortly dipped and gently massaged in warm 
water (35–38 °C, for 10 s) and was then immediately placed for 
5 min between a prewarmed (38 °C) heating pad and warm wet 
gauzes. The suspension of 1 × 106 BMSCs in 300 µl was injected 
IV at once using a 30-gauge needle attached to a 1 ml syringe. 
The injection caused a short heart arrest (approximately 10 s) in 
some animals that recovered either spontaneously or after short 
thoracic massaging. For IP transplantations, animals were briefly 
(30–60 s) anesthetized with isoflurane just before the injection 
and then received IP injection of 1 × 106 BMSCs in 300µl of PBS 
at once. Following successful injections, animals recovered from 
anesthesia in a heat chamber (set at 30–31 °C) for approximately 
30 min before returning to their home cage. The control animals 
were injected with PBS. 3 h after injection, we euthanized the 
animals for uDISCO.
Imaging setup, light-sheet microscopy. We used LaVision 
BioTec Ultramicroscope II light-sheet microscope (Supplementary 
Table 2). The axial resolution of the Ultramicroscope is 4 µm, and 
the lateral resolution is 0.5–2 µm, depending on the objective 
used (details are in Supplementary Table 2). We used exposure 
times of 250 ms to 50 ms, laser power of 1 to 3mW (25% to 70% 
of the power level at a given wavelength, mostly centered around 
470 nm, 545 nm, or 640 nm), distributed across a Gaussian light 
sheet of variable width and NA; according to the manufacturer 
specifications, the light sheet has a thickness of 4.5 µm at its waist 
at 488 nm. A typical width spanning between 0.5 mm and 0.3 mm 
was chosen to adjust the illumination extent to the field of view of 
the objective used. The excitation branch of the imaging setup was 
used as provided, without further calibration. The microscope 
features a zoom body (Olympus revolving zoom unit U-TV, 1×, 
2×, and 4×) equipped with an automated filter box for 25 mm 
mounted filters. An enhanced fluorescence acquisition branch 
consists of refractive-index-corrected long working distance 
objectives (Clear4brain, Munich): Olympus 2×/0.15 NA (WD 
10 mm), Olympus 4×/0.28 NA (WD 10 mm) and Olympus 
20×/0.45 NA (WD 5 mm). Making use of the entire scanning 
area, defined by the built-in scanner capabilities, we acquired tile 
scans to cover the entire specimens.
Imaging setup, laser-scanning confocal microscopy. Cleared 
specimens such as brain slices or whole organs were incubated in 
BABB-D solution for a minimum of 2 h. Samples were mounted 
on histological glasses using transparent silicone gel (OBI, 
4799656): a pool on glass was created with the glass as the bottom 
surface and silicone as walls, then samples were put into the pool 
filled with BABB-D. Eventually, glass coverslips were used 
to seal the pool, creating a closed chamber to prevent leakage 
of BABB-D.
Regions of brain slices were imaged with an inverted laser- 
scanning confocal microscopy system (Zeiss, LSM 880) using 
a 25× water-immersion long working distance objective lens 
(Leica, 0.95 NA, WD = 2.5 mm) mounted on a custom mounting 
thread. The z-step size was 3–5 µm, and whole stacks of the slices 
were acquired (Supplementary Table 2).
Imaging setup, fluorescence stereomicroscopy. Cleared and 
uncleared specimens such as brain slices, whole bodies, or organs 
were immersed either in BABB-D or in PBS, respectively, and 
imaged with Zeiss AxioZoom EMS3/SyCoP3 fluorescence ster-
eomicroscope using a 1× long working distance air objective lens 
(Plan Z 1×, 0.25 NA, WD = 56 mm; Supplementary Table 2).
Image processing. Processing and 3D rendering was executed 
by HP workstation with 8 core Xeon processor, 196 GB RAM, 
and Nvidia Quadro k5000 graphics card. We used Imaris, Amira, 
and Fiji (ImageJ2) for 3D and 2D image visualization. Stitching 
of tile scans was done via Fiji’s stitching plugin49. Stitched images 
were saved in tiff format to enable fast processing using different 
software. We removed acquisition errors using Fiji’s TrakEM2 
plugin and Imglib2 (ref. 50) library.
Image processing consists of three main steps: error correction, 
image quality enhancement, and quantification.
Error correction. (e.g., Fig. 3j) Errors in image acquisition and 
following steps may occur for various reasons, such as physical 
interference with the microscope during image acquisition or 
miscalibration of a dynamic plate of the microscope, resulting 
in unwanted shifting of tiles or drifting effects between different 
slices of the same image series.
Quality enhancement. (e.g., Fig. 5b) We used filtering tech-
niques (such as Gaussian, median, and anisotropic diffusion fil-
tering) in the spatial domain for noise reduction. Morphological 
filters were used to correct the artifacts based on their shapes. 
Owing to the big size of data sets, filtering in the frequency 
domain is not feasible. Image intensity manipulation and equali-
zation employed local (CLAHE in Fiji) and pseudo flat-field 
correction in Fiji (Supplementary Video 1).
Quantification. (e.g., Fig. 5c) To quantify the density of 
Qdot-positive BMSCs, we developed a simple workflow based 
on Fiji (Supplementary Figure 29).
Quantifications. Normalized fluorescence signal profile plots and 
total signal intensity.
Normalized signal profiles demonstrate the quality of the sig-
nal over the background, which defines the ability to trace the 
individual cellular structures in the scans (e.g., axon tracing in 
Supplementary Video 6). We calculated the total signal intensity 
to compare the remaining fluorescence signal after each clearing 
method. We presented details of these calculations with example 
images in Supplementary Figure 30.
For normalized signal profile measurement, a straight line 
was drawn across the specific area, which includes signal and 
background, and plotted via Fiji’s ‘plot profile’ option. To cal-
culate the mean background intensity, we chose another line 
adjacent to the profile line with no intersection to any specific 
signal. Subsequently, the profile plot was normalized by dividing 
the profile data over the calculated mean background intensity. 
Normalized profile of each sample was shown in the representa-
tive line chart (Supplementary Figs. 2,5,6 and 10).
For total signal intensity quantification, we selected a rectangu-
lar area covering the signal (several cellular structures), and mea-
sured the integrated density as the representative of the total signal 
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intensity of selected area. To calculate the mean background, a 
straight line was drawn across the area. Eventually, the total sum 
of the signal intensity in the sample area was determined as:
Sum of background intensity =  Number of background pixels 
+ Mean background value
Sum signal intensity =  Total sum of intensity of the area − Sum 
of background intensity
We calculated the average total signal intensity by dividing 
the sum of the signal intensity over the pixel number of the 
rectangular selection (Supplementary Figs. 2,5,6,9 and 10).
Signal-to-noise ratio (SNR). A small part of the image was 
selected, and pixels belonging to a specific signal were separated 
from the background by thresholding the input image, f, and 
applying the binary image as the mask to the same image. 
f n m S o p X i j( , ) ( , ) ( , )= +  
o i p j≠ ≠,
S is the image that contains only the specific signal, and X is the 
background image. SNR was calculated based on Jahr et al.51 
SNR Mean Std= ( )/ ( )S X
Peak signal-to-noise ratio (PSNR). PSNR was calculated as previ-
ously described52. In brief, we used a mean square error (MSE) cal-
culation between the sample image and a reference image. We took 
the average intensity of the background pixels as the reference image 
without the noise. Then, we calculated the MSE and PSNR as: 
MSE
N M
X i j Y i j
j
M
i
N
= −
=
−
=
−
∑∑1 2
0
1
0
1
*
[ ( , ) ( , )]
Y is the reference image with N × M dimension. 
PSNR
MAX
MSE
= 

20 10* log
MAX represents the maximum intensity of the input image f in 
the selected neighborhood.
RMSE calculation. The root mean square (RMS) of the morphol-
ogy deformation error at single-cell scale was used as a quantification 
factor for isotropy. RMSE calculation includes three steps: 1) 
Postclearing and preclearing images of a single cell were regis-
tered by similarity transformation in Fiji’s TrakEM2 plugin. To 
achieve perfect overlay, output images from step 1 were registered 
with nonrigid transformations using Fiji’s bUnwrapj plugin53. 2) 
The deformation parameter for preclearing image pixels was 
masked with a skeletonized preclearing image to remove irrel-
evant deformation parameters. 3) RMS of the deformation error 
with respect to the distance from the center of the cell or vessel 
(constant point) was calculated37.
Fluorescence level. Fluorescence level quantification was 
expressed as a signal-to-background ratio and was calculated 
using Fiji at the following timepoints after clearing: 0, 4, 7, 19, 
and 37 d (Fig. 1b). From each brain scan, a z-projection of three 
consecutive images in Tiff format was made at the same anatomic 
region for all the samples. The mean value of the background 
for each z-projection was obtained by averaging the background 
values of 15–20 regions from equally sized areas of the projection 
without signal. To calculate the mean value of the signal of each 
z-projection, we used the threshold function of the software; the 
threshold was adjusted to consider the fluorescence signal visible 
in the projection. After adjusting the threshold, only the sharp 
signal from specific cellular structures was analyzed per each 
z-projection. To this end, we used Fiji’s “analyze particles” to 
measure the signal intensity only of particles sized between 10 
and 150 pixels (visible fluorescent cells), and we calculated the 
mean value from all the particles. Next, this value was divided by 
the mean value of the background of the respective projection, 
obtaining the fluorescence level on the background.
Imaging depth quantification. To assess the imaging depth between 
different clearing methods (CUBIC, PARS, PACT, and uDISCO), 
the tile scans of three whole brains per clearing method were 
taken with a light-sheet microscope with 4 µm z step (in Fig. 1h,i, 
and Supplementary Fig. 11). 3D reconstructions at the same 
anatomic level (from the surface of the brain to the center of 
the brain, including the region of the hippocampus) of each 
sample were shown in the coronal view using Imaris. Next, the 
images of the 3D reconstructions were analyzed in Fiji. Using 
the scale bar provided by Imaris, the distance of imaging depth 
was measured from the surface (where the signal was sharp) 
to the inner part of the brain until the last identifiable signal 
over the background coming from cell body or cellular structure 
(e.g., axons or dendrites) was detected.
Statistical analysis. Data are presented as mean ± s.d. in Figures 
1b–d,h,i;3i;6h,n and in Supplementary Figures 4,7b,8c,11b,12e, 
13s,25i,26. Data are presented as mean ± s.e.m. in Figure 5c and 
in Supplementary Figures 2c,5h,6h,9g,10h. The data distribution 
in each experiment was checked for normality using Shapiro–Wilk 
test in IBM SPSS statistics software. P values were calculated using 
unpaired t-test to compare data between two groups (Supplementary 
Figs. 2c,4,8c,25i). One-way ANOVA was used to compare more 
than two groups of data (Fig. 1b–d,h,i; and Supplementary 
Figs. 5h,6h,9g,10h,11b,12e,13s); if ANOVA was significant, it 
was followed by post hoc Dunnett’s test for multiple comparisons 
(Figs. 1b–d,h,i and Supplementary Figs. 5h,6h,9g,10h,11b).
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 Supplementary Figure 1: Whole-body clearing and imaging of adult mice with 3DISCO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Whole-bodies of adult GFP-M mice (3 months old) were cleared with 3DISCO (same protocol as used in uDISCO). 
Before (a) and after (b) 3DISCO whole-body clearing images of a representative mouse body. 3DISCO whole-body 
clearing provided a comparable optical transparency to uDISCO (see Fig. 2b). (c-g) In contrast, preservation of 
endogenous GFP signal was weak after 3DISCO whole-body clearing. (c) Fluorescence stereomicroscope acquisition 
could not detect any identifiable neuronal structures unlike the uDISCO sample (see Fig. 2c). (d-g) Light-sheet 
microscopy of entire GFP-M mouse brain after 3DISCO whole-body clearing. While a weak GFP signal remained in 
some cell bodies, neuronal projections were completely undetectable due to diminished signal after 3DISCO whole-body 
clearing (see Fig. 4c-f). 
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 Supplementary Figure 2: Fluorescence signal quality comparison after whole body uDISCO and 3DISCO clearing  
 
Representative light-sheet microscopy images of GFP-M brains at 2.5 mm depth from the dorsal surface after whole-body 
uDISCO (a) or 3DISCO (b) clearing. (c) Signal intensity (calculations are explained in Methods and Supplementary Fig. 
30) comparison after whole-body uDISCO and 3DISCO clearing. Statistical significance (***P < 0.001) was assessed by 
unpaired t-test at each brain region. Values are mean ± s.e.m.; n=3 brains for each group (3 months old GFP-M mice). (d) 
Normalized signal profiles (calculations are explained in Methods and Supplementary Fig. 30) after whole body uDISCO 
and 3DISCO clearing at different depths (distance from brain surface) to compare the fluorescence signal: cortex (0.5 
mm), hippocampus (1.2 mm), corpus callosum (2.5 mm) and midbrain (4.0 mm); n=3 brains for each group plotted (each 
magenta or green line profile represents one brain). 
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Supplementary Figure 3: The details of chemicals used in 3DISCO and uDISCO  
 
Tetrahydrofuran (THF) used in dehydration step of 3DISCO has an ether functionality, which is prone to oxidation and 
further reactions. In contrast, tert-butanol used in uDISCO is a tertiary alcohol and more stable to oxidation and less 
reactive. 3DISCO utilizes dibenzyl ether (DBE) or BABB (benzyl alcohol and benzyl benzoate) in refractive index 
matching step. Both of these chemicals have reactive benzylic C-H and C-O bonds, hence, they can form peroxidase and 
quench the fluorescence signal. To reduce chemical interactions that could diminish the endogenous fluorescence signal in 
uDISCO, 1) we performed refractive index matching in the presence of diphenyl ether (DPE): DPE does not have reactive 
benzylic C-H and C-O bonds, therefore, it is less prone to radical and other oxidative reactions; 2) we used antioxidant 
vitamin E to scavenge further the peroxides that can destroy the fluorescent proteins. 
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 Supplementary Figure 4: Endogenous fluorescent signal stabilization in uDISCO  
 
 
We measured the fluorescence signal of the same uDISCO and 3DISCO samples presented in Fig. 1b, 3 months after the 
clearing. We observed some decrease in signal level within the first few weeks (most probably due to the further 
dehydration of tissues in final clearing solutions), which got stabilized after about a month. At all-time points the level of 
fluorescence after uDISCO was higher compared with the level of fluorescence after 3DISCO. Values are mean ± s.d.; 
n=3 and 4 mice for uDISCO and 3DISCO, respectively. Statistical significance (*P < 0.05, **P < 0.01, ***P < 0.001) 
was assessed by unpaired t-test. 
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 Supplementary Figure 5: Fluorescence signal quality comparison after uDISCO, 3DISCO, 1-proponal BABB, 
PACT, CUBIC, ScaleS and SeeDB clearing in Thy1-GFP-M mice 
Representative images of normalized signal profiles at 0.5 mm and 2.5 mm depth from the dorsal surface after uDISCO 
(a), PACT (b), CUBIC (c), 3DISCO (d), 1-proponal BABB (e), ScaleS (f) and SeeDB (g) clearing of GFP-M brains. 
Normalized signal profile for each sample demonstrates the dynamic range of the obtained signal, which is the primary 
parameter for the tracing of imaged structures (separation of specific signal from the background). (h) Quantification of 
total signal intensity on specific cellular structures (cell bodies) at different depths (0.5 mm and 2.5 mm) of the samples 
after respective clearing (see the Methods and Supplementary Fig. 30). uDISCO cleared brains resulted in greater signal 
intensity compared with other methods. Statistical significance (***P < 0.001) was assessed by one-way ANOVA 
followed by Dunnet’s post-hoc test. Values are mean ± s.e.m.; n=3 brains for each group (3 months old GFP-M mice). 
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 Supplementary Figure 6: Fluorescence signal quality comparison after uDISCO, 3DISCO, 1-proponal-BABB, 
PACT, CUBIC, ScaleS and SeeDB clearing in CX3CR1-GFP mice  
Representative images and normalized signal profiles at 0.5 mm and 2.5 mm depth from the dorsal surface after uDISCO 
(a), PACT (b), CUBIC (c), 3DISCO (d), 1-propanol BABB (e), ScaleS (f) and SeeDB (g) clearing of CX3CR1-GFP 
brains. In all cases, regions at the same depth and anatomical locations were quantified. Note that tissue shrinkage by 
uDISCO allowed visualization of larger volumes with the same imaging parameters, while tissue expansion e.g. by PACT 
allowed visualization of more details as cells appear larger. (h) Signal intensity quantifications at different depths of the 
samples after respective clearing. While uDISCO showed comparable results to PACT and CUBIC clearing, it has 
outperformed 3DISCO, 1-propanol BABB, ScaleS and SeeDB at deeper brain regions (2.5 mm depth). Statistical 
significance (*P < 0.05, **P < 0.01) was assessed by one-way ANOVA followed by Dunnett’s post-hoc test. Values are 
mean ± s.e.m.; n=6 brains for uDISCO group, n=3 brains for each other group (3 months old CX3CR1-GFP mice). See 
also Supplementary Video 1.   
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 Supplementary Figure 7: Clearing performance of uDISCO for dissected organs and shrinkage quantifications  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) Individual organs before and after uDISCO clearing. They became optically transparent after uDISCO clearing. The 
redness after the clearing is due to the residual blood, which did not impede the imaging of fluorescent structures as 
shown in Fig. 5 and Supplementary Fig. 22. (b) Volume quantifications of individual organs, showing that brain, spinal 
cord, heart, lungs, kidneys, gut, liver and bones shrank in average 50.54%, 45.92%, 30.22%, 46.85%, 64.94%, 53.44%, 
51.76% and 8.08%, respectively. Values are mean ± s.d.; n=4 mice (5 months old) for each organ. 
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 Supplementary Figure 8: uDISCO clearing resulted in similar shrinkage of hard bone and bone marrow 
 
(a) Femurs from 6 months old CX3CR1-GFP mice were cut into half for visualization of hard bone (red arrowheads) and 
bone marrow regions (purple arrowheads). (b) Same bones are shown after uDISCO clearing. (c) Quantification of 
diameter change before and after uDISCO clearing: the shrinkage rate was slightly higher for bone marrow regions, even 
though it did not reach statistical significance (unpaired t-test, n.s. = P > 0.05). Values are mean ± s.d.; n=3 bones. (d) 
Illustration of how the quantification is performed: 1) the bone images before and after clearing were overlapped with 
each other, 2) 3 lines were drawn at different positions along the bone, and 3) the diameter change of the same hard bone 
(white line) and bone marrow (red line) regions were calculated at these three different axes using ImageJ. 
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 Supplementary Figure 9: Different clearing protocols on intact bones: assessment of endogenous GFP signal in 
CX3CR1-GFP mice 
The bones from CX3CR1-GFP transgenic mice were cleared by uDISCO, Murray’s clear and CUBIC methods. Maximum 
intensity projections at 0.4 mm and 0.66 mm depth from the bone surface for uDISCO (a,b), Murray’s clear (c,d), and 
CUBIC (e,f) protocols are shown. (g) Quantification of total signal intensity through the bones; statistical significance 
(***P < 0.001) was assessed by one-way ANOVA followed by Dunnett’s post-hoc test; values are mean ± s.e.m.; n=8 
ROI in uDISCO bones, n=5 ROI in Murray’s clear and CUBIC bones (5 months old CX3CR1-GFP mice).  
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 Supplementary Figure 10: Test of IHC with different bone clearing protocols  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3D reconstruction of CX3CR1-GFP mice bones after (a) uDISCO, (b) Murray’s clear and (c) CUBIC clearing. The bones 
were immunolabeled with AlexaFluor-647 conjugated anti-GFP rabbit polyclonal antibody before clearing. (d-f) 
Projections at 0.66 mm depth (~half-way through the cut bone) showing the signal quality after respective clearing. (g) 
Normalized signal profile plots of AlexaFluor-647 positive cells in uDISCO (magenta line), Murray’s clear (green line) 
and CUBIC (blue line) cleared cut bones. (h) Quantification of signal intensity of antibody labeling in the bones after 
respective clearing. Statistical significance (***P < 0.001) was assessed by one-way ANOVA followed by Dunnett’s 
post-hoc test. Values are mean ± s.e.m.; n=8 ROI in uDISCO and Murray’s clear cut bones; n=5 ROI in CUBIC cut bone 
(5 months old CX3CR1-GFP mice). 
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 Supplementary Figure 11: CUBIC PARS/PACT uDISCO size and imaging comparison 
 
(a) 3D reconstruction of brains after CUBIC, PARS and uDISCO whole-body clearing. Imaging depth quantifications on 
brains in (a) are shown in Fig. 1h. (b) Volume changes of brains of 4 months old GFP-M mice after CUBIC, PARS and 
uDISCO whole-body tissue clearing methods. The final brain volume after uDISCO was significantly lower than after 
CUBIC and PARS whole-body clearing. Statistical significance (***P < 0.001) was assessed by one-way ANOVA 
followed by Dunnett’s post-hoc test. Values are mean ± s.d.; n=4, 3, 3 GFP-M mice for CUBIC, PARS and uDISCO, 
respectively. (c) 3D reconstruction of brains after CUBIC, PACT and uDISCO passive tissue clearing of dissected brains. 
Imaging depth quantifications on brains in (c) are shown in Fig. 1i. With the same imaging settings at a single scan, more 
neurons can be imaged with uDISCO (owing to shrinkage) while more detailed structures of individual neurons can be 
resolved by PACT and CUBIC (owing to expansion) (see also Fig. 1g). 
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 Supplementary Figure 12: Comparison of gross tissue structures before and after uDISCO clearing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 mm coronal brains slices from GFP-M mice (5 months old) at different levels were imaged with a fluorescence 
stereomicroscope before (a) and after (b) uDISCO clearing. The borders of main structures before and after clearing are 
highlighted in orange and blue, respectively. (c) The overlay of borders by ratio-metric enlargement of shrunken tissue 
shows a substantial overlap. (d) To quantify the proportions of size change on same the slice, we assessed the width of 
different brain regions (indicated by numbered lines) before and after clearing. (e) The quantifications showed that 
different tissue regions shrank at a similar rate (~30%) in length after clearing (one-way ANOVA, n.s. = P > 0.05). Values 
are mean ± s.d.; n=4, 4, 3, 4, 4 for regions 1, 2, 3, 4, 5, respectively.  
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 Supplementary Figure 13: Microscale changes of different cells and tissues before and after uDISCO clearing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To assess the uniformity of shrinkage on different types of cells and tissues, we measured shrinkage of neurons, microglia 
and vessels with respect to each other. To this end, we immunolabeled 1 mm thick GFP-M brain slices (from 2 months old 
mice) with Iba1 (microglia) and Collagen4 (vessels) and acquired confocal images before and after uDISCO clearing. (a-
i) Single channel views from the same tissue location containing neurons (a-c), microglia (d-f) and vessels (g-i). Overlay 
channels show a substantial overlap of before and after images. (j-r) Double channel views from the same tissue location 
demonstrating neurons-microglia (j-l), neurons-vessels (m-o) and microglia-vessels (p-r) together. To simplify the 
interpretation of overlay channels, we used only two colors (red and cyan) and swapped the colors before and after 
clearing channels, resulting in white color for overlay of tissue components. (s) The distances between neurons-neurons, 
microglia-microglia, vessels-vessels, neurons-microglia, neurons-vessels and microglia-vessels were measured before and 
after uDISCO and normalized to the rate of gross shrinkage of the slice (n=7 per each tissue structure/cell type from at 
least 3 different slices). The quantification showed that the relative distances between the structures and cells were not 
significantly changed after clearing (one-way ANOVA, n.s. = P > 0.05). Values are mean ± s.d. 
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 Supplementary Figure 14: Comparison of single cells and vessels before and after uDISCO clearing 
Confocal images of 1 mm coronal brains slices from GFP-M mouse (2 months old) before and after uDISCO clearing, 
showing individual neurons (a), Iba1 stained microglia (b), and Collagen4 stained vessels (c). The overlay after ratio-
metric enlargement of shrunken cells and vessels shows a substantial overlap suggesting that individual cell morphology 
is preserved after uDISCO clearing. Note that more structures are visible after clearing (cyan in “after” and “overlay” 
images). (d) Quantifications of RMSE to evaluate the degree of morphological deformations for neurons (left), microglia 
(middle) and vessels (right). After defining a center of a cell or a structure as the constant point, displacements of cellular 
and vascular structures before and after clearing have been plotted with regular intervals from the center point. The degree 
and direction of regional deformations are shown with arrows in overlay images (n ≥ 6 cells from at least 3 different slices 
and n ≥ 3 vessel structures from at least 3 different slices). Values are mean ± s.e.m. 
 
Nature Methods: doi:10.1038/nmeth.3964
 Supplementary Figure 15: Details of light-sheet microscope and sample holders for whole mouse body imaging 
 
(a) LaVision Biotec light-sheet ultramicroscope featuring: (1) Andor Neo 5.5 sCMOS camera; (2) Olympus U-TVCAC 
revolving zoom unit enabling 1x, 2x, 4x additional magnification with a fourth slot for a shutter plate; (3) LaVision 
autofocusing unit for automatic focus correction at different wavelengths; (4) filter box with 8 slots for 25 mm mounted 
filters; (5) BABB corrected Olympus objective; (6) imaging chamber, where LaVision Biotec suspension trays for sample 
holders are placed; (7) fiber coupled laser outlet for supercontinuum laser (SuperK EXTREME EXW 9 - 450-1000); (8-9) 
beam profile generation units. (b) Half of the central part of the commercial sample holder suspension (LaVision Biotec) 
is cut to make space, which allows flexible positioning of the mouse body at the center of the imaging beam. Silver plated 
copper wires are used to secure the mouse (c) to the branches of the suspension by its fore- and hind-limb (green 
arrowheads). (d) View of cleared adult mouse body immersed in the imaging chamber. Note that there is a large space left 
from the sleek immersion objective (Olympus air immersion corrected for RI 1.56), which facilitates the repositioning of 
the mouse in the chamber. (e) Demonstration of laser light sheets crossing the cleared mouse body. After imaging a region 
(f), the mouse is repositioned (g) so that next body part is now in the center of imaging area (purple rectangles). 
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 Supplementary Figure 16: Details of customized sample holders for individual brain and other organs 
(a) To allow maximum flexibility, we used 0.33 mm thick fine needles (BD Micro-Fine Ultra, 325118) in combination 
with commercially available sample suspension (Lavision Biotec). The plastic cup is trimmed (b, arrow) to avoid contact 
with the bottom of the imaging chamber. The needle is inserted into the hole of sample holder and bent as shown (b, 
arrowheads). (c) An example of an uDISCO-cleared brain secured to the fine needle: the resinous consistency of uDISCO 
cleared brains allows a clean piercing that is not visible in the sample once imaged, owing to the multiple sheets coming 
from different angles and compensating for cast shadows. (d-f) Variation of customized sample holders for long 
specimens, such as entire CNS (brain and spinal cord together). To this end, in addition to the fine needle holding the 
brain, we used a cooper wire to stabilize the long spinal cord. The copper wire is prepared as follows: first, we inserted it 
into a Pasteur pipette tube (d, arrowheads) and into the hole of suspension. Finally, we looped the ends as shown (e, 
arrows). The brain is imaged first while the spinal cord lies in a loop of the wire to keep it at a suitable height. After 
imaging, the sample is swept along its axis (f, arrow), so that a different part of the unsectioned CNS can be imaged, until 
completion. (g-i) Customized sample holders for specimen clarified with water-based clearing methods. If the samples 
have jelly-like textures, they cannot be held in place with fine needles. Instead, we trimmed a plastic Pasteur pipette as 
shown (g, arrowhead) and glued the specimens on top (h,i, arrows). A mounted CUBIC brain is shown from the side (h) 
and bottom (i). 
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 Supplementary Figure 17: 10 mm depth z-scan across rodent body parts after uDISCO clearing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3D Volren surface reconstructions (red-orange) of 10 mm z-scans obtained by light-sheet microscopy. An ortho-slice 
(black-white) is shown in the corner-cut view (Amira software) to demonstrate the details throughout the scans. (a-c) 
Different body parts of the whole-body light-sheet microscopy scanned mouse in Fig. 2d: the pelvic area (a), hindlimb (b) 
and the head (c); voxel size: 1.625 x 1.625 x 6 µm. (d) A 10 mm z-scan through vasculature labeled (FITC-lectin) mouse 
brain; voxel size: 1.625 x 1.625 x 4 µm3. (e) 10 mm z-scan through the shoulder of a vasculature labeled (Texas Red) 
adult rat. Vessels and fine structure are well defined. 
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 Supplementary Figure 18: Rat organs after uDISCO clearing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Grid images of individual organs from rat after whole-body uDISCO clearing, showing that the heart, liver, kidney, lung 
and intestine were rendered optically transparent. The redness after the clearing in liver and kidney images is due to the 
residual blood. 
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 Supplementary Figure 19: BMSCs characterization 
 
Characterization of β-actin EGFP BMSCs loaded with Qdots. (a) Representative picture of BMSCs (passage 4-5) that 
were harvested for IV transplantation (arrowheads mark some of the BMSCs). The purple insert shows the EGFP+ cells 
(superimposed image of wide-field and GFP channels). (b-d) The osteogenic (b), chondrogenic (c) and adipogenic (d) 
potential of the BMSCs confirms their mesenchymal origin. (e) BMSCs loaded with Qdots, shown as red cytoplasmic 
aggregates (superimposed image of wide-field and Qdot channels). (f) FACS characterization of the EGFP+ and Qdot+ 
BMSCs before their harvest for transplantation. (g) BMSCs were sca1+, CD34-, CD45- and CD11b- while expressing 
medium levels of CD105 and CD90.2 as characterized by FACS; the population only contained a small fracture of 
CD11b+ and CD45+ monocytes, as expected. (h,i) Colocalization of GFP and Qdot signals in cleared lungs from animals 
injected with BMSCs, imaged by confocal microscopy. White and magenta rectangles show high-magnification single 
channel images (EGFP (green), Qdot (magenta)) of dashed marked regions in the same images. 
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 Supplementary Figure 20: Whole-body clearing and imaging of mouse after BMSCs transplantation 
 
BMSCs were collected and labeled with Qdots, then transplanted into 2 months old C57BL/6N mice through IV injection. 
The mice were transcardially perfused and cleared with uDISCO. The intact mouse bodies could readily be screened by 
fluorescent stereomicroscope (a-c). (d) Whole-body stereomicroscope imaging of intact host mouse body. The individual 
cells were identifiable throughout the body, e.g. in the lung (e), liver (f) and bone marrow (g). No BMSCs were detected 
in the brain as expected (h).   
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 Supplementary Figure 21: 3D reconstruction of internal organs from intact mouse transplanted with Qdot labeled 
BMSCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Light-sheet microscopy images from intact mice, which were transplanted with Qdot loaded BMSCs. (a) Lungs, liver 
layers, right kidney and part of the intestine shown in 3D surface rendering view. (b-d) The projection images of regions 
marked in (a): lung (b), upper liver layer (c) and intestine (d). (e) 3D surface reconstruction of lungs from another mouse. 
(f) The projection image of region marked in (e). 
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 Supplementary Figure 22: Distribution of mouse BMSCs in kidney, spleen and intestine 
 
Images of kidney, spleen and intestine from host mice in control, IP and IV groups. We found a sparse distribution of 
Qdot positive BMSCs throughout the kidney, spleen and intestine in both IP and IV groups  
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 Supplementary Figure 23: AVV tracing of whole adult mouse CNS 
 
 
Individual channels of traced adult mouse CNS (a) shown in Fig. 6. AAV-syn-GFP signal in the entire CNS is shown in 
(b), AAV-syn-RFP signal in (c). 
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 Supplementary Figure 24: Microglia/macrophage IHC on mouse brain 
 
Iba1 and TO-PRO-3 labeling of coronal sections from the cortex of 4 months old mouse brain. (a-c) 3D reconstructions 
showing the homogeneous labeling of microglia and cell nuclei stained with Iba1 antibody (a) and TO-PRO-3 (b) and 
their merge (c). (d,e) Maximum intensity projections of the z-positions marked by purple boxes in (c); microglia are 
shown in red and TO-PRO-3 staining in cyan. 
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 Supplementary Figure 25: Microglia/macrophage IHC on short and long-term formalin-fixed human clinical tissue 
slices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Iba1 and TO-PRO-3 labeling of short-term (1-month) (a-d) and long-term (14-months) stored (e-h) clinical cortical tissue 
samples of human brains. 3D reconstructions showing the homogeneous labeling of microglia (Iba1) (a,e) and cell nuclei 
(TO-PRO-3) (b,f) and their merge (c,g) throughout the 1 mm human tissue samples stored short-term (a-c) or long-term 
(e-g). (d,h) Maximum intensity projections of the z-position marked by the purple box in (c,g), respectively. Nuclei are 
shown in cyan, microglia and their processes are in red. All the images were taken by confocal microscopy with 3-4 µm z-
steps. (i) Fluorescence level quantification. Antibody (microglia) and dye (cell nuclei) labelings were complete and 
specific on both short-term and long-term stored human clinical tissue samples even though the fluorescence level was 
significantly lower in long-term stored tissues, mostly owing to the increased background in long-term storage. Note that 
the 1-month fixed sample was obtained from an individual without any obvious brain pathology reported vs. the 14-
months fixed sample from an individual who suffers from obesity. Values are mean ± s.d.; n=6, 4 slices for short-term 
fixed samples and long-term fixed samples, respectively. Statistical significance (**P < 0.01) was assessed by unpaired t-
test. 
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 Supplementary Figure 26: SNR and PSNR in uDISCO cleared samples 
 
 
Signal-to-noise ratio (SNR) (a) and peak signal-to-noise ratio (PSNR) (b) range at different depths for uDISCO clearing 
as assessed on 3 months old GFP-M mice. Lines represent mean ± s.d.; n=3 brains for each group. The exact formulas and 
more details are given in the Methods part.  
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 Supplementary Figure 27: Different objectives in BABB-D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The quality comparison of four commercially available objectives (as indicated in the respective images) in BABB-D (RI 
1.56) after uDISCO clearing of GFP-M brains. All images were generated using light-sheet microscopy at 1.5 mm depth 
from the cortex surface. It is worth mentioning that the water (a) and CLARITY (b) corrected objectives (therefore not 
corrected for BABB-D refractive index) generated comparable quality images to BABB corrected objectives (c,d). NA = 
numerical aperture, WD = working distance, RI = refractive index. 
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 Supplementary Figure 28: The transcardiac circulatory system for uDISCO whole body tissue clearing 
 
(a) Components of the circulation loop: 2x Viton reference tubing (Gilson, F1817745) (blue arrow), 4x tubing connectors 
(Omnilab, 5434482) (red arrow), 4x PVC tubing for extension (Omnilab, 5437920) (orange arrow), 1x transcardiac 
perfusion needle (Leica, 39471024) (green arrow), 1x needle connector cut from 1 ml syringe (Braun, 9166017V) (black 
arrow). The red box shows the connection of each Viton tubing ending indicated in (b). (b) A completed setup of the 
transcardiac circulatory system. Green dash highlights the first channel for pumping the clearing solution through whole 
mouse body. The yellow dash shows the second channel for collecting and recirculating the solution back to the original 
bottle. (c) Insert the cutting connector (black arrow) into the outflow tubing of the pumping channel (orange arrow) and 
fix it with a transcardiac perfusion needle (green arrow). After pushing the air bubble out of the tubing system, the animal 
is placed in the glass clearing chamber and the perfusion needle is inserted into the left ventricle of the heart. 
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 Supplementary Figure 29: Workflow for cell counting 
 
To count the number of bone marrow stem cells (BMSCs), we used publicly available ImageJ and its plugins as detailed 
below. Here we showed each step of the analysis on a sample image (a single optical section from a liver scan at 1.62 
x1.62 x 12 µm voxel size). 1) To improve the background, we used convoluted median background subtraction option in 
BioVoxxel plugin. This plugin works fast, and removes the background smoothly in our samples because of low artifacts. 
2) Median filtering was performed to remove artifacts coming from background subtraction. In this filtering, the radius is 
equal to the smallest object to be maintained (4 µm in our example). 3) Unsharpen mask was used when the signal-to-
background ratio was lower than 2. In this mask, R stands for the average radius of the cells (6 um in our example). 4) To 
remove all the artifacts smaller than the cells, we used Grayscale opening morphological filter option in MorpholibJ 
plugin. In this filter, R is the radius of the biggest object to be removed (3 µm in our example) and disk option was used as 
structuring elements. 5) To decrease complexity of the quantification, we converted processed images to binary images by 
thresholding. To perform automatic thresholding, we used Otsu Limited function in DeadEasy plugin, which can perform 
multi-level thresholding. In addition, watershed can be used to separate the connected cells in densely labeled samples 
(this step was not performed in the example above because of sparse distribution). 6) Finally, detected cells were overlaid 
with the original data to check accuracy of the cell detection.   
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 Supplementary Figure 30: Methods for normalized signal profile and intensity quantifications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Fiji (ImageJ2) software, a straight line was drawn across the specific signal spots and the plot profile of the signal was 
measured (a). Another straight line was drawn across the background area close to the specific signal spot to measure the 
mean value of the background (red box) (b). Next, the profile was divided by the selected background value and 
normalized profile of each sample was shown in the representative line chart (Supplementary Figs. 2, 5, 6, and 10). For 
signal intensity quantification, a rectangular selection covering the signal spot (a specific cellular structure) was made 
within the defined region and the integrated density of the signal was recorded (purple box) (c). A straight line was drawn 
across the background area close to the signal spot and the mean gray value of the background was measured (blue box) 
(d). (e) Formula for the signal intensity: 1) the total mean value of the background of the rectangular selection was 
subtracted from the integrated density of the signal to get the total signal density in the rectangular selection, and 2) the 
average intensity of the signal without background was calculated by dividing the total signal density with the pixel 
number of the rectangular selection (green box) (Supplementary Figs. 2, 5, 6, 9 and 10). 
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Supplementary Protocol 
Perfusion and tissue preparation 
Before intracardial perfusion, anesthetize the animals deeply with a combination of anesthetics, such as 
midazolam/medetomidine/fentanyl (MMF) (1ml/100g of body mass for mice).  
1. Transcardially perfuse the animals (e.g. using Leica perfusion one system at 100-125 mmHg pressure) 
first with heparinized (10U/ml of Heparin, ratiopharm GmbH, N68542.03) 0.1 M PBS for 5-10 minutes 
then with 4% paraformaldehyde (PFA, Morphisto, 11762.01000) in 0.1 M PBS for 20 minutes at room 
temperature.  
TIP: Skipping the Heparin when vasculature is labeled can increase the quality of labeling. For all 
perfusion steps, the needle should be placed and kept in the left ventricle of the heart and should not 
cross to the right side of the heart.  
2. For whole-body clearing, remove the skin and carefully open the skull and vertebra without damaging 
the CNS tissue. At this point, the whole body clearing can be performed immediately, or the mouse body 
can be stored in 0.1M PBS at 4 °C up to 4 weeks. For clearing dissected organ, collect the tissues directly 
and post-fix them in 4% PFA for 1-2 days at 4°C. Wash the samples once in 0.1M PBS for 5 min before 
clearing. 
 
Preparation of uDISCO solutions  
1. Prepare tert-butanol (Sigma, 360538) solutions with distilled water at 30 Vol%, 50 Vol%, 70 Vol%, 80 
Vol%, 90 Vol%, 96 Vol% and 100 Vol% for gradient dehydration.  
2. Use Dichloromethane (DCM) (Sigma, 270997) as a pure solution, for delipidation step.  
3. Prepare refractive index matching solutions by mixing BABB (benzyl alcohol + benzyl benzoate 1:2, 
Sigma, 24122 and Sigma, W213802, respectively) and diphenyl ether (DPE) (Alfa Aesar, A15791) at 
following ratio: BABB-D4, BABB:DPE at a ratio 4:1 (Vol/Vol); BABB-D10, BABB:DPE at a ratio 10:1 
(Vol/Vol); BABB-D15, BABB:DPE at a ratio 15:1 (Vol/Vol). Add 0.4% Vol vitamin E (Alfa Aesar, 
A17039) into BABB-D solutions to scavenge the peroxides. 
Tert-butanol is flammable, DCM is toxic and BABB-D components can cause skin irritation, therefore they 
should be handled carefully. Waste should be treated and discarded accordingly. 
 
uDISCO passive clearing procedure for dissected organs 
All incubation steps are performed in a fume hood with gentle rotation or shaking using 5 ml tubes (Eppendorf, 
0030 119.401) for whole mouse brain or smaller samples, or using 80 ml glass chambers (omnilab, 5163279) 
for bigger samples such as rat tissues or whole brain + spinal cord. The samples are covered with aluminum foil 
to keep them in dark.  
1. Incubate the fixed samples in 30 Vol%, 50 Vol%, 70 Vol%, 80 Vol%, 90 Vol%, 96 Vol% and 100% 
tert-butanol for 2-12 hours at 34-35°C (Supplementary Table 1).  
2. Incubate in DCM for 45-60 minutes at room temperature (small tissues such as mouse spinal cord or 1 
mm thick coronal slices can skip this step). 
3. Incubate in BABB-D for 2-6 hours until the samples become optically transparent. 
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TIP: The higher amount of DPE in BABB yields better signal preservation (e.g. BABB-D15), while the 
lower amount of DPE in BABB results in higher transparency (e.g. BABB-D4). We recommend to use 
BABB-D4 for small tissues e.g. spinal cord or tissue slices, and BABB-D15 for large tissues e.g. for rat 
brain clearing. For whole-body clearing with perfusion system, use BABB-D10.  
4. Samples can be stored in BABB-D at room temperature in the dark for several weeks. TIP: It is 
recommended to image sample as soon as possible to yield the best outcome.  
 
uDISCO whole-body clearing procedure with perfusion system 
Establish the transcardial-circulatory system as in Supplementary Fig. 28. Here, we used a peristaltic pump 
(Gilson, Peristaltic Pump MINIPULS 3) with one pumping channel (green dash line) and one recirculating 
channel (yellow dash line). All steps should be performed in a fume hood. 
1. Connect the Viton reference tubing to the peristaltic pump.  
TIP: As the clearing solutions can be corrosive to various tubing material, we recommend usage of 
Viton tubing (Gilson, F1817745).  
2. Insert the tubing connectors (Omnilab, 5434482) (red arrow) at each end of the Viton tubing (blue 
arrow). 
3. Connect the tubing connectors (red arrow) with additional PVC tubing (Omnilab, 5437920) for 
extension (orange arrow).  
TIP: Transparent PVC tubing, which is compatible with clearing solutions, helps for checking unwanted 
air bubbles in the tubing system. 
4. Cut the head part of the 1 ml syringe (Braun, 9166017V) as a connector (black arrow) and insert it into 
the outflow tubing of the pumping channel (orange arrow).  
5. Connect the transcardiac perfusion needle (Leica, 39471024) (green arrow) for mouse or the thinnest 
perfusion needle (Leica, 39471022) without rubber head for rat with this connector. Subsequently, fix 
the inflow tubing of the recirculating channel in the glass chamber containing animal body ready for 
clearing.  
TIP: Fix the tubing with tapes (any kind). Keep a certain height between the inflow tubing head and 
bottom of the glass chamber to ensure that the sample is covered by clearing solutions during clearing at 
all times. 
6. Keep the inflow tubing of the pumping channel beneath the surface of the clearing solution and start the 
circulation until air bubbles are pushed out from the tubing system. 
TIP: Avoid pumping air bubbles by keeping the tubing always immersed into solution while pumping.  
7. Set the perfusion needle into the heart of the animal through the same pinhole made during perfusion 
and circulate the clearing solutions one by one as indicated in Supplementary Table 1.  
TIP 1: When starting the circulation, it might be visible that some ripples occur beside the right atrial 
appendage because the PBS in the sample is pushed into 30 Vol% tert-butanol solutions. This would be 
a good signal that the pumping is working appropriately. If not, try to change the angle of the perfusion 
needle to reach the best position and fix it with tapes. Because of the shrinkage during dehydration, the 
needle should stay in the heart without slipping out. 
TIP 2: Stop the pump temporarily when changing the clearing solutions between steps. Collect the last 
solution back to the bottle by using a serological pipette and fill the glass chamber with the next solution 
quickly to minimize exposure to air. Because serological pipettes are not stable in BABB-D, use them 
only in the prior steps. Hold the inflow tubing ending of the pumping channel carefully to avoid any air 
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bubble and put it beneath the surface of next solution. If there are large air bubbles within the tubing, 
they can be eliminated by a brief run of the pump in the reverse direction.  
TIP 3: As the melting point of tert-butanol is between 23 and 26 °C (close to room temperature), use a 
heating plate at 35-40 °C for 100% tert-butanol circulation steps to prevent the solution from 
solidification. 
TIP 4: The amount of solutions for circulation depends on the capacity of the clearing chamber and the 
size of the animal that is being cleared. For example, for mice, a 400 ml capacity glass chamber with 
300 ml working clearing solution and for rats, a 1000 ml capacity glass chamber with 800 ml working 
clearing solution would be sufficient. 
TIP 5: For rat clearing, because PVC tubing is not resistant to DCM, the DCM step can be performed 
with gentle shaking to increase the efficiency. 
TIP 6: The flowing rate was set at 8-10 ml/min for mouse clearing and 15-20 ml/min for rat clearing. 
8. At the final step, circulate BABB-D10 until full transparency is achieved (about 6-12 hours for mouse 
and ~24 hours for rat). 
TIP: It is recommended to image sample as soon as possible to yield the best outcome. 
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 Supplementary Table 1: Notes for clearing steps 
 
Times for each experiment step can be shortened (e.g to half) or extended (e.g. to double) depending on tissue size to 
improve antibody penetration or clearing performance. To preserve the signal better in low fluorescence conditions, 
dehydration can be ceased at 90% or 96% and proceed to the BABB-D step. We found that active (perfusion mediated) 
whole-body clearing provided superior transparency compared to passive clearing of dissected organs e.g. the brain. 
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                                     Supplementary Table 2: Imaging specifications 
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2.2 Research Article 2: Panoptic imaging of transparent mice reveals whole-
body neuronal projections and skull–meninges connections 
 
Previous tissue clearing methods including uDISCO could not provide the reliable 
quantification of the signals from fluorescent proteins in deep tissue through intact 
skull, vertebra and skin because the widely used fluorescent proteins such as EGFP, 
EYFP and mCherry emit light in the visible spectrum, in which muscles and bone 
tissue creates severe obstructive autofluorescence. Too overcome this obstacle, a 
whole-body immunolabeling protocol is needed to stabilized the fluorescence signal 
by using synthetic fluorophores and to shift the emission signal into far red spectrum 
with less tissue autofluorescence.  
 
Here, we developed vDISCO, a nanobody-based whole-body immunolabeling 
technology which enhances the signal of fluorescent proteins by up to two orders of 
magnitude and allows the reliable imaging and quantification of subcellular details of 
neuronal structures and immune cells through muscles, bones and skin in intact 
transparent mice. By using various lines of transgenic mice, we visualized the details 
of meningeal lymphatic vessels and studied their drainage function. Furthermore, we 
revealed the short vascular connections between skull marrow and brain meninges 
functioning as an additional immune cell infiltration route. After stroke, the cell 
number of Lysm+ neutrophils in these short connections increased significantly 
comparing with the unlesioned control. Overall, vDISCO significantly enhances the 
imaging quality of intact cleared sample and enables comprehensive studies of the 
nervous system and immune system with cellular level resolution at the whole-body 
scale in an unbiased way.  
 
Author contribution: developed the vDISCO protocol with Ruiyao Cai; cleared and 
imaged whole-body samples from CX3CR1-GFP line, Prox1-EGFP line, double 
transgenic line, Lysm-EGFP line, CD68-GFP line and VEGFR3-YFP line; performed 
experiments for comparing different clearing protocols and perfusion pressure; 
analyzed the CD68 line after SCI; wrote the manuscript with colleagues (please see 
section 7 for further details). 
 
  
 68 
 
 
  
TECHNICAL REPORT
https://doi.org/10.1038/s41593-018-0301-3
1Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians University Munich, Munich, Germany. 2Graduate 
School of Systemic Neurosciences Munich, Munich, Germany. 3Institute of Clinical Neuroimmunology, Klinikum der Universität München, Ludwig-
Maximilians University Munich, Munich, Germany. 4Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany. 5Department of 
Computer Science and Institute for Advanced Study, Technical University of Munich, Munich, Germany. 6Center for Translational Neuromedicine, Faculties 
of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 7Center for Translational Neuromedicine, University of Rochester,  
New York, NY, USA. 8Anatomy Institute, University of Leipzig, Leipzig, Germany. 9Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. 
10These authors contributed equally: Ruiyao Cai, Chenchen Pan. *e-mail: ali.ertuerk@med.uni-muenchen.de
M
ost diseases, even when arising in a specific site, eventually 
affect the entire organism. Histological techniques devel-
oped in the last century have been the standard procedure 
for charting pathology, yet a more complete understanding of bio-
logical mechanisms requires an unbiased exploration of the whole 
organism, not just pre-defined tissues.
However, mammalian tissues are naturally opaque, hindering 
high-resolution imaging in any tissue deeper than a few hundred 
micrometers, a major reason why sectioning is needed for histo-
logical examination of target organs1. Recent innovations in tissue 
clearing technology now allow three-dimensional (3D) histologi-
cal examination of intact organs2–12. Tissue clearing is a chemical 
process aiming to match refractive indices throughout intact tis-
sues, thus rendering them transparent and allowing deep-tissue 
fluorescent microscope imaging. Most initial applications of tis-
sue clearing relied on the assessment of endogenous fluorescent 
proteins expressed in the mouse CNS. More recently, deep-tissue 
immunolabeling methods have enhanced the quality of imaging 
for whole rodent organs as well as human embryos thanks to the 
conjugation of bright fluorescent dyes with secondary antibod-
ies4,13,14. A few studies have even rendered entire adult mouse bodies 
transparent after removal of the skin3,15–18 and allowed head-to-toe 
light-sheet microscopy imaging of intact adult mice17,18. All whole-
body clearing and imaging methods to date rely on transgenic 
expression of fluorescent proteins such as enhanced green fluores-
cent protein (EGFP), enhanced yellow fluorescent protein (EYFP) 
and mCherry17,18. While these fluorescent proteins emit light in the 
visible spectrum, skeletal muscles and other bodily tissues possess 
obstructive autofluorescence in this range19. In addition, fluores-
cent proteins are often less bright compared with many synthetic 
fluorophores, and their signal intensity is further attenuated dur-
ing the clearing and imaging procedure. Together, these bottlenecks 
hinder reliable detection and quantification of subcellular details in 
centimeters-thick transparent mice and therefore require reliance 
on imaging of dissected organs for quantifications, compromising 
the benefits of whole-body transparency.
Here we developed a whole-body immunolabeling method, 
named vDISCO (nanobody(VHH)-boosted 3D imaging of solvent-
cleared organs), to boost the signal of fluorescent proteins using 
nanobodies, which consist of the variable domain of heavy chain 
antibodies (VHH)
20. This technology can enhance fluorescent sig-
nals more than 100 times and thereby allows head-to-toe light sheet 
microscopy scanning of transparent mice (panoptic imaging) and 
quantification of subcellular details. We used this technology to 
construct the first neuronal projection map of an adult mouse and 
to reveal far-reaching changes in neuronal projections and inflam-
matory processes following acute CNS injuries. Panoptic imaging 
also revealed short vascular connections between the skull marrow 
Panoptic imaging of transparent mice  
reveals whole-body neuronal projections and 
skull–meninges connections
Ruiyao Cai1,2,10, Chenchen Pan1,2,10, Alireza Ghasemigharagoz1, Mihail Ivilinov Todorov1,2, 
Benjamin Förstera1, Shan Zhao1, Harsharan S. Bhatia1, Arnaldo Parra-Damas1, Leander Mrowka1, 
Delphine Theodorou3,4, Markus Rempfler5, Anna L. R. Xavier   6, Benjamin T. Kress6,7, Corinne Benakis1, 
Hanno Steinke8, Sabine Liebscher3,4,9, Ingo Bechmann8, Arthur Liesz1,2,9, Bjoern Menze5, 
Martin Kerschensteiner   3,4,9, Maiken Nedergaard6,7 and Ali Ertürk   1,2,9*
Analysis of entire transparent rodent bodies after clearing could provide holistic biological information in health and disease, 
but reliable imaging and quantification of fluorescent protein signals deep inside the tissues has remained a challenge. Here, we 
developed vDISCO, a pressure-driven, nanobody-based whole-body immunolabeling technology to enhance the signal of fluo-
rescent proteins by up to two orders of magnitude. This allowed us to image and quantify subcellular details through bones, skin 
and highly autofluorescent tissues of intact transparent mice. For the first time, we visualized whole-body neuronal projections 
in adult mice. We assessed CNS trauma effects in the whole body and found degeneration of peripheral nerve terminals in the 
torso. Furthermore, vDISCO revealed short vascular connections between skull marrow and brain meninges, which were filled 
with immune cells upon stroke. Thus, our new approach enables unbiased comprehensive studies of the interactions between 
the nervous system and the rest of the body.
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and meninges (both at the brain surface and sagittal sinus), which 
may serve as immune gateways following stroke.
Results
vDISCO principles and signal enhancement. Quantitative assess-
ments of intact transparent mouse bodies remained a major chal-
lenge impeding the study of neurological diseases at the whole-body 
scale. We reasoned that fluorescent proteins such as EGFP and red 
fluorescent protein (RFP) are relatively dim compared with bright 
fluorochromes (for example, Alexa and Atto dyes) after tissue clear-
ing, making them difficult to detect in centimeters-thick mouse 
bodies, especially through intact thick bones (for example, skull and 
vertebrae) and skin. Therefore, we set out to enhance the signal of 
fluorescent proteins via whole-body immunolabeling with brighter 
and more stable fluorescent dyes to provide a much higher contrast 
(signal-to-background ratio) in cleared mice. Furthermore, using 
fluorescent dyes in the far-red spectrum could help to overcome tis-
sue autofluorescence, thus allowing reliable detection of subcellular 
details in all tissues4,19 (Supplementary Fig. 1). We reasoned that 
nanobodies are particularly suited to achieve thorough immunola-
beling throughout entire adult mouse bodies because of their small 
molecular weight (12–15 kDa) compared with that of conventional 
antibodies (~150 kDa)3,20. Indeed, nanobodies were more efficient 
for labeling large tissues compared with conventional antibodies 
(Supplementary Figs. 2 and 3).
First, we tested the signal quality of nanobody labeling in dis-
sected mouse brains from Thy1-GFP-M mice, in which a subset of 
neurons express EGFP21. Following the nanoboosting, the tissues 
were cleared using organic solvents6,7. We found that nanoboosting 
enhanced the signal intensity by one to two orders of magnitude 
compared with direct imaging of fluorescent proteins (Fig. 1a–i). 
In the nanoboosted samples, fine details of neurons were evident 
even in the deep brain regions of Thy1-GFP-M mice (compare 
Fig. 1b,c with Fig. 1e,f). We also obtained a similar signal intensity 
increase in the cerebellum of Thy1-GFP-M brains (compare Fig. 1g 
with Fig. 1h), which is notoriously difficult to clear due to the 
high lipid content.
A major aim of tissue clearing approaches is to perform auto-
mated quantifications in large imaging datasets in an unbiased and 
timely way. Towards this goal, we used the NeuroGPS-Tree algo-
rithm, a robust, automated neuron-tracing tool that was recently 
developed for tracing neurons in scans of cortical regions obtained 
by high-resolution confocal microscopy22. We found that virtu-
ally all of the neuronal cell bodies and neurites were detected and 
linked to each other as complete neurons upon vDISCO nanoboost-
ing in light-sheet microscopy scans (Supplementary Figs. 4 and 5). 
In contrast, in unboosted samples or in standard immunoglobu-
lin G antibody-boosted samples, many fine extensions of neurons 
were not identified or not connected to somas and neuronal trees 
(Supplementary Fig. 4). Nanoboosting allowed imaging not only of 
neuronal details but also of smaller individual cells such as microg-
lia cells and immune cells (Fig. 1j–m and Supplementary Fig. 6). 
Compared with unboosted samples, we could resolve fine details 
of microglia cells in intact transparent brains of CX3CR1GFP/+ 
mice using light-sheet microscopy (Fig. 1j–m and Supplementary 
Video 1). Nanoboosting also enabled automated quantification of 
CX3CR1 GFP+ cells using the ClearMap algorithms23: we found 
approximately 2.3 million microglia cells in the adult mouse 
brain (Supplementary Fig. 7a). We also automatically quantified 
microglia in all brain regions annotated by the Allen Brain Atlas. 
Thereby we found, for example, ~150,000 microglia in the hippo-
campus and ~50,000 in the thalamus of adult mice (Supplementary 
Fig. 7b–k). Furthermore, we found no significant decrease in signal 
intensity over time of the same samples, suggesting that vDISCO 
nanoboosting stabilizes the fluorescent signal (Fig. 1n,o), allowing 
long-term preservation and re-imaging of the samples. Thus, owing 
to the enormous enhancement and stabilization of fluorescent sig-
nals using nanobodies, we could use available computational tools 
to automatically trace neurons and count cell numbers in images 
acquired by light-sheet microscopy.
vDISCO allows panoptic imaging of intact adult mouse bodies. 
To apply whole-body clearing technology at the systems level, it is 
critical to obtain information not only from dissected organs but 
also from intact transparent bodies. Towards this goal, we aimed 
at establishing an approach to achieve nanoboosting in the entire 
mouse body. We reasoned that vDISCO amplification of the fluo-
rescent signals would allow reliable quantification of cells through 
intact thick bones and highly autofluorescent muscles. To ensure 
homogeneous delivery of nanobodies into all body regions, we 
used high-pressure cardiac perfusion with two- to three-fold 
increased pressure compared with standard perfusion protocols 
(160–230 mmHg compared with 70–110 mmHg (ref. 24)). We also 
illustrated the effect of high-pressure delivery compared with 
standard pressure using methylene blue. This novel high-pressure 
delivery approach facilitated a consistent distribution of the dye 
into deep tissues (Supplementary Fig. 8). Assessing the tissue integ-
rity upon high-pressure delivery, we did not observe any structural 
changes (Supplementary Fig. 9). Furthermore, we used a permea-
bilization solution containing Triton X-100, methyl-β -cyclodextrin 
(to extract the cholesterol from membranes) and trans-1-acetyl-
4-hydroxy-l-proline (to loosen the collagen network)12. To further 
reduce the background signal caused by the residual blood and to 
decalcify the bones, we treated whole mouse bodies with aminoal-
cohols5,15 and EDTA25 before the whole-body immunolabeling step. 
Combination of these diverse improvements allowed us to achieve 
whole-body immunolabeling in adult mice with a high degree of 
transparency (Fig. 2a and Supplementary Fig. 10) and to obtain 
quantitative information on single cells in deep brain regions 
through the intact skull3,15–18,23 (Supplementary Figs. 11 and 12). 
Here, we used anti-XFP nanobodies conjugated with bright Atto 
dyes (called nanoboosters) to boost the fluorescent protein signal 
in transparent mice. Moreover, we used anti-vimentin nanobodies 
to label activated glia cells in the brain upon trauma, demonstrat-
ing that our approach also works with nanobodies targeting endog-
enously expressed proteins (Supplementary Fig. 13).
In addition to the specific boosted signal, we also visualized and 
segmented other major tissues in the transparent body: muscles by 
their autofluorescence within the blue–green spectrum, and bones 
and internal organs by propidium iodide (PI) labeling (Fig. 2b,c and 
Supplementary Fig. 14a–d). Usage of organic solvents, which induce 
isotropic tissue shrinkage17, allowed us to perform head-to-toe pan-
optic imaging of entire mice by light-sheet microscopy.
Being able to image subcellular details of neurons through intact 
bones and highly autofluorescent muscles in the whole mouse body 
using vDISCO panoptic imaging, we constructed the first whole-
body neuronal projection map of a Thy1-GFP-M transgenic mouse 
(Fig. 2d,e, Supplementary Fig. 14 and Supplementary Video 2). We 
noticed that in the peripheral nervous system, mainly axons inner-
vating muscles were labeled in this mouse line, which enabled us to 
investigate the neuromuscular junctions in greater detail. We also 
observed fluorescent labeling of the internal organs, such as kidneys 
of Thy1-YFP-H mice21 (Supplementary Fig. 15). Owing to the great 
increase in signal-to-background ratio by vDISCO, we could read-
ily visualize axonal projections from the spinal cord through intact 
vertebrae to their terminals into the muscles, even in very remote 
locations such as toes (Fig. 2f–i and Supplementary Videos 3 and 4). 
Panoptic imaging of individual neuronal projections through 
intact bones can now provide more details on neuroanatomy. For 
example, how axons coming from consecutive roots enter the spinal 
cord—that is, in an overlapping or non-overlapping manner—has 
been unclear26. Using our technology, we observed that in mice, the 
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Fig. 1 | Enhancement and permanent preservation of the fluorescence signal with vDISCO. a–f, Signal quality comparison between vDISCO-boosted 
(a) and unboosted (d) half-brain samples coming from the same 11-month-old Thy1-GFP-M mouse. To achieve the best comparison between the two 
procedures, we divided the mouse brains in two halves for light-sheet microscopy imaging (one hemisphere boosted and imaged in the far-red channel, 
the other hemisphere unboosted and imaged in the green channel for endogenous EGFP). The boosted hemisphere showed highly distinguishable cellular 
details (b,c) such as axonal projections not visible in the unboosted hemisphere (e,f), especially in the regions with dim GFP labeling in Thy1-GFP-M 
mice, such as mid-brain (b,e) and cerebellum (c,f) (representative images, repeated at least on 3 different samples). g,h, Comparison of signal quality in 
cerebellum from the boosted (g) and unboosted (h) samples (repeated with at least 3 mice per group). i, Plots of signal intensity profiles from boosted 
samples (left) versus unboosted samples (right) along the blue and orange lines in g and h, respectively; n =  3 brains for each group (2- to 6-month-old 
Thy1-GFP-M mice). j–m, Light-sheet microscopy images (× 4 and × 25 magnification) of the microglia from CX3CR1GFP/+ mice in boosted (j,k) versus 
unboosted samples (l,m) showing the fine details of microglia ramifications obtained with vDISCO boosting (similar results repeated with at least 3 mice 
per group). n, Representative light-sheet microscopy images of 1 of 3 CX3CR1GFP/+ mouse brains at 0, 2, 12 and 18 months after boosting, showing the 
preservation of the fluorescence signal over 18 months. o, Fluorescence level quantifications, in arbitrary units (a.u.), in CX3CR1GFP/+ brains after boosting 
at different time points postclearing (n =  3 mice, 2–6 months old).
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axonal bundles coming from different roots enter the spinal cord 
at non-overlapping territories (Supplementary Fig. 16). Thus, the 
vDISCO approach provides a holistic view of the intact mouse, 
which should lead to novel discoveries on how interconnected 
organ systems function in health and what happens during their 
perturbation in disease.
Clearing of the whole body without removal of the skin. The skin 
is the largest organ, forming ~15–20% of the body. Among many 
other components, it consists of nerve endings, glands, immune 
cells, blood and lymphatic vessels, signifying its diverse biological 
roles in addition to being a physical barrier against the external envi-
ronment27. However, clearing and imaging whole mice with skin has 
not been reported. Towards this goal, we adopted the vDISCO pro-
tocol to clear and image mice with skin. We observed that vDISCO 
could efficiently clear whole nude mice without removal of the skin 
(Fig. 3a,b). In addition, we cleared C57BL/6J (BL6) background mice 
after shaving the fur. In CX3CR1GFP/+ mice, we could readily image 
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Fig. 2 | vDISCO panoptic imaging uncovers neuronal projections in intact mice. a, An example of a transparent 6-week-old mouse generated by vDISCO 
(similar results were observed from at least 20 independent mice). b–e, Three-dimensional reconstruction of complete neuronal projections of a 6-week-
old Thy1-GFP-M mouse obtained by light-sheet microscopy imaging (similar labeling and imaging results were achieved at least in 5 different mice; whole-
body reconstruction was performed on 2 mice). vDISCO boosted GFP+ neuronal structures are shown in green, bones and internal organs are prominent 
with PI labeling in white, and the muscles visualized by autofluorescence background imaging are in red (b–d). The depth color-coding shows the neuronal 
projections at different z levels in the 2.5-cm-thick whole mouse body (e). f,g, High-resolution 3D reconstruction views of the left torso and forelimb from 
the same animal as in b–e. Details of innervation throughout muscles and bones are evident. h,i, Surface reconstruction of the paw (h) and its nerves (i) 
from the boxed region in f. See also Supplementary Videos 2–4.
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Fig. 3 | vDISCO panoptic imaging on mice with the intact skin. a,b, Adult NMRI nu/nu nude mouse, 3–4 months old (a), cleared with the vDISCO method 
(b): the insets show close-up views of the cleared lungs (magenta) and skin (cyan) in b (similar results were observed from 3 independent NMRI nu/nu 
mice). c–h, vDISCO on 6-week-old CX3CR1GFP/+ mouse with intact skin. c, Cleared body, with the inset (cyan) showing visible inguinal lymph nodes (black 
arrowhead) through the transparent skin. d, Light-sheet images of CX3CR1GFP/+ mouse boosted with anti-GFP 647-nanobooster (cyan) and labeled with PI 
(magenta), showing CX3CR1 GFP+ cells (cyan) densely located in the lymph node and sparsely located in and under the skin, such as around hair follicles 
(magenta). e–h, Confocal 1-mm z-scan of the skin and lymph node in d with visible CX3CR1 GFP+ cells (cyan) and nuclei (magenta). e, Three-dimensional 
rendering of the stack showing the skin and the lymph node beneath. f, Two-dimensional image at the level of the skin with individual CX3CR1 GFP+ cells 
in the tissue and in the hair follicles (yellow arrowheads). g, The fine details of the ramifications of the immune cells at the surface of the skin are visible 
(green arrowheads). h, Two-dimensional image of the lymph node with visible immune cells (yellow arrowheads) in the organ. See also Supplementary 
Video 5. i–k, vDISCO on 2-month-old Thy1-GFP-M mouse with intact skin. i, Cleared body, with the inset (magenta) showing a visible inguinal lymph node 
through the skin. j, Light-sheet images of Thy1-GFP-M mouse boosted with anti-GFP 647-nanobooster (green) and labeled with PI (magenta), showing 
Thy1-GFP-expressing immune cells (white arrowheads) and neuronal projections coming from the spinal cord and projecting to the rest of the body, 
including the skin (green); the insets show close-up details of a neuronal projection (green fibers and yellow arrowheads) projecting into the skin. k, High-
magnification confocal image of the region in j (yellow dashed rectangle) showing details of the immune cells (white arrowheads) and neuronal projections 
(green and yellow arrowheads) into the skin of the animal. All the results from c to k were similarly observed in 2 independent mice for each mouse line.
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immune cells through the intact skin owing to the increase of fluo-
rescent signal by vDISCO (Fig. 3c–h and Supplementary Video 5). 
In Thy1-GFP-M mice, we observed the axonal innervations in the 
skin in addition to Thy1 GFP+ immune cells28 located under the skin 
(Fig. 3i–k). These results demonstrate that vDISCO allows detailed 
imaging of intact mice with skin, which may be of great value for 
studying skin-related pathologies.
Degeneration of peripheral nerve terminals after brain injury. 
Traumatic brain injury (TBI) is a major cause of death and dis-
ability, and currently there is no disease-modifying treatment 
available to combat especially chronic sequelae. In addition to its 
acute consequences, TBI often leads to chronic focal and global 
neurological impairments, such as dementia, epilepsy, progres-
sive motor decline, peripheral neuropathy and dystonia29,30. These 
impairments could be due to degeneration of the corresponding 
brain regions and/or the dysfunction of nerves outside of the brain. 
However, so far, the impact of TBI on long-range neuronal pro-
jections outside of the brain has not been assessed. For example, 
while TBI-induced sensory-motor dysfunction has been observed 
in both animal models and human pathologies31–34, the underly-
ing mechanisms remain unknown, hampering the development of 
effective therapeutic approaches. Here, imaging the whole CNS, we 
found extensive neurodegeneration of the descending motor axons 
in the brainstem and spinal cord upon TBI over the right somato-
sensory and motor cortices (Supplementary Fig. 17). However, 
how TBI alters neuronal projections in the peripheral nervous 
system remains elusive. We used panoptic imaging to examine 
neuronal changes throughout the body more than a month after 
the brain injury (chronic stage) in comparison with control ani-
mals. As mainly axons innervating muscles are labelled in Thy1-
GFP-M mice, we primarily focused on these nerve terminals. Our 
quantifications conducted in intact cleared mouse bodies demon-
strated that the complexity of nerve terminals at the neuromuscu-
lar junctions was reduced after TBI, especially in the upper torso, 
compared with unlesioned control mice (Fig. 4a–d). We observed 
that nerve endings were reduced in complexity at the contralateral 
body regions, with fewer axonal ramifications left, implying partial 
degeneration of these axon terminals (Fig. 4e,f). Interestingly, we 
also observed changes at the ipsilateral axons, albeit to a smaller 
degree with respect to the contralateral body region (Fig. 4e). 
Overall, these data demonstrate that light-sheet microscopy imag-
ing of entire transparent mouse bodies by vDISCO holds great 
promise for discovering hitherto unknown biological and patho-
physiological processes.
Visualizing new routes for immune cell trafficking in the brain 
and spinal cord. The lymphatic system, which connects various 
lymphatic organs in the body, is crucial for immune responses. Until 
recently, the brain was considered to be devoid of any lymphatic 
vessels. In recent years, brain lymphatic vessels were re-discovered 
and are considered to play critical roles in brain pathologies35–38. 
As these lymphatic vessels are located between the brain and the 
skull39, their connections are largely destroyed when the brain is 
harvested for standard histology.
We utilized panoptic imaging to overcome this hurdle and 
imaged details of meningeal vessels in intact transparent mice. We 
used Prox1-EGFP reporter mice, in which lymphatic endothelial 
cells express EGFP40. We readily observed previously described 
brain lymphatic structures, particularly along the sagittal sinus, 
pterygopalatine artery and transverse sinus (Fig. 5a–e and 
Supplementary Fig. 18) in addition to many other body regions 
(Supplementary Fig. 19 and Supplementary Video 6). Next, we 
imaged multiple subtypes of immune cells within and outside the 
meningeal vessels using the CX3CR1GFP/+ × CCR2RFP/+ mice by mul-
tiplexing with two different nanoboosters (anti-GFP conjugated 
to Atto-647N and anti-RFP conjugated to Atto-594N). The 
CX3CR1 GFP+ microglia cells in the brain parenchyma (Fig. 5f,g) 
and CCR2 RFP+ peripheral immune cells in the meningeal vessels 
were clearly identifiable (Fig. 5g,h and Supplementary Video 7). 
As expected, we also observed CX3CR1 GFP+ immune cells in 
meningeal vessels, which likely represent meningeal monocytes 
and macrophages (Fig. 5h). It remains unclear how the immune 
cells within meningeal vessels contribute to the pathology of acute 
brain injuries, as they may be in an advantageous position to 
invade the brain. To start addressing this query, we used the mid-
dle cerebral artery occlusion (MCAO) model of stroke, which was 
performed in LysM-EGFP mice, a transgenic mouse line express-
ing EGFP in myeloid cells (mainly in neutrophils and monocytes) 
but not in microglial cells41. The mice with MCAO showed an inva-
sion of LysM GFP+ cells into the brain parenchyma, especially in 
the peri-infarct region, compared with sham-operated controls 
(Fig. 5i,j). Numbers of LysM GFP+ cells also increased in the men-
ingeal structures after MCAO (Fig. 5i), suggesting that the menin-
ges might play a role as entry and/or exit routes of the brain in 
addition to the disrupted blood–brain barrier and the choroid 
plexus42. Thus, vDISCO panoptic imaging of transparent mice is 
a powerful tool to study the anatomy and cellular repertoire of 
meningeal vessels in health and disease.
Next, we aimed at investigating vascular connections between 
the skull and the meninges in greater detail. Towards this goal, we 
injected a cerebrospinal fluid (CSF) tracer (fluorophore-conjugated 
ovalbumin) into the cisterna magna in VEGFR3-YFP mice, another 
commonly used reporter line for meningeal vessels. We observed 
that the CSF tracer was quickly transported into the VEGFR3+ 
meningeal vessels (Fig. 6a–d). Interestingly, we also observed that 
the tracer-labeled vessels extended into the skull (Fig. 6b,c). We fur-
ther investigated the details of these new connections using lectin, 
another vessel tracer binding to endothelial cells. We found that 
these vascular connections are mostly located between the skull 
marrow and the outer surface of the meninges (both at the brain 
and sagittal sinus interfaces; Fig. 6e,f, Supplementary Fig. 20 and 
Supplementary Videos 8 and 9). We measured that they have an 
average size of 46.9 ± 5.8 µ m in length and 19.2 ± 2.5 µ m in width at 
the brain interface and of 83.7 ± 0.3 µ m in length and 28.5 ± 1.8 µ m 
in width at the sagittal sinus interface (mean ± s.e.m., n = 3 mice; 
Supplementary Fig. 20); therefore, we named them as short skull–
meninges connections (SMCs). They also occasionally contain cells 
(Fig. 6e,f and Supplementary Fig. 20). To address whether the SMCs 
might play a role in neuropathological conditions, we studied the 
distribution of LysM GFP+ immune cells in these connections after 
MCAO. The mice with MCAO showed significantly more LysM 
GFP+ cells in the SMCs compared with sham-operated controls 
(Fig. 6g–i and Supplementary Video 10), suggesting that they might 
represent an entry route for myeloid cells from the skull marrow 
to the meningeal compartments after brain injury. Thus, vDISCO 
imaging revealed connections between skull and meninges, which 
might be important for immune cell trafficking, especially during 
brain pathologies.
Finally, we explored the immune cell trafficking after spinal cord 
injury using vDISCO panoptic imaging. To this end, we induced 
a spinal cord injury in CD68-EGFP transgenic mice expressing 
EGFP in monocytes and macrophages43. Upon spinal cord injury, 
we observed an influx of CD68 GFP+ cells at the lesion site as well as 
a rather widespread increase in CD68 GFP+ cells around the spinal 
cord (Supplementary Fig. 21 and Supplementary Video 11). Indeed, 
only 3.5% of these phagocytes were seen in the injured spinal cord, 
while ~96.5% of the CD68 GFP+ cells were located in the surround-
ing tissues of the spinal cord including adjacent muscles, spinal cord 
roots and meningeal vessels, similar to sham mice (Supplementary 
Fig. 22). Thus, vDISCO is a powerful tool to image and quantify the 
trafficking of immune cells to and within the injured CNS.
NATURE NEUROSCIENCE | www.nature.com/natureneuroscience
TECHNICAL REPORTNATURE NEUROSCIENCE
Discussion
Panoptic imaging of transparent adult mouse bodies from head 
to toe holds the promise of providing an unbiased and highly 
resolved view of entire organ systems in health and disease. Here, 
we developed a new whole-body nanobody labeling method in 
conjunction with whole-body tissue clearing, enabling a reliable 
visualization and quantification of subcellular details through-
out centimeters-thick tissues of intact mouse bodies. This new 
panoptic imaging technology is straightforward in application 
and is suitable for systemic analysis of a vast range of biomedi-
cal inquires, as demonstrated here in visualization of the neuronal 
projections in whole mouse bodies, the description of vascular 
pathways between the skull and meninges, and the visualization of 
remote neuronal and immune consequences of acute CNS injury 
models. While we developed vDISCO for panoptic imaging of the 
whole mouse body, it is readily applicable for individual organs, 
using a simplified protocol to drastically increase and stabilize the 
signal contrast, as we show for mouse brains imaged more than 
a year after boosting and clearing (Supplementary Video 12 and 
Supplementary Table 1).
The panoptic imaging of nervous and immune systems in intact 
mouse bodies was achieved owing to the massive enhancement of 
the signal intensity by one to two orders of magnitude via whole-
body immunolabeling employing nanobodies conjugated to bright 
dyes in the far-red spectrum. Therefore, the strong autofluorescence 
of tissues in shorter-wavelength spectra, in which traditional fluo-
rescent proteins such as GFP are excited and imaged, is avoided. 
Here, we primarily used Atto dyes at 647 nm, and additional Atto 
594 nm for multiplexing two different cell types. In the future, usage 
of nanobodies conjugated to dyes that emit in the near-infrared 
range44 can further facilitate multiplexed detection of more than two 
targets. While the number of commercially available nanobodies is 
still limited, the nanoboosters used in this study can stain a broad 
selection of 21 different fluorescent proteins including EGFP, YFP, 
Venus, mCherry, and mRFP. Our method can also be used with 
nanobodies against endogenous proteins, as we demonstrated using 
anti-vimentin nanobodies labeling activated glia cells in the brain 
upon trauma45,46. Currently, nanobodies are developed mainly for 
in vivo applications due to their small size (for example, for crossing 
the blood–brain barrier)47; therefore, they are mostly selected for 
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in vivo epitopes but not for fixed tissues. We believe that our study 
will encourage the production of diverse nanobodies for deep-tissue 
immunolabeling.
Here, we used transgenic mice endogenously expressing fluo-
rescent proteins; however, the labeling can also be achieved by 
rabies virus retrograde tracing, systemic adeno-associated virus 
injections48 or transplantation of genetically engineered cells (such 
as stem cells or adoptive transfer of immune cells). Another key 
advantage of vDISCO panoptic imaging is that upon staining with 
Atto dyes through nanoboosting, the signal becomes permanent, 
permitting long-term imaging sessions and future re-analysis of the 
same sample if needed. This also enables high-resolution imaging 
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of desired body parts by confocal or two-photon microscopy. 
Indeed, the samples from this study are available to the scientific 
community upon request for further studies. We believe making 
vDISCO-treated samples accessible to other labs for further studies 
can save time and resources, reduce the number of mice used in 
experimental research and create more powerful datasets by allow-
ing direct correlation of various inquiries by multiple studies from 
the same animals.
A current limitation is the absence of light-sheet microscope sys-
tems that could image the entire body of a mouse in one session 
without any displacement and turning of the sample. Construction 
of such new light-sheet microscopes should further decrease the 
time needed for data acquisition and simplify data processing for 
3D reconstruction. In fact, as shown here, optics and light sources of 
current commercial light-sheet microscopes are sufficient to image 
intact mouse bodies at subcellular resolution, although the whole 
body has to be manually moved in the imaging chamber to achieve 
the scanning of different body regions. In addition, development 
of machine learning-based (artificial intelligence) algorithms to 
automatically identify and quantify cellular changes on the whole-
organism scale will be important to further scale up this technology 
in the future.
Using panoptic imaging, we constructed a neuronal projec-
tion map for the Thy1-GFP-M transgenic line, showing subcel-
lular details of long-range neuronal connections from the CNS to 
the distal extremities. Here, we visualized neuronal details in Thy1-
GFP-M mice, in which only a subset of CNS neurons and peripheral 
nervous system neurons innervating skeletal muscles are labeled. 
In the future, panoptic imaging of other transgenic lines labeling a 
greater and more diverse subset of neurons will allow the explora-
tion of other biological systems such as the autonomic innervation 
of internal organs.
In recent years, researchers have been providing more evidence 
on post-TBI changes that seem to form the basis of chronic com-
plications, such as epilepsy, neuropsychiatric disorders, dementia 
and progressive motor decline29. However, the effects of a localized 
brain lesion on the rest of the body have been poorly understood, 
mainly due to the technical challenges in studying long-range neu-
ronal projections. Because vDISCO fluorescent signal boosting 
allows both imaging and quantifications of light-sheet microscopy 
images of transparent mouse bodies, we identified TBI-induced 
changes at the peripheral axonal projections innervating the skel-
etal musculature of the torso. These data are in line with recent 
work by others and us demonstrating the functional deficits in fine 
motor movements in mice and the presence of sensory-motor dys-
functions in TBI patients29,30,33. Our data provide a possible cellular 
mechanism for these functional impairments, suggesting that they 
could arise due to degeneration of long-range axons throughout the 
spinal cord and peripheral nervous system. This discovery opens 
alternate avenues for the identification of therapeutic targets. For 
instance, recent literature showed that microtubule stabilization is a 
powerful way to block degeneration of axons in spinal cord injury49. 
In this regard, it would be important to assess whether microtu-
bule stabilization would also counteract axon degeneration outside 
of the brain and circumvent the development of chronic sensory-
motor dysfunctions. Here, we also demonstrated that meningeal 
vessels extending between the cranium and CNS tissue and their 
cellular content can readily be imaged by vDISCO panoptic imag-
ing in naïve animals and acute CNS injury models. Importantly, we 
observed short vascular connections between the skull and menin-
ges both at the brain interface (recently seen also by others50) and 
at the sagittal sinus, which were filled with immune cells follow-
ing ischemic stroke injury. Most of the SMCs seem to be open both 
at the skull marrow and meningeal ends without being connected 
to the vascular system of the brain/head (Supplementary Video 9). 
In the future, it will be important to identify to which meningeal 
compartment or compartments (subdura, subarachnoid or sub-
pial) the SMCs are connected. In addition, due to the present lack 
of appropriate reporter mice, it was not possible to distinguish the 
type of SMCs (blood or lymphatic vessels) with increased LysM+ 
cells after stroke. In the future, vDISCO imaging of immune cells 
in a lymphatic vessel reporter mouse line with different fluorescent 
proteins (for example, LysM-EGFP + Prox1-RFP double reporter) 
could reveal more details of this new route for immune cell infil-
tration. As neuroinflammation is a major determinant of neuronal 
function and survival following CNS injuries of various etiolo-
gies, our technology should accelerate investigation of these novel 
immune cell infiltration routes in various CNS pathologies.
In conclusion, vDISCO enhancement and stabilization of fluo-
rescent proteins combined with signal acquisition in far-red spec-
tra should facilitate discovery of previously inaccessible biological 
information. For example, imaging and quantification of neuronal 
projections, vascular organizations and immune cell populations in 
the entire mouse body should contribute to a more comprehensive 
understanding of the initiation, progression and extent of neuro-
logical conditions.
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Methods
Animals. We used the following mixed-gender animals in the study: CX3CR1GFP/+ 
(B6.129P-Cx3cr1tm1Litt/J; Jackson Laboratory strain code 005582)51, !y1-GFP-M 
and !y1-YFP-H21, Prox1-EGFP (Tg(Prox1-EGFP)KY221Gsat/Mmucd; Mutant 
Mouse Resource and Research Centers strain code 031006-UCD), VEGFR3-YFP, 
CX3CR1GFP/+ × CCR2RFP/+ (B6.129(Cg)-Ccr2tm2.1Ifc/J; Jackson Laboratory strain 
code 017586), LysM-EGFP (Lyz2tm1.1Graf, Mouse Genome Informatics strain code 
2654931), CD68-EGFP (C57BL/6-Tg(CD68-EGFP)1Drg/j; Jackson Laboratory 
strain code 026827), C57BL/6J, and NMRI nu/nu mice. #e animals were housed 
under a 12/12 h light/dark cycle. #e animal experiments were conducted 
according to institutional guidelines (Klinikum der Universität München/Ludwig 
Maximilian University of Munich), a$er approval of the ethical review board of 
the government of Upper Bavaria (Regierung von Oberbayern, Munich, Germany) 
and the Animal Experiments Council under the Danish Ministry of Environment 
and Food (2015-15-0201-00535), and in accordance with the European directive 
2010/63/EU for animal research. Ages of the animals are indicated in the 'gure 
legends. All data are reported according to the Animal Research: Reporting of In 
Vivo Experiments (ARRIVE) criteria. Sample sizes were chosen on the basis of 
prior experience with similar models and are speci'ed in 'gure legends. Within 
each strain, animals were randomly selected. Animals that resulted negative for the 
expression of <uorescent proteins by genotyping were excluded from the study. No 
statistical methods were used to pre-determine sample sizes, but our sample sizes 
are similar to those reported in previous publications17.
TBI. TBI was performed using a controlled cortical impact device (Leica 
Benchmark Stereotaxic Impactor, 39463923). At 30 min before surgery, 
we administered carprofen (4 mg per kg body weight) and buprenorphin 
(0.05 mg per kg) to the animals via subcutaneous injection. Then, anesthesia was 
induced in animals with 4% isoflurane in a N2O/O2 (70%/30%) mixture and 
afterwards maintained with 1.5% isoflurane in the same mixture for the whole 
surgery. As soon as the animals did not show any pedal reflex, they were placed in 
the associated stereotaxic apparatus, and their body temperature was kept at 37 °C 
using a heating pad for the whole surgery procedure. Next, the scalp of the animals 
was shaved, aseptically prepared by wiping with Octenisept (Schülke, 22580-A) 
as disinfectant and the skin of the scalp was incised longitudinally between the 
occiput and forehead. We identified the target area of the injury, which was the 
right somatosensory cortex extending to the motor cortex, using the stereotaxic 
frame (bregma coordinates: 2 mm posterior, 5 mm right lateral). The injury 
was then triggered via controlled cortical impact machine using the following 
parameters: impact speed, 6.9 m s−1; impact duration, 400 ms; impact depth, 2 mm. 
With these parameters, the resulting injury was severe, with cracks in the skull, 
bleeding and exposed brain tissue. After the impact, the skin was sutured with 
metallic wound closure clips (VWR, 203-1000), and the animals were kept at 31 °C 
in a recovery chamber (Mediheat, 34-0516) for at least 30 min until they recovered 
from the anesthesia. In the following days, animals were subcutaneously injected 
with carprofen (4 mg per kg) once per day for 4 d and sacrificed at > 1 month post-
injury by transcardial perfusion according to the ‘Perfusion and tissue preparation’ 
section below.
MCAO model. Experimental stroke was induced using the intraluminal filament 
model of MCAO (fMCAO) for transient, focal brain ischemia. Mice were 
anesthetized with isoflurane delivered in a mixture of 30% O2 and 70% N2O. 
A heat-blunted nylon suture (6/0) was inserted into the external carotid artery 
and advanced until it obstructed the middle cerebral artery together with the 
ligation of the common carotid artery for 30 min. Regional cerebral blood flow 
(bregma coordinates: 2 mm posterior, 5 mm lateral) was continuously recorded by 
transcranial laser Doppler flowmetry from the induction of ischemia until 10 min 
after reperfusion. Following fMCAO, mice were placed in temperature-controlled 
recovery cages for 2 h to prevent post-surgery hypothermia. For the survival period 
(3 d), the mice were kept in their home cage with facilitated access to water and 
food. Sham-operated mice received the same surgical procedure without insertion 
of the filament. Body temperature was maintained throughout surgery using 
a feedback-controlled heating pad and kept constant (37.0 ± 0.5 °C). Exclusion 
criteria were as follows: insufficient MCAO (a reduction in blood flow to 15% of 
the baseline value) and blood flow recovery > 80% within 10 min of reperfusion. 
Mice were sacrificed at 3 d post-injury by transcardial perfusion according to the 
‘Perfusion and tissue preparation’ section below.
Cisterna magna injection for meningeal vessel labeling. For the cisterna 
magna injections, mice (VEGFR3-YFP; 6 months old) were anesthetized with a 
mixture of ketamine and xylazine (100 mg per kg and 10 mg per kg, respectively) 
via intraperitoneal injection. After toe pinch reflexes ceased, mice were fixed in 
a stereotaxic frame by the zygomatic arch, with the head slightly tilted to form 
an angle of 120° in relation to the body. The head and neck regions were shaved 
to expose the neck muscles, which were bluntly dissected to expose the cisterna 
magna. Cannulas composed of a dental needle (SOPIRA Carpule 30 G 0.3 × 12 mm; 
Kulzer, AA001) and polyethylene tubing (0.024 in OD (outside diameter) × 0.011 
in ID (interior diameter); Scandidact, PE10-CL-500) were used to perform the 
cisterna magna injections. A cannula filled with CSF tracer (2% ovalbumin 45 kDa 
conjugated to Alexa Fluor 647 (Thermo Fisher Scientific, O34784), diluted in 
artificial CSF (126 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 2 mM Mg2SO4, 
2 mM CaCl2, 10 mM glucose, 26 mM NaHCO3; pH 7.4 when gassed with 95% O2 
and 5% CO2)) was inserted into the cisterna magna. With the aid of an injection 
pump (LEGATO 130 Syringe pump; KD Scientific, 788130), 10 µ l of CSF tracer was 
injected into the cisterna magna at a rate of 1 µ l min−1. At the end of the injection, 
CSF tracer was allowed to circulate in the subarachnoid and paravascular spaces 
for 1 h. Mice were then transcardially perfused according to the ‘Perfusion and 
tissue preparation’ section below.
Spinal cord injury model. Mice were deeply anesthetized by intraperitoneal 
injection of a combination of midazolam (5 mg per kg), medetomidine 
(0.5 mg per kg) and fentanyl (0.05 mg per kg). The mid-thoracic spinal cord of 
anesthetized CD68-EGFP mice was surgically exposed by a dorsal laminectomy 
as previously described52. A hemisection of the spinal cord was performed using 
fine-tip surgical scissors (Fine Science Tools 15000-08 spring scissor, 2.5 mm 
cutting edge). For sham surgery, the dorsal laminae of mid-thoracic vertebrae were 
surgically exposed in anesthetized CD68-EGFP mice. After spinal cord injury or 
sham surgery, muscle tissue and skin were sutured with a surgical thread (Ethilon 
suture 6-0, 667 H) and animals were allowed to recover on a heating pad. After 
48 h, mice were transcardially perfused according to the ‘Perfusion and tissue 
preparation’ section below.
Perfusion and tissue preparation. Mice were deeply anesthetized using a 
combination of midazolam, medetomidine and fentanyl (MMF; 1 ml per 100 g body 
mass for mice; intraperitoneal). As soon as the animals did not show any pedal 
reflex, they were intracardially perfused with heparinized 0.1 M PBS (10 U ml−1 of 
heparin, Ratiopharm; ~110 mmHg pressure using a Leica Perfusion One system) 
for 5–10 min at room temperature until the blood was washed out, followed by 
4% paraformaldehyde (PFA) in 0.1 M PBS (pH 7.4; Morphisto, 11762.01000) for 
10–20 min. Next, optionally, skin and eyes as well as premaxilla and maxilla bones 
were carefully removed, the palate of the animal was opened (without damaging 
the tissue beneath), and the feces were gently washed out from the intestine with 
0.1 M PBS through small cuts using a syringe. For the animals cleared with skin, 
the skin was not removed from the bodies, and in case of BL6 background animals, 
the fur was shaved off using a razor blade (Personna, 604305-001001). Then, the 
bodies were post-fixed in 4% PFA for 1 d at 4 °C and later washed with 0.1 M PBS 
for 10 min 3 times at room temperature. Either the whole-body nanoboosting 
procedure was started immediately or whole mouse bodies were stored in PBS at 
4 °C for up to 4 weeks or in PBS containing 0.05% sodium azide (Sigma-Aldrich, 
71290) for up to 6 months.
For the collection of dissected tissues such as brains, mice were perfused 
with PBS and PFA as described above. Subsequently, the organs of interest were 
dissected out and post-fixed in 4% PFA overnight at 4 °C, washed with 0.1 M PBS 
for 10 min 3 times at room temperature and kept in PBS plus 0.05% sodium azide 
for up to 3 weeks.
Clearing of unboosted samples. For the quantification of fluorescence signal 
after clearing, without boosting, we followed the uDISCO passive clearing 
protocol as described by Pan et al.17. In brief, dissected brains were placed in 5 ml 
tubes (Eppendorf, 0030 119.401) and covered with 4.5 ml of clearing solution. 
All incubation steps were performed in a fume hood with gentle shaking or 
rotation, with the samples covered with aluminum foil to keep them in dark. 
To clear the samples, we incubated them in a gradient of tert-butanol (Sigma-
Aldrich, 360538): 30 vol%, 50 vol%, 70 vol%, 80 vol%, 90 vol%, 96 vol% (in distilled 
water), and 100 vol% twice at 35 °C for 12 h each step followed by immersion in 
dichloromethane (Sigma-Aldrich, 270997) for 45–60 min at room temperature 
and finally incubation with the refractive index matching solution BABB-D15, 
containing 15 parts BABB (benzyl alcohol + benzyl benzoate 1:2; Sigma-Aldrich, 
24122 and W213802), 1 part diphenyl ether (Alfa Aesar, A15791) and 0.4 
vol% vitamin E (dl-α -tocopherol; Alfa Aesar, A17039), for at least 6 h at room 
temperature until transparency was achieved.
Nanobodies, antibodies and fluorescent dyes used in this study. The nanobodies, 
antibodies and fluorescent dyes used in this study are as follows: Atto594-
conjugated anti-RFP nanobooster (Chromotek, rba594-100), Atto647N-conjugated 
anti-GFP nanobooster (Chromotek, gba647n-100), Atto488-conjugated anti-
GFP nanobooster (Chromotek, gba488-100), Atto488-conjugated anti-vimentin 
nanobooster (Vimentin-Label_Atto488; Chromotek, vba488-100), Alexa647-
conjugated anti-GFP antibody (Invitrogen, A31852), and PI (Sigma-Aldrich, 
P4864). For the nanobody and antibody validation information, see the Life 
Sciences Reporting Summary.
Validation of nanoboosters for vDISCO. Post-fixed brains from fluorescent protein-
expressing mice (for example, Thy1-GFP-M) were cut into 400 µ m slices using a 
vibratome (Leica, VT1200S). The slices were imaged before staining with a Zeiss 
AxioZoom EMS3/SyCoP3 fluorescence stereomicroscope to make sure that the 
samples have fluorescent protein expression. All the following steps were done with 
gentle shaking. The slices were first incubated for 3 h in a 24 multiwell (Falcon, 
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353504) at 37 °C with 1 ml of permeabilization solution containing 1.5% goat 
serum (Gibco, 16210072), 0.5% Triton X-100 (AppliChem, A4975,1000), 0.5 mM  
of methyl-β -cyclodextrin (Sigma-Aldrich, 332615), 0.2% trans-1-acetyl-4-hydroxy-
l-proline (Sigma-Aldrich, 441562) and 0.05% sodium azide (Sigma-Aldrich, 
71290) in 0.1 M PBS. Subsequently, they were incubated overnight at 37 °C with  
the same permeabilization solution, and the nanobooster of interest was  
added with dilution 1:500 considering final volume = 500 µ l. The multiwell was 
covered with aluminium foil to keep the slices in dark and was sealed well with 
parafilm (Bemis, PM-992) to prevent the solution from drying out. One slice was 
kept as negative control where there was no adding of nanobooster. After the 
incubation, slices were washed with the washing solution (1.5% goat serum, 0.5% 
Triton X-100, 0.05% sodium azide in 0.1 M PBS) at room temperature for 15 min 
4 times and then washed with 0.1 M PBS at room temperature for 10 min 3 times. 
Then the slices were imaged again after staining with the AxioZoom microscope 
to check whether the staining worked. In the end, slices were moved to 5 ml 
Eppendorf tubes wrapped with aluminium foil to keep them in dark and cleared 
with 3DISCO protocol: first they were incubated at room temperature in the 
following gradient of tetrahydrofuran (THF; Sigma-Aldrich, 186562) in distilled 
water (45 min for each step): 50 vol% THF, 70 vol% THF, 80 vol% THF, 100 vol% 
THF and 1 h 100 vol% THF; after dehydration, samples were incubated for 15 min 
in dichloromethane, and finally in BABB until transparency. Finally, the slices 
were imaged again with the AxioZoom microscope to make sure that the staining 
worked even after clearing. For more details of the AxioZoom imaging setup, see 
the ‘Fluorescence stereomicroscopy imaging’ section below.
vDISCO whole-body immunostaining, PI labeling and clearing. In order to 
remove remaining blood and heme after PFA perfusion, and to decalcify the 
bones, the animals were subjected to perfusion with decolorization solution and 
decalcification solution before immunostaining. The decolorization solution was 
made with 25–30 vol% dilution of CUBIC reagent 15 in 0.1 M PBS. CUBIC  
reagent 1 was prepared with 25 wt% urea (Carl Roth, 3941.3), 25 wt% N,N,N′ , 
N′-tetrakis (2-hydroxypropyl)ethylenediamine (Sigma-Aldrich, 122262) and 
15 wt% Triton X-100 in 0.1 M PBS. The decalcification solution consisted of  
10 wt/vol% EDTA (Carl Roth, 1702922685) in 0.1 M PBS, adjusting the pH to  
8–9 with sodium hydroxide (Sigma-Aldrich, 71687).
The solutions for the immunolabeling pipeline were pumped inside the body 
of the animal by transcardial-circulatory perfusion, exploiting the same entry point 
hole into the heart created during the PBS and PFA perfusion step (see above) and 
following the procedure described by Pan et al.17. In brief, the mouse body was 
placed in a 300 ml glass chamber (Omnilab, 5163279) filled with 250–300 ml of 
appropriate solution, which covered the body completely. Next, the transcardial-
circulatory system was established involving a peristaltic pump (ISMATEC, 
REGLO Digital MS-4/8 ISM 834; reference tubing, SC0266), keeping the pressure 
at 160–230 mmHg (45–60 r.p.m.). One channel from the pump, made by a single 
reference tube, was set for circulation of the solution through the heart into the 
vasculature: one ending of the tube was connected to the tip of a syringe (cut 
from a 1 ml syringe; Braun, 9166017V) which held the perfusion needle (Leica, 
39471024), and the other ending was immersed in the solution chamber where 
the animal was placed. The perfusion needle pumped the appropriate solution 
into the mouse body, and the other ending collected the solution exiting the 
mouse body to recirculate the solution, pumping it back into the animal. To fix the 
needle tip in place and to ensure extensive perfusion, we put a drop of superglue 
(Pattex, PSK1C) at the level of the hole where the needle was inserted inside the 
heart. Using the setting explained above, after post-fixation and PBS washing, 
the mice were first perfused with 0.1 M PBS overnight at room temperature; 
then, the animals were perfused with 250 ml of decolorization solution for 2 d at 
room temperature, exchanging with fresh decolorization solution every 6–12 h 
until the solution turned from yellowish to clear and the spleen became lighter in 
color (indicating that the blood heme was extracted). Then, they were perfused 
with 0.1 M PBS, washing for 3 h 3 times, followed by perfusion with 250 ml of 
decalcification solution for 2 d at room temperature and again perfusion/washing 
with 0.1 M PBS for 3 h 3 times. After this, the animals were perfused with 250 ml 
of permeabilization solution containing 1.5% goat serum, 0.5% Triton X-100, 
0.5 mM of methyl-β -cyclodextrin, 0.2% trans-1-acetyl-4-hydroxy-l-proline and 
0.05% sodium azide in 0.1 M PBS for half a day at room temperature. Subsequently, 
the perfusion proceeded further, through connection of a 0.20 µ m syringe filter 
(Sartorius, 16532) to the ending of the tube not holding the needle to efficiently 
prevent accumulation of dye aggregates into the sample. At the same time, from 
this step we used an infrared lamp (Beuer, IL21) directed to the chamber to heat 
up the solution to 26–28 °C. With this setting, the animals were perfused for 6 d 
with 250 ml of the same permeabilization solution containing 35 µ l of nanobooster, 
which is 20–35 µ g in 250 ml (0.08–0.14 µ g ml−1), 1:7,000 in dilution (stock 
concentration 0.5–1 mg ml−1; the amount of nanobody was adjusted depending on 
the expected presence of fluorescent protein in the mouse body) and 290 µ l of PI 
(stock concentration 1 mg ml−1). Next, we removed the animals from the chamber, 
and with fine scissors we removed a tiny piece from the back of the skull (above the 
cerebellum) at the level of the occipital bone; we then placed the bodies in a 50 ml 
tube (Falcon, 352070) filled with the same permeabilization solution containing 
an extra 5 µ l of nanobooster and incubated the tubes at 37 °C with gentle shaking 
for an additional 2–3 d of labeling. After that, the mice were placed back in the 
perfusion system, and labeling solution was washed out by perfusing with washing 
solution (1.5% goat serum, 0.5% Triton X-100, 0.05% of sodium azide in 0.1 M 
PBS) for 3 h 3 times at room temperature and 0.1 M PBS for 3 h 3 times at room 
temperature.
After the staining, the animals were cleared using a 3DISCO-based passive 
whole-body clearing protocol optimized for big samples. The mice were incubated 
at room temperature in dehydration and clearing solutions inside a 300 ml glass 
chamber, kept with gentle rotation on top of a shaking rocker (IKA, 2D digital) 
inside a fume hood. For dehydration, mice bodies were incubated in 200 ml of 
the following gradient of THF in distilled water (12 h for each step): 50 vol% THF, 
70 vol% THF, 80 vol% THF, 100 vol% THF and again 100 vol% THF, followed 
by 3 h in dichloromethane and finally in BABB. During all incubation steps, the 
glass chamber was sealed with parafilm and covered with aluminum foil. See 
Supplementary Table 1 and http://www.discotechnologies.org/vDISCO/.
vDISCO whole-mount immunolabeling of individual organs. vDISCO was 
performed on dissected organs as well: dissected brains were stained using the 
immunolabeling protocol for dissected organs. First, the post-fixed brains were 
pretreated, incubating them for 2 d at 37 °C with gentle shaking in 4.5 ml of 
same solution used at the permeabilization step (see above). Subsequently, the 
brains were incubated in 4.5 ml of this same permeabilization solution plus the 
nanobooster of interest with the concentration adjusted to expression of the 
target (for example, Atto647N-conjugated anti-GFP nanobooster dilution 1:600, 
which is ~5–8 µ g of nanobooster in 4.5 ml (1.1–1.8 µ g ml−1; stock concentration, 
0.5–1 mg ml−1) for Thy1-GFP-M brains) for 12–14 d at 37 °C with gentle shaking, 
then brains were washed for 2 h 3 times and once overnight with the washing 
solution (1.5% goat serum, 0.5% Triton X-100, 0.05% of sodium azide in 0.1 M 
PBS) at room temperature and in the end washed for 2 h 4 times with 0.1 M PBS at 
room temperature. The immunostained brains were cleared with 3DISCO clearing: 
first they were put in the Eppendorf 5 ml tubes, and then they were incubated at 
room temperature with gentle shaking in 4.5 ml of the following gradient of THF 
in distilled water (2 h for each step): 50 vol% THF, 70 vol% THF, 80 vol% THF, 
100 vol% THF and overnight ;vol% THF; after dehydration, the samples were 
incubated for 1 h in dichloromethane and finally in BABB until transparency. 
During all the clearing steps, the tubes were wrapped with aluminum foil to keep 
them in dark. See Supplementary Table 1.
For the comparison of deep-tissue staining efficiency in terms of penetration 
of the staining of nanobody versus conventional antibody (Supplementary Fig. 2), 
we followed the same protocol described above in this section for both nanobody 
and antibody experimental groups. The only exception was that for the antibody 
group, in the immunostaining step, we replaced the nanobooster with Alexa647-
conjugated anti-GFP antibody (Invitrogen, A31852) with the same concentration 
(see above).
Pumping pressure measurement. A KKmoon Digital Manometer Pressure 
Gauge Manometer (HT-1891) was used to measure the pressure. To achieve 
one additional measuring channel to connect with the manometer, a two-head 
connector (B.Braun Discofix C Dreiwegehahn, 16494C) was inserted into the 
pumping channel, and the second head was further connected to the manometer 
with extended PVC tubing. The pumping channel was set in the standard way as 
described including a transcardiac perfusion needle. First, the switch on the two-
head connector was set without connecting the measuring tubing, and pumping 
was started until all the air bubbles were excluded from the pumping channel. 
Subsequently, the switch was set to connect the measuring tubing while pumping 
was continued, and the pressure was measured when the manometer readouts 
stabilized. Three measurements were made at different time points including 
morning, afternoon and evening to exclude the variation of room temperature, and 
the data were quantified by averaging.
Comparison of high-pressure versus low-pressure perfusion with methylene 
blue. The diffusion of methylene blue (Sigma-Aldrich, M9140), perfused into the 
body of the animals, was used to compare the efficiency of high-pressure versus 
low-pressure perfusion (Supplementary Fig. 8). For this purpose, we used 3 BL6 
animals (4 months old) per experimental group: post-fixed whole bodies were 
perfused for 15 min with 0.05% methylene blue in 0.1 M PBS, at either 50 r.p.m. 
(~180 mmHg) for the high-pressure group or 25 r.p.m. (~70 mmHg) for the low-
pressure group. The same pump setting explained in the section ‘vDISCO whole-
body immunostaining, PI labeling and clearing’ was used, including the usage of 
superglue to fix the needle in place inside the hole in the heart.
iDISCO+. Antibody validation: methanol compatibility test. Before performing the 
comparison of the e]ciency between vDISCO nanobody staining and iDISCO+ 
antibody staining on whole brains, we veri'ed the compatibility of the chosen 
antibody with the iDISCO+ protocol (Supplementary Fig. 3a–d). #is was done 
performing the antibody validation step, which tested the compatibility of the 
antibody with the methanol pretreatment required by iDISCO+ . To do so, we 
followed the original iDISCO+ publication23 and the latest protocol updates from 
https://idisco.info. Brie<y, post-'xed brains from !y1-GFP-M and CX3CR1GFP/+ 
NATURE NEUROSCIENCE | www.nature.com/natureneuroscience
TECHNICAL REPORT NATURE NEUROSCIENCE
mice (2–3 months old) were cut into 600 µ m slices with a vibratome. First, the slices 
were incubated overnight in 100% methanol (Roth, 4627.6) at room temperature; 
then, a$er rehydrating and washing with 0.1 M PBS, the iDISCO+ immunostaining 
protocol was done as normally using 3 h as permeabilization time, 6 h as blocking 
time and overnight as immunolabeling time, adding 1:850 of Alexa647-conjugated 
anti-GFP antibody (already used in the previous section) in 500 µ l of incubation 
solution. Non-methanol-treated slices were used as positive controls. In the 
end, the slices were imaged using the Zeiss AxioZoom stereomicroscope (see 
‘Fluorescence stereomicroscopy imaging’ section below).
iDISCO+ on dissected brains. After having verified that the previously mentioned 
conventional anti-GFP antibody is compatible with iDISCO+ , we performed 
comparison of staining efficiency between vDISCO with nanobody and iDISCO+ 
with conventional antibody (Supplementary Fig. 3e–i). For this purpose, 3 
CX3CR1GFP/+ post-fixed brains (6–7 months old) were used per experimental 
group. The brains allocated into the vDISCO group were processed following  
the vDISCO protocol for dissected brains (see ‘vDISCO whole-mount 
immunolabeling of individual organs’ section), while the brains allocated into the 
iDISCO+ group were processed using 1:730 of the above-mentioned Alexa647-
conjugated anti-GFP antibody following the iDISCO+ protocol and its updates 
from https://idisco.info (ref. 23).
Different whole-body labeling protocols comparison. To show that vDISCO with 
nanobody is the only method that can efficiently boost the GFP signal in mouse 
whole bodies, we performed the following comparison using 3 GFP-M animals 
(2–3 months old) per experimental group: (1) high-pressure active perfusion 
vDISCO with nanobody, (2) passive incubation vDISCO with nanobody, (3) high-
pressure active perfusion vDISCO with conventional antibody, (4) high-pressure 
active perfusion iDISCO+ with conventional antibody, and (5) high-pressure 
active perfusion iDISCO+ with nanobody. Group 1 was processed using the above-
described vDISCO whole-body immunostaining and clearing method; the group 2 
was processed following all the steps of the vDISCO whole-body immunostaining 
and clearing protocol described above, but replacing all the original steps done in 
perfusion with passive incubation; group 3 was processed using the same vDISCO 
whole-body immunostaining and clearing protocol, but replacing the nanobooster 
with Alexa647-conjugated anti-GFP antibody at the same concentration as the 
nanobooster during the staining step; groups 4 and 5 were processed performing 
the iDISCO+ methanol pretreatment on the animals followed by sequential 
perfusion of all the iDISCO+ solutions23 (except that the clearing was done with 
passive incubation): the timing of each iDISCO+ step was adjusted considering 
the size of a whole body compared with a dissected brain (for example, during 
the methanol dehydration, each step was increased to 5 h versus 1 h for dissected 
brains). The antibody used for group 4 is the Alexa647-conjugated anti-GFP 
antibody mentioned above.
Previously published whole-body clearing methods for comparison. For PARS 
clearing, 10% EDTA adopted from Bone-CLARITY25 was transcardially perfused 
through the whole mouse bodies after PFA fixation for 5–7 d to decalcify the bones. 
Then, the standard PARS procedure was followed53. CUBIC18, uDISCO17 and 
PEGASOS16 were conducted based on the original publications. It is worth noting 
that among all the clearing methods tested, PARS, PEGASOS and vDISCO were 
characterized by a decalcification step using EDTA solutions.
Light-sheet microscopy imaging. Single-plane illuminated (light-sheet) image 
stacks were acquired using an Ultramicroscope II (LaVision BioTec), featuring an 
axial resolution of 4 μ m with the following filter sets: ex 470/40 nm, em 535/50 nm; 
ex 545/25 nm, em 605/70 nm; ex 560/30 nm, em 609/54 nm; ex 580/25 nm,  
em 625/30 nm; ex 640/40 nm, em 690/50 nm. For low-magnification whole-body 
imaging of the Thy1-GFP-M mouse, we used a × 1 Olympus air objective (Olympus 
MV PLAPO × 1/0.25 NA (WD = 65 mm)) coupled to an Olympus MVX10 zoom 
body, which provided zoom-out and zoom-in ranging from × 0.63 up to × 6.3. 
Using × 1 objective and × 0.63 of zoom, we imaged a field of view of 2 × 2.5 cm, 
covering the entire width of the mouse body. Tile scans with 60% overlap along 
the longitudinal y axis of the mouse body were obtained from ventral and dorsal 
surfaces up to 13 mm in depth, covering the entire volume of the body using a  
z-step of 8 µ m. Exposure time was 120 ms, laser power was adjusted depending on 
the intensity of the fluorescent signal (in order to never reach the saturation) and 
the light-sheet width was kept at maximum. After tile imaging of the sample within 
the entire field of view, already scanned regions were cut using a thin motorized 
dental blade (0.2 mm; Dremel 8200) for further imaging. After low-magnification 
imaging of the whole body, a forelimb of the Thy1-GFP-M animal was imaged with 
a × 2 objective (Olympus MVPLAPO2XC/0.5 NA (WD = 6 mm)) coupled with the 
same Olympus MVX10 zoom body at zoom magnification × 1.6. Moreover, the 
same × 2 objective with different zooms was used to perform high-magnification 
imaging of specific body regions (for example, the back of the animal at the level 
of lumbar vertebra, the inguinal lymph node area or the head). Individual organs 
(including brain, lungs, intestine and thymus) were imaged individually using 
high-magnification objectives: × 2 objective (Olympus MVPLAPO2XC/0.5 NA 
(WD = 6 mm)) coupled with the same Olympus MVX10 zoom body, × 4 objective 
(Olympus XLFLUOR × 4 corrected/0.28 NA (WD = 10 mm)), × 25 objective 
(Olympus XLPLN × 25/0.95 NA (WD = 4 mm)) and × 20 objective (Zeiss × 20 Clr 
Plan-Neofluar/0.1 NA (WD 5.6 = mm)) coupled to an Olympus revolving zoom 
body unit (U-TVCAC) kept at × 1. High-magnification tile scans were acquired 
using 8–30% overlap, and the light-sheet width was reduced to obtain maximum 
illumination in the field. For the specific imaging settings used in each figure panel, 
see Supplementary Table 2.
Fluorescence stereomicroscopy imaging. For images in Supplementary Fig. 3, 
brain slices were kept immersed in PBS. For nanobody validation, cleared slices 
were put on a glass lid and kept immersed in BABB. The imaging was performed 
with Zeiss AxioZoom EMS3/SyCoP3 fluorescence stereomicroscope using  
Zen 2 software (v.2.0.0.0; Carl Zeiss AG) using a × 1 long-working-distance  
air objective lens (Plan Z × 1, 0.25 NA, WD = 56 mm; Supplementary Table 2).  
For the comparison of YFP-H mouse tissues after high-pressure pumping versus 
low-pressure pumping in Supplementary Fig. 9, the mouse brains were cut into 
1 mm slices using a vibratome and imaged with magnification × 7 for overview  
and with magnification × 112 in GFP channel for their detailed cell structures.  
See Supplementary Table 2.
Laser-scanning confocal microscopy imaging. After imaging with light-sheet 
microscopy, areas of interest from the cleared specimens, such as whole heads and 
body parts, were imaged with an inverted laser-scanning confocal microscope 
(Zeiss, LSM 880) using Zen 2 software (v.10.0.4.910; Carl Zeiss AG). Before 
imaging, samples were mounted by placing them onto the glass surface of a 35 mm 
glass-bottom petri dishes (MatTek, P35G-0-14-C) and adding a few drops of BABB 
to make sure that the imaging region was immersed in BABB. Closing or sealing  
of the petri dish was not necessary because BABB has a high evaporation point  
and doesn’t dry out for several days. The only precaution taken was to check  
the resistance of the dish against BABB, by testing that the glue sealing the  
glass to the dish and the plastic parts were not dissolved after several hours of  
exposure to BABB.
The imaging was done using a × 40 oil-immersion objective lens  
(Zeiss, ECPlan-NeoFluar × 40/1.30 oil DIC M27, 1.3 NA, WD = 0.21 mm)  
and a × 25 water-immersion long-working-distance objective lens (Leica,  
0.95 NA, WD = 2.5 mm) mounted on a custom mounting thread. See 
Supplementary Table 2.
Reconstructions of whole-mouse body scans. We acquired light-sheet microscope 
stacks using ImSpector (v.5.295, LaVision BioTec) as 16-bit grayscale TIFF images 
for each channel separately. In each pair of neighboring stacks, alignment was done 
by manually selecting 3 to 4 anatomic landmarks from the overlapping regions, 
and then the stitching was done sequentially with the Scope Fusion module of the 
Vision4D (v.2.12.6 × 64, Arivis) software. Landmarks were mainly chosen from the 
skeletal bones or occasionally from the neuronal structures on the basis of visual 
inspection of the anatomical features. After completing the 3D reconstructions, the 
data visualization was done with Amira (v.6.3.0, FEI Visualization Sciences Group), 
Imaris (v.9.1, Bitplane) and Vision4D in both volumetric and maximum-intensity 
projection color mapping. Depth coding was done using the Temporal-Color Code 
plugin in Fiji (ImageJ2, v.1.51, https://fiji.sc/).
Image processing. Processing, data analysis, 3D rendering and video generation 
for the rest of the data were done on an HP workstation Z840, with 8 core Xeon 
processor, 196 GB RAM, and Nvidia Quadro k5000 graphics card and HP 
workstation Z840 dual Xeon 256 GB DDR4 RAM, nVidia Quadro M5000 8GB 
graphic card. We used Imaris, Amira and Fiji (ImageJ2) for 3D and 2D image 
visualization. Tile scans were stitched by Fiji’s stitching plugin49. Stitched images 
were saved in TIFF format and optionally compressed in LZW format to enable 
fast processing. We removed tiles with acquisition errors using Fiji’s TrakEM2 
plugin and Imglib2library. In case of tiling errors in the z dimension, we used 
TeraStitcher (v.1.10; https://abria.github.io/TeraStitcher/) with its default settings to 
globally optimize the tiled volumes and reconstruct the entire dataset. To increase 
the quality of the images, we used the following functions in Fiji: to enhance the 
contrast of microglia cells (Fig. 1n and Supplementary Fig. 2a–f), we used ‘Enhance 
Local Contrast (CLAHE)’; to equalize the images (Fig. 4a,b and Supplementary 
Fig. 2a–f), we used ‘Pseudo Flat-Field Correction’; to enhance the contrast over the 
background of the axonal terminals in Fig. 4c,d, we used the custom-made macro 
for Fiji that we utilized to generate the pre-processed data for NeuroGPS-Tree  
(see the section ‘Neuron tracing’ below).
Neuron tracing. For automated neuron tracing in our light-sheet datasets 
obtained with Zeiss × 20 Clr Plan-Neofluar/0.1 NA (WD = 5.6 mm) objective, 
we used the NeuroGPS-Tree algorithm22. NeuroGPS-Tree was developed for 
tracing relatively small volumes of confocal microscopy data; therefore, we 
initially reduced the file size to under 1 GB (approximate maximum data size 
for NeuroGPS-Tree computation) by using the Fiji scale function. Due to high 
signal intensity discrepancy between soma and neurites, we next pre-processed 
the data with a custom-made macro in Fiji (available upon request), which 
consisted of background removal, pseudo-background correction, noise filtering 
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and sharpening. Next, the pre-processed data were loaded and analyzed first in 
NeuroGPS for soma detection and later in NeuroGPS-Tree for neurite detection 
(both steps are part of the same algorithm package). The best parameters for soma 
and neurite detection were chosen following the original publication. To quantify 
the features (such as the number of neurites per cell and the number of somas with 
at least one neurite) of these detected neuronal cells, we used Amira software: we 
chose the 10 neurons with the biggest file size per group and analyzed them using 
the Spatial Graph Statistics function of the software.
Quantifications. All the details of imaging settings used to acquire the data for the 
quantifications described in this section are available in Supplementary Table 2.
Analysis of fluorescence signal profiles from light-sheet images. The fluorescence 
signal profiles from each channel (excitation 470 nm, 560 nm and 647 nm) were 
plotted in the same z-stack and normalized as percentage over the maximum peak 
using Fiji (Supplementary Fig. 1).
To compare vDISCO boosted and unboosted protocols and consequently the 
reduction of the background and the improvement of the signal over background 
ratio in the far-red channel, we analyzed neurons and axonal bundles expressing 
GFP imaged with excitation at 470 nm, and neurons and axonal bundles labeled 
with anti-GFP nanobody conjugated with Atto647N imaged with excitation at 
640 nm at the same anatomic region. First, the scans were taken with the light-
sheet microscope using the × 4 objective (Olympus XLFLUOR × 4 corrected/0.28 
NA (WD = 10 mm)). Then, the signal profiles were analyzed in Fiji and measured 
from a defined straight line covering the neuronal structure and surrounding 
tissue background, and the normalized plots of the signal profile (Fig. 1i) were 
calculated by normalizing the plots of neuronal structures obtained as described 
above over the average signal intensity of the respective surrounding background. 
Each experimental group consisted of 3 animals, and for each animal at the same 
anatomic region we plotted 3 profiles.
The same analysis of signal profile was used to compare the labeling efficiency 
of vDISCO with nanobody and iDISCO+ with antibody (Supplementary Fig. 3g–i):  
in this case the signal of interest was the one coming from microglia. Each 
experimental group consisted of 3 animals, and for each animal at the same anatomic 
region we plotted 3 profiles from 3 different microglia. The same analysis of signal 
profile was used to compare different clearing methods in Supplementary Fig. 12.
Fluorescence level. Fluorescence level quantification was expressed as a signal-
to-background ratio and was calculated using Fiji17 at the following time points: 
0, 2, 3, 4.5, 5.5, 12 and 18 months after nanoboosting (Fig. 1n,o). Each × 4 light-
sheet microscopy brain scan was taken with the same imaging parameters, and 
an image in TIFF format of the same anatomic region for all the samples was 
quantified. The mean value of the background for each image was obtained by 
averaging the background values of 12–40 regions from equally sized areas of 
the image in regions of the sample without signal. To calculate the mean value 
of the signal for each image, we used the threshold function of the software: 
the threshold was adjusted to consider the fluorescence signal visible in the 
image. After adjusting the threshold, only the sharp signal from specific cellular 
structures was analyzed per image. To this end, we used Fiji’s ‘analyze particles’ 
function to measure the signal intensity only of particles sized between 5–10 
and 100–150 pixels (visible fluorescent cells) and calculated the average value 
from all the particles. Next, this value was divided by the mean value of the 
background of the respective image, obtaining the fluorescence level over the 
background. The corresponding images, visually showing the preservation of 
signal over time in relation to the respective fluorescence levels, were processed 
using the Enhance Local Contrast (CLAHE) function in Fiji to increase the 
contrast of fluorescent cells in the tissue.
Quantification of deep-tissue staining efficiency of nanobody versus antibody. To 
quantify the depth of staining and therefore to compare whole-organ staining 
efficiency of nanobody versus antibody labeling (Supplementary Fig. 2), we 
used CX3CR1GFP/+ animals (3–7 months old), 3 whole brains per experimental 
group. The tile scans of the brains were taken with light-sheet microscopy in 
axial view using the × 4 objective (Olympus XLFLUOR × 4 corrected/0.28 NA 
(WD = 10 mm)). After stitching we chose the z-plane showing the same anatomic 
structures from all brains for comparison. These axial-view 2D images of whole 
brains were analyzed in Fiji; the distance of staining depth was quantified using the 
‘line’ function in the z-plane at the greatest width of the brain, measuring from the 
surface until the last visible boosted microglia. Then, for each image, this staining 
depth value was normalized over the total thickness of the brain at the considered 
z-level, measuring a line drawn from the same point of the surface until the axial 
middle line of the brains.
Quantification of whole-body labeling efficiency of different whole-body labeling 
protocols. To quantify the rate of staining of the different whole-body labeling 
protocols in Supplementary Fig. 11, the tile scans of 3 whole heads per method 
were taken with light-sheet microscopy in axial view using the × 2 objective 
described in the ‘Light-sheet microscopy imaging’ section above with a total 
magnification of × 1.26. For the analysis, we used Fiji to choose 3 regions in 
z in the 2D visualization, to have comparative data in 3 different depths (see 
Supplementary Fig. 2a,b). For each region, we chose the z-plane displaying the 
same anatomic structures in each sample. Next, the 2D images were opened in Fiji 
and, after adjusting the threshold to the fluorescence signal visible in the image, 
the stained area in the brain in each image was quantified using the ‘freehand 
selections’ function. Next, this stained area value was normalized over the total 
area of the brain visible in that 2D image. This total area was quantified using the 
same ‘freehand selections’ function in Fiji, following the brain outline. Statistical 
comparison was performed considering each set of corresponding regions from the 
different samples separately.
ClearMap. To quantify microglia distribution, we used ClearMap23. Since the script 
was originally developed for quantification of the cFos+ cells, to comply with the 
offered method, we did the following pre-processing steps on our microglia data 
using Fiji before ClearMap:
t Background equalization to homogenize intensity distribution and appearance 
of the microglia cells over di+erent regions of the brain, using pseudo-<at-'eld 
correction function from Bio-Voxxel toolbox.
t Convoluted background removal, to remove all particles bigger than relevant 
cells. #is was done with the median option in the Bio-Voxxel toolbox.
t Two-dimensional median 'lter to remove remaining noise a$er background 
removal. #e 'lter radius was chosen to ensure the removal of all particles 
smaller than microglia cells.
t Unshapen mask to amplify the high-frequency components of a signal and 
increase overall accuracy of the cell detection algorithm of ClearMap.
After pre-processing, ClearMap was applied by following the original 
publication and considering the threshold levels that we obtained from the 
pre-processing steps. As soon as the quantification was completed, the data was 
exported as an Excel file for further analysis. For example, the cellular density per 
brain region was obtained considering the absolute number of cells detected by 
ClearMap and the volume of that specific brain region, which was calculated using 
a custom script (available upon request) based on ClearMap (Elastix registration).
Quantification of peripheral neuronal degeneration in acute brain injury. Peripheral 
neuronal degeneration in TBI animals versus unlesioned control animals was 
done in the Thy1-GFP-M line and was assessed considering the complexity of 
axonal ramifications that projected from the left (left = contralateral side) cervical 
and thoracic vertebra to the left muscles of the back at the level of the torso of 
the mouse, including the left spinotrapezius and latissimus dorsi. The complexity 
was expressed as number of axonal endpoints (nerve terminals that appear as a 
button-like shape; see Fig. 4) over the total length of axonal ramifications that were 
protruding from a main branch. To calculate this index, first a 3 × 3 tile of z-stacks 
of this anatomic region was taken from the animals by light-sheet microscopy 
using the × 2 objective described in the ‘Light-sheet microscopy imaging’ section 
with a total magnification of × 5, to have enough resolution to manually trace the 
axonal ramifications and axonal end-feet. Then, the analysis was done over the 
maximum intensity projections of the tile scans with Fiji software. To measure 
the length of the ramifications, we used the ‘free hand line’ function and the ‘ROI 
manager tool’ of Fiji to record all the traced axonal ramifications of interest, which 
were coming from a main branch; later, we calculated the sum of the length of all of 
the recorded ramifications with the ‘measure’ function of Fiji. To count the nerve 
terminals, we used the ‘point tool’ function and the same ‘ROI manager tool’ to 
record all the visible axonal endpoints protruding from the traced ramifications. 
The analysis was performed over 2–4 branches from the same anatomic region 
for each animal, in 6 animals (3–6 months old) per experimental group. The same 
quantification procedure was followed to analyze the complexity at the equivalent 
ipsilateral (right side from dorsal view) side of the animals, in 6 and 5 animals for 
the TBI and unlesioned groups, respectively.
Quantification of CD68 GFP+ cells with spinal cord injury. The spine areas of 
interest from CD68-EGFP line mice with spinal cord injury or sham surgery 
and from naïve animals were imaged with light-sheet microscopy using the × 2 
objective described in the ‘Light-sheet microscopy imaging’ section with a total 
magnification of × 3.2 and with 2 × 3 tile z-stacks. After stitching, the entire z-stacks 
of scans were loaded in Fiji software with the ‘use virtual stack’ mode. To segment 
the spinal cord tissue from surrounding tissue, including bone and muscles, and 
count the cell numbers separately, the border of the spinal cord was marked by 
using the ‘free hand line’ function in Fiji as a manual selection. These manual 
selections were done in every 6–9 image slices and were recorded by the ‘ROI 
manager tool’ function. The complete selections for the entire z-stacks were then 
achieved by using the ‘interpolate ROIs’ function and were saved as .zip files. Then, 
the entire z-stacks of scans were loaded in Fiji software again, without selecting the 
‘use virtual stack’ mode. By loading the complete selections generated from former 
steps respectively, each spinal cord was segmented by using a custom-made macro 
with the ‘clear outside’ function and saved as a new ‘image sequence’. To maintain 
the integrity of the raw data, one should not save the changes when closing the 
window after running the macro. Then, the intact original z-stacks and complete 
selections were loaded again in the same way, and surrounding tissues including 
bone and muscles were segmented by using another custom-made macro with 
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the ‘clear’ function. All the custom-made macros are available upon request. Next, 
the segmented image stacks of spinal cord or surrounding tissue were loaded with 
Imaris respectively, and the ‘surface’ function was used to segment the CD68 GFP+ 
cells. By generating the ‘surface’ selection, the ‘statistic’ function was available to 
count the number of cells in the region of interest.
Quantification of short SMCs with MCAO. The transparent skulls from LysM-EGFP 
line mice with MCAO or sham were imaged with intact heads from the sagittal 
view with light-sheet microscopy using the × 2 objective described in the ‘Light-
sheet microscopy imaging’ section with a total magnification of × 3.2 and with 
2 × 4 tile z-stacks. After stitching, the entire z-stacks of scans were loaded in Imaris, 
and the length, width and cell numbers in the SMCs were manually calculated by 
using the ‘measure-line’ function. Then, the length and width of the channels were 
corrected by a shrinkage rate of DISCO clearing17.
Statistical analysis. Data collection and analysis were not performed blind to the 
conditions of the experiments. Data distribution was assumed to be normal, but 
this was not formally tested. Data are presented as mean ± s.d. except for in Fig.6 
and Supplementary Fig. 22, where they are presented as mean ± s.e.m. Sample sizes 
are indicated in the figure legends. Statistical analysis was performed using Prism 
GraphPad software v.6 with 95% confidence interval. P values were calculated 
using two-tailed unpaired t test to compare data between two groups. P values 
were calculated using one-way ANOVA followed by Dunnett’s post hoc test to 
compare data in Supplementary Figs. 4 and 11. For CD68-EGFP quantification in 
Supplementary Fig. 22, P values were calculated using one-way ANOVA followed by 
Tukey multiple comparison test to compare data between SCI (spinal cord injury),  
sham and naïve groups. A P value of< 0.05 was considered statistically significant.  
In ANOVA analysis the reported P values are adjusted in GraphPad prism to account 
for multiple comparisons. The protocols described in this study were replicated 
successfully more than five times in independent experiments, and they were  
also reproduced at least by three different operators. See also the Life Sciences  
Reporting Summary.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Code availability. The custom codes used to analyze the data in this study are 
available from the corresponding author upon request.
Data availability
The data that support the findings of this study are available from the 
corresponding author upon reasonable request.
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2.3 Research Article 3: Deep learning reveals cancer metastasis and 
therapeutic antibody targeting in whole body 
 
9 out of 10 cancer patients die because of the global cancer metastasis but not the 
primary tumors suggests that understanding the metastasis mechanism is extremely 
critical for cancer therapy. Although tissue clearing has been widely used in 
biomedical research field, mapping the cancer metastasis and therapeutic drugs 
through the whole mouse body requires an advanced methodology for reliable 
detection and automated high-throughput quantification.  
 
As a robust whole-body tissue clearing method which improves the imaging quality 
two orders of magnitude, vDISCO enables the unbiased detection of cancer 
metastasis with single cell level resolution. To improve the efficacy of signal 
identification and quantification, we developed a deep learning based algorithm, 
termed DeepMACT, to automatically quantify the breast cancer metastasis and 
therapeutic antibody distribution through the whole mouse bodies. Applying the 
DeepMACT pipeline, we found that the majority of metastasis were located in lungs, 
which is line with previous report that lungs are one of the most common metastasize 
target for breast cancer (Jin et al., 2018). Comparing with the performance of human 
operator, DeepMACT reached similar detection accuracy while 300 times faster in 
speed. Next, in order to study the bio-distribution and targeting efficacy of therapeutic 
antibody, we injected  6A10 antibody conjugated with Alexa dye and found that 77% 
of metastasis were targeted, specifically 85% in lungs and 66% in rest body tissue. 
Furthermore, we did not find the correlation between the size and targeting effect of 
metastasis but Intriguingly, we found that the targeted metastasis are clustered and 
close to each other. This indicates that microenvironment of the metastasis niches 
might play an important role in antibody targeting. Overall, DeepMACT achieved 
reliable detection and automated quantification of cancer metastasis throughout the 
whole mouse body and is a robust platform readily applicable to various types of 
cancer and therapeutic drug studies. 
 
Author contribution: performed 2D epifluorescence microscopy of cleared whole-body 
samples; performed 3D high resolution light-sheet microscopy for individual organs; 
performed confocal microscopy and analysis for vessel quantification; wrote the 
manuscript with colleagues (please see section 7 for further details). 
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Deep learning reveals cancer metastasis and 
therapeutic antibody targeting in whole body
SUMMARY 
Reliable detection of disseminated tumor cells and 
of the biodistribution of tumor-targeting therapeutic 
antibodies within the entire body has long been 
needed to better understand and treat cancer 
metastasis. Here, we developed an integrated 
pipeline for automated quantification of cancer 
metastases and therapeutic antibody targeting, 
named DeepMACT. First, we enhanced the 
fluorescent signal of tumor cells more than 100-fold 
by applying the vDISCO method to image single 
cancer cells in intact transparent mice. Second, we 
developed deep learning algorithms for automated 
quantification of metastases with an accuracy 
matching human expert manual annotation. Deep 
learning-based quantifications in a model of 
spontaneous metastasis using human breast cancer 
cells allowed us to systematically analyze clinically 
relevant features such as size, shape, spatial 
distribution, and the degree to which metastases 
are targeted by a therapeutic monoclonal antibody 
in whole mice. DeepMACT can thus considerably 
improve the discovery of effective therapeutic 
strategies for metastatic cancer.
INTRODUCTION
Metastasis is a complex process affecting diverse 
organs1-3. As most cancer patients die of metastases 
at distant sites developing from disseminated tumor 
cells with primary or acquired resistance to therapy, 
a comprehensive and unbiased detection of 
disseminated tumor cells and tumor targeting drugs 
within the entire body at the single cell level is crucial4. 
Such technology would help to explore mechanisms 
affecting tumor metastasis and drug targeting much 
more reliably, hence substantially contributing to 
the development of improved therapeutics. So far, 
such efforts have been hampered by the lack of 1) 
imaging technologies to reliably detect single cancer 
cells in intact mouse bodies, and 2) algorithms to 
quickly and accurately quantify large-scale imaging 
data. Here, we developed an analysis pipeline that 
allows us to efficiently solve these limitations.
First, we built upon recently developed whole 
mouse clearing methods5-8 to address the imaging 
problem. Typically, fluorescent labeling of cancer 
cells in vitro or in vivo is achieved by endogenous 
expression of fluorescent proteins such as GFP, 
YFP, and mCherry, which emit light in the visible 
spectrum. However, many tissues in the body 
show high autofluorescence in this range9,10, 
which hinders reliable detection of single cancer 
cells or small cell clusters in intact mouse bodies 
based on their endogenous fluorescent signal. To 
circumvent this problem, we chose to implement 
the vDISCO technology8, which amplifies the signal 
of fluorescent proteins of cancer cells more than 
100-fold, enabling reliable imaging not only of large 
metastases but also micrometastases down to 
single cells throughout the entire body.
Second, systematic analysis of metastasis in whole 
adult mouse bodies requires quantitative information 
such as location, size and shape of all individual 
metastases. Manual detection and segmentation of 
numerous metastases in highly resolved full body 
scans is an extremely laborious task that may take 
several months per mouse for an expert annotator. 
In addition, automation by filter-based 3D object 
detectors is not reliable as different body tissues 
have different levels of contrast5, causing a high 
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2rate of false positive and false negative cancer cell 
detection. Recent studies have started to show the 
high-efficacy of deep learning-based analysis of 
biomedical images, as well as pre-clinical studies, 
compared to filter-based or manual segmentation 
methods11-17. To enable automated, robust, and 
fast mapping of all tumor cells in transparent mice, 
we developed an efficient deep learning approach 
based on convolutional neural networks (CNNs) 
and optimized it for the vDISCO imaging data and 
tumor cell distribution patterns. 
Together, resolving these two bottlenecks allowed 
us to build an integrated, highly automated pipeline 
for analysis of metastasis and tumor-targeting 
therapeutics, which we named DeepMACT (Deep 
learning-enabled Metastasis Analysis in Cleared 
Tissue). Using DeepMACT, we detected cancer 
metastasis and therapeutic antibody targeting at the 
single cell level in entire mouse bodies, including 
many metastases previously overlooked by human 
annotators. As a scalable, easily accessible, fast, 
and cost-efficient method, DeepMACT enables a 
wide range of studies on cancer metastasis and 
therapeutic strategies. To facilitate adoption, the 
protocols for clearing and imaging, as well as the 
deep learning algorithm, the training data, and 
the trained model are freely available online for 
adaptations to address diverse questions in pre-
clinical and clinical research.
RESULTS
Focusing on a clinically relevant tumor model, 
we transplanted human MDA-MB-231 mammary 
carcinoma cells, expressing mCherry and firefly 
luciferase, into the mammary fat pad of NOD scid 
gamma (NSG) mice and allowed the tumors to grow 
and metastasize for 6-10 weeks (Figure 1A)18-20. 
Furthermore, we injected the fluorescently-tagged 
6A10 therapeutic antibody that has been shown to 
reduce tumor burden in this model19,20. To investigate 
cancer metastasis and therapeutic antibody targeting 
in whole mouse bodies at the single cell level, we 
developed DeepMACT. In short, we transcardially 
perfused the animals using standard PFA fixation 
and applied the vDISCO method to boost the 
fluorescent signal of tumor cells in transparent 
mice. After light-sheet microscopy, the 3D image 
stacks of whole mouse bodies were analyzed 
using deep learning algorithms. The DeepMACT 
pipeline consists of 1) vDISCO panoptic imaging of 
transparent mice at the single cell level and 2) deep 
learning-based analysis of cancer metastasis and 
antibody drug targeting (Figure 1B). 
DeepMACT step 1: vDISCO imaging of cancer 
metastases at cellular resolution in intact mice 
We previously developed the vDISCO technology 
to image single cells in mouse bodies through 
intact bones and skin8. The vDISCO method utilizes 
bright fluorescent dyes tagged to nanobodies to 
boost the signal of fluorescent proteins expressed 
in the target cells. Here, we first applied vDISCO 
to increase the fluorescence signal of mCherry-
expressing cancer cells. Boosting the tumor 
cell fluorescence with anti-mCherry nanobodies 
conjugated to Atto-594 or Atto-647N dyes, we 
found that nanoboosters can enhance the signal 
quality of cancer cells over 100 times compared to 
imaging the endogenous mCherry signal (Figure 
S1). Owing to this significant enhancement in signal 
contrast, we could readily detect single cancer cells 
buried in centimeters-thick mouse bodies, e.g., in 
deep brain regions through the intact skull (Figure 
S1F, yellow arrowhead). To confirm the specificity 
of vDISCO boosting of mCherry expressing cancer 
cells, we performed the following experiments: 1) 
we stained control mice without a tumor transplant, 
thereby lacking mCherry expression, and found 
no labeling in any of the analyzed organs; 2) we 
analyzed the primary tumors and lung metastases 
from the vDISCO-processed mouse bodies by 
staining them using a specific anti-luciferase 
antibody, which confirmed that endogenous 
mCherry fluorescence co-localized with both the 
nanobooster and the luciferase signals; and 3) we 
confirmed the colocalization of nanoboosters with 
mCherry expressing single tumor cells (Figure S2).
Since the detection of smaller-sized tumor cell 
clusters, which may represent dormant cancer cells 
or incipient metastatic nodules, is critical, we next 
tested if vDISCO allows imaging cancer metastases 
in whole-mouse bodies at the single cell level. In 
order to compare our approach to conventional 
methods, we also acquired bioluminescence images 
of mice before applying DeepMACT. In line with 
previous findings18, we detected the earliest large 
metastasis of transplanted MDA-MB-231 cells at 
the axillary lymph node of mice by bioluminescence 
(Figure 2A, Figure S3). However, bioluminescence 
imaging did not reveal any detailed information such 
as size or shape and failed to show the presence of 
micrometastases. 
After bioluminescence assessment, we applied 
vDISCO using anti-mCherry nanoboosters 
conjugated to Atto-647N and imaged the whole-
mouse bodies first using epifluorescence in 2D 
(Figure 2B-G), then using light-sheet microscopy 
in 3D (Figure 2H-O). In epifluorescence, we could 
readily see both the primary tumor (Figure 2F) 
and the major metastases at the axillary lymph 
node (Figure 2D), which were also detected by 
bioluminescence imaging (Figure 2A), albeit as 
3Figure 1
Experimental design and schematic of DeepMACT pipeline for analysis of cancer metastases and antibody 
drug targeting at single cell level 
(A) Illustration of the experimental workflow for tumor transplantation and antibody application. (B) Steps of the Deep-
MACT pipeline on whole mouse bodies. First, the whole mice are fixed and processed with the vDISCO protocol to 
amplify the fluorescent signal of cancer cells. Whole transparent mice are subsequently imaged using light-sheet mi-
croscopy from head to toe at single cell resolution. Light-sheet images are assembled into a complete 3D image of the 
mouse. Next, convolutional neural networks are trained to identify and segment all micrometastases in the fluorescence 
signal. The trained algorithms are then applied to 3D images to detect cancer metastases and an antibody-based drug 
targeting in whole transparent mice at single cell level.
a bulk signal, lacking information on real size and 
shape. By contrast, our approach allowed the 
visualization of several micrometastases in the 
lungs with conventional epifluorescence imaging, 
which were not visible in bioluminescence (compare 
the magenta marked regions in Figure 2A with 
Figure 2B, and red arrowheads in Figure 2E; more 
examples shown in Figure S3). Thus, vDISCO 
followed by epifluorescence imaging, which can be 
completed within minutes, already provided greater 
details and sensitivity compared to bioluminescence 
imaging. Next, we imaged entire transparent mice 
using a light-sheet microscope8 at cellular resolution 
in 3D to detect micrometastases throughout the 
4Figure 2
DeepMACT step 1: vDISCO visualization of metastases in an intact whole mouse body
(A) Bioluminescence image of a tumor-bearing mouse before vDISCO.  (B-G) Epifluorescence images of the same 
mouse after vDISCO show metastases (magenta) in greater detail compared to bioluminescence, including small mi-
crometastases that can be readily detected in the lungs (E, red arrowhead) and in the leg (G), in addition to the primary 
tumor (F) and major metastases (C and D) that are also visible in bioluminescence as bulk signal (A). (H) 3D visuali-
zation of the intact transparent body of the same mouse, imaged by light-sheet microscopy. (I) Lateral views of the 3D 
segmentation obtained from the light-sheet imaging data corresponding to the magenta-boxed region indicated in (A, 
B, and H). For simplicity, only a few organs are segmented: the heart (cyan) and the lungs (yellow); the mouse body is 
shown in transparent gray and the metastases are in magenta.  (J-L) Original light-sheet microscopy data (500 µm pro-
jections) showing tumors from the sagittal planes indicated in (J). (M-O) High resolution light-sheet microscopy images 
(single planes) showing single tumor cells (magenta) and nuclei (labeled with propidium iodide, PI; cyan) revealed by 
vDISCO. See Figure S1-S4, Movie S1 and S2.
5body (Figure 2H). In the chest area, we could see 
various metastases not only in the lungs (yellow 
segmented region in Figure 2I) and lymph nodes, 
but also at the base of the neck and surrounding 
tissues (Figure 2J-L and Movie S1). Importantly, 
light-sheet microscopy scanning allowed us to 
image micrometastases down to the single cell level 
in the intact mouse body. An example of a single-cell 
metastasis is shown in the dashed box in Figure 2M 
(also see Movie S2) as verified by nuclear staining 
with PI (Figure 2N-O). Thus, our approach allows, 
for the first time, to image micrometastases in intact 
mice in 3D down to single cell resolution.
DeepMACT step 2: Deep learning for detection 
and quantification of metastases
We developed a novel deep learning-based 
approach to detect and segment all cancer cells 
in whole mouse bodies. This framework solves the 
3D task of detecting and segmenting metastases 
in volumetric scans with CNNs that process 2D 
projections of small sub-volumes (Figure 3A). In 
brief, we first derived three 2D maximum intensity 
projections (aligned with the x-, y-, and z-axes) for 
each sub-volume in order to increase the signal-to-
noise ratios (SNR). We fed the resulting projections 
to the CNN and obtained 2D probability maps, in 
which each pixel value represents the estimated 
probability that this pixel identifies a metastasis 
under the given projection. We then reconstructed 
a 3D segmentation from the three projections 
observing increased reliability in detecting true 
positive metastases while safely ignoring non-
metastatic tissue that would be false positives in the 
individual projections. For example, in Figure 3B, 
the green arrows show successful detection of a 
real metastasis and the red arrows show successful 
ignoring of a structure that could be mistaken for 
a metastasis from a single 2D projection. This 
approach was highly effective in detecting and 
segmenting metastases in the imaging data, yielding 
a binary mask for all metastases in the body.
The core of the architecture makes use of CNNs 
(Figure 3C), structurally similar to the established 
U-net21, which learn to distinguish metastases 
from the background signal. This is achieved by 
using a deep stack of encoding units, which detect 
characteristic cancer features, and a corresponding 
stack of decoding units, which segment each 
metastasis at pixel-level. Each encoding unit 
performs two convolutions, extracting information 
about the environment for each pixel and 
representing that information in a third dimension 
- the feature channels. Before being passed on to 
the next encoding unit, the image is spatially down-
sampled. Together, this means that the neural 
network is steadily increasing the feature channels 
and steadily decreasing the spatial resolution, 
enforcing the network to learn even more abstract 
representations of the data (i.e., features) in the 
deeper layers, before mapping the information 
relevant to cancer cells back to the original resolution 
in the decoding upward path. This happens by up-
sampling the abstract, low-resolution information 
from lower layers and concatenating it with the 
less abstract, but higher-resolution information 
from the encoding path via skip connections (some 
exemplary visualizations of the computational 
stages are presented in Figure S4A-C).
To assess the reliability of our automated deep 
learning architecture, we applied it to a fresh test 
set of a full-body scan, which was neither used for 
training the CNNs nor to optimize hyperparameters. 
The data sets were manually annotated by human 
experts and any disagreements between experts 
were jointly reviewed and discussed in order to derive 
a refined, commonly agreed reference annotation 
(see methods for details). We then systematically 
compared the performance of our deep learning 
approach to that of established detection methods 
as well as the performance of a single human 
annotator, calculating F1-score (also known as Dice 
score), a common performance measure based on 
both the metastasis detection rate (recall) and false 
positive rate (precision). 
We found that DeepMACT reached an F1-score of 
80%, outperforming existing filter-based detectors 
by a large margin and coming very close to the level 
of a single human annotator with an F1-score of 
83% (Figure 3D). The slightly higher F1-score of a 
single human annotator is mainly driven by the high 
precision. However, the human annotator missed 
around 29% of all micrometastases (examples 
are shown in Figure S4D-F) and detecting those 
false negatives would require a repetitive and very 
laborious re-analysis of the whole animal scans – 
several months of human work time. On the other 
hand, the F1-score of DeepMACT is a result of 
a balance between precision and recall, which 
can be freely adjusted via the model’s threshold. 
For DeepMACT, we can increase detection rate 
(recall) over 95%. While this also increases the 
false-positive rate, correcting the false positive 
data requires only a review of marked signals by a 
human annotator, which we completed within hours 
for the data of this study (an example is shown in 
Figure S4G-I). A more detailed analysis on the 
trade-off between precision and recall is shown 
in Figure S4J. Notably, DeepMACT could detect 
micrometastases about 30 times faster than filter-
based detectors and over 300 times faster than 
a human annotator (Figure 3E) who was already 
supported by a dedicated and interactive software, 
custom-built for this task and these data; without 
annotation software, the human manual annotation 
6would be estimated to take several months for a 
single mouse. Thus, DeepMACT can complete 
months to years of human labor in within hours 
without compromising on segmentation quality.
DeepMACT detects micrometastases at the 
cellular level 
After establishing the DeepMACT pipeline, we used 
it to analyze whole mouse bodies. In addition to 
Figure 3
DeepMACT step 2: Architecture and performance of the deep learning algorithm
(A) Representation of the deep learning inference workflow to efficiently derive 3D detection and segmentation exploit-
ing three 2D computational operations. (B) Visualization of the computational stages; the green arrow shows successful 
detection of a metastasis, the red arrow shows elimination of a potential false positive detection after 3D recombination. 
(C) High-level representation of the network architecture with an encoding and a decoding path. (D-E) Comparison of 
our deep learning pipeline to alternative automated methods and manual segmentation by a human expert in terms of 
performance (D) and speed (E).
7the primary tumor and the macrometastasis in the 
axillary lymph node, we could detect hundreds of 
micrometastases of varying sizes throughout the 
body, especially in the lungs (Figure 4A-B). Overall, 
DeepMACT identified 520 micrometastases 
throughout the entire body in this particular mouse, 
of which there were 306 in the lungs, 5 in the liver, 
1 in the left kidney and 208 in the rest of the body 
(Figure 4C). We found that micrometastases are 
mostly located in the inner tissue layers (about 1 cm 
depth from the surface), as shown by color-coding 
in Figure 4D, making them extra difficult to detect 
by other methods. To analyze the spatial distribution 
with regard to the lung anatomy, we registered 
all 306 lung micrometastases to the mouse lung 
lobes. We found that micrometastases were evenly 
distributed in all lobes (Figure 4E,F). Interestingly, 
the micrometastases were randomly distributed 
throughout the lungs regardless of their size, 
suggesting independent colonization at multiple 
sites. Furthermore, we quantified the size and 
relative location of all micrometastases in the entire 
body (Figure 4G-L). While 79% of micrometastases 
were within 1 mm to the nearest neighboring 
micrometastasis, we also found highly isolated 
micrometastases as distant as 9.3 mm apart from 
their nearest neighbor (Figure 4G). Importantly, we 
found a large number of micrometastases with only 
a few hundred cells (Figure 4H) and diameters less 
than 50-100 µm (Figure 4I), which would be very 
difficult to detect in intact mice by other methods. 
Comparing the micrometastases in the lungs 
with the torso, we found that the tumor burden in 
the lungs was more than a hundred times higher 
(Figure 4J). Also, micrometastases in the lungs 
were, on average, 30% larger in diameter (Figure 
4K) containing more than twice as many cells per 
metastasis as micrometastases in the rest of the 
torso (Figure 4L). In sum, our pipeline is the first to 
enable quantitative analyses of whole-body scans 
at cellular resolution, yielding important insights into 
understanding the metastatic process. 
DeepMACT reveals therapeutic antibody 
targeting at the cellular level
A number of tumor-targeting monoclonal antibodies 
have become part of the standard treatment for 
various solid and hematological malignancies and 
many more are in early or late stages of clinical 
development22,23. However, so far there has been 
no methodology to determine the distribution of 
therapeutic antibodies in the entire body at cellular 
resolution. Here, we used DeepMACT to assess 
biodistribution of the therapeutic monoclonal 
antibody 6A10 directed against human carbonic 
anhydrase XII (CA12)19,20,24. CA12 is overexpressed 
in various types of cancers and blocking its activity 
with the antibody 6A10 reduces tumor growth19 and 
increases the sensitivity of tumor to chemotherapy20. 
We intravenously injected 20 µg of 6A10 conjugated 
to Alexa-568 (with tumor signal boosted with Atto-
647N) nine weeks after transplantation of MDA-
MB-231 cells and perfused the mice two days after 
the antibody injection for whole-body analysis. 
Because Alexa-568 excitation/emission spectra 
overlap with the endogenous mCherry signal of 
the transplanted cancer cells, we confirmed that 
the vDISCO pipeline eliminates all the signal from 
endogenously expressed mCherry8 (Figure S5).   
We first acquired 2D images with epifluorescence 
microscopy and observed an accumulation of the 
6A10 antibody at the primary tumor (Figure 5A,E; 
tumor shown in magenta, therapeutic antibody in 
cyan) and the metastases at the axillary lymph node 
(Figure 5A,B). Focusing on the lungs, we detected 
micrometastases that were targeted by the 6A10 
antibody (Figure 5C, white arrow) and others that 
were not (Figure 5D, yellow arrow). Acquiring 3D 
scans with light-sheet microscopy, we assessed the 
complete biodistribution of the therapeutic antibody 
and micrometastases in the whole body at cellular 
resolution (Figure 5F-H, Movie S3). The axillary 
lymph node metastases and the micrometastases 
in the lungs are shown in Figure 5F. Analyzing the 
signal of individual micrometastases and the 6A10 
antibody by light-sheet microscopy in 3D, we could 
evaluate the efficiency of antibody drug targeting 
for even the smallest micrometastases (Figure 5G, 
white arrowhead). We also verified the targeting of 
micrometastases by the 6A10 antibody in various 
organs such as lungs and kidney, using confocal 
microscopy (Figure S6).
Next, we used DeepMACT to systematically assess 
and quantify the effectiveness of antibody drug 
targeting in whole animals at the cellular level 
(Figure 5I). While overall 77% of all metastases 
were targeted by the antibody, we found that 
significantly more micrometastases (p < 0.001, 
two-sided t-test) were targeted in the lungs (85%) 
as compared to the rest of the body (66%) (Figure 
5J, Movies S3 and S4). To further assess the 
efficacy of drug targeting for micrometastases in the 
lung versus the rest of the body, we assessed the 
antibody concentration by quantifying the antibody 
signal contrast (relative signal strength versus local 
surrounding; see methods for details) (Figure 5K). 
Metastases in the lungs generally tend to have a 
higher antibody signal ratio. This is in line with 
the higher share of targeted metastases. Also, 
the antibody signal ratio is much more narrowly 
distributed compared with micrometastases outside 
the lungs. The lower average and wider distribution 
8Figure 4
Deep learning-based detection and segmentation enables quantitative analysis at the level of individual metas-
tases
(A,B) 3D rendering of the entire mouse after light-sheet microscopy imaging in ventral and lateral views, respectively. 
Metastases in the mouse body are shown in magenta. The white arrow indicates the primary tumor and  the yellow arrow 
indicates metastases in the axillary lymph node (A.L.N.). (C,D) Deep learning reconstructions of all detected metastases 
(A.L.N. and primary tumor indicated with dashed circles) color-coded by organ (C) and depth along z-axis (D), cropped 
to white box of (A) to show higher level of detail. (E,F) Detailed view of metastases in the lung region (corresponding 
to the black box in C) in a maximum intensity projection of a 3D light-sheet scan (E) and projection of 3D deep learn-
ing-based detection, with metastases registered to individual lung lobes (shown in different colors) (F). (G-L) Deep 
learning-based distributions; blue bars show individual metastases, the black line shows the Gaussian kernel density 
estimation. (G) 3D distance to nearest neighboring metastasis. (H) Cell count estimation per metastasis. (I) Metastasis 
diameter averaged in 3D space. (J-L) Quantitative comparison between metastases in the lungs and the rest of the 
torso; bars indicate 95%-confidence intervals. (J) Tumor density as share of metastatic tissue of the entire volume. (K) 
Metastasis diameter averaged in 3D space. (L) Cell count estimation per metastasis.
9of antibody signal ratio in the micrometastases in the 
rest of the body indicates that there is a substantially 
higher variance in the antibody targeting to the cells 
of those micrometastases. While some are very 
strongly targeted, many others are not targeted at 
all. Also, the largest quartile of micrometastases 
was significantly more likely (p < 0.001, two-sided 
t-test) targeted (88%) than the smallest quartile 
(67%) (Figure 5L). We also identified various off-
target binding sites throughout the body, i.e. binding 
of the therapeutic antibody to mouse tissues, which 
is presumably due to unspecific binding since 
Figure 5
The DeepMACT pipeline enables quantitative analysis of drug delivery effectiveness at the level of single me-
tastases
(A) Epifluorescence images of a processed mouse show details (B-E) of both tumor metastases (boosted with Alexa647 
nanobody, shown in magenta) and 6A10 antibody (conjugated with Alexa568, shown in cyan) distributions and their 
overlay. While most of the micrometastases are targeted by the antibody (C, white arrow), there are some that are not 
(D, yellow arrow). (F) Full body 3D light-sheet scan, cropped to the chest region, shows the distributions of metastases 
(magenta) and antibody (cyan). (G) Detailed view of the boxed region in (F) showing very small micrometastases tar-
geted by the therapeutic antibody (white arrows). (H) 3D rendering of a whole mouse body light-sheet scan showing the 
tumor signal in magenta, the 6A10 antibody signal in cyan (co-localization of the signals is shown in white). The cyan 
inlet shows an example of off-target accumulation of the 6A10 antibody. (I) Deep learning-based reconstruction of the 
animal in (H) showing targeted metastases in green and untargeted metasases in red; the dashed circles represent the 
primary tumor A.L.N metastases. (J) Comparison of the share of targeted metastases in the lungs versus the rest of 
torso. (K) Comparison of the distributions of 6A10 antibody signal ratio (signal strength in metastasis versus local sur-
rounding; see the methods for further details) per metastasis in the lungs versus the rest of torso. (L) Share of targeted 
metastases as a function of their size (split into quartiles of average metastasis diameter).
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6A10 does not bind to murine CA12 (cyan inlet in 
Figure 5H). Overall, these data demonstrate that 
DeepMACT provides a powerful platform to track 
the biodistribution of therapeutic antibodies along 
with micrometastases in intact mouse bodies. 
Thus, it represents the first methodology that allows 
quantitative analysis of the efficacy of antibody-
based drug targeting in the whole body at cellular 
resolution.
Exploring potential mechanisms of antibody 
drug targeting 
The above results demonstrated that antibody-
based drugs, which are the basis of many targeted/
personalized treatments, may miss as many as 23% 
of the micrometastases. Next, we aimed to explore 
potential mechanisms that might explain this failure. 
We first hypothesized that the efficacy of targeting 
of micrometastases might depend on the presence 
of nearby blood supply transporting the therapeutic 
antibody. To explore if the vascularization of defined 
tissue regions can have an effect on antibody drug 
targeting, we performed lectin labeling of vessels 
in the lungs, where most of the micrometastases 
are located. Analyzing diverse micrometastases 
of different sizes, we found that each of them had 
blood vessels as close as 1-6 µm (Figure 6A,B). 
This distance is smaller than even a single cell 
diameter (˜10 µm) suggesting that the proximity of 
blood vessels could not be the major reason for the 
lack of antibody drug targeting25. 
Next, we hypothesized that the tumor micro-
environment at the sites of metastases could be 
related to the efficiency of targeting. If so, we would 
expect a non-random spatial distribution of targeted 
and untargeted metastasis on a local scale. To 
address this, we turned to DeepMACT and assessed 
Figure 6
Potential mechanisms of tumor targeting by therapeutic antibody 
(A) Confocal images of a large and a small metastasis (less than 5 cancer cells) in lungs labeled with Lectin (green) and 
Hoechst (blue). (B) Distribution of metastasis size and  distance to the nearest vessel, showing that most of the metas-
tases are close to vessels (distance less than 6 µm) (n=50). (C) Deep learning-based reconstruction of lung metastases 
with and without 6A10 antibody targeting. (D) Deep learning-based quantification of distance between metastases and 
their nearest neighbor, showing local clustering of targeted and untargeted metastases (see the Methods for further 
details)
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local clustering of micrometastases targeted by the 
antibody. We quantified the distances between 
micrometastases and their nearest neighbor for all 
micrometastases in the entire body, differentiating 
between targeted and untargeted nearest neighbors. 
The distance between two neighboring metastases 
is significantly smaller for two targeted metastases 
(about 0.8 mm) than for two untargeted or a mixed 
pair of an untargeted and a targeted metastasis 
(consistently at about 1.7-2.0 mm) (Figure 
6C,D). Importantly, the average distance from an 
untargeted to the nearest targeted metastasis is 
significantly larger than from a targeted one. This 
would not be expected in a random distribution and 
indicates a clustering on a local scale. Thus, these 
analyses suggest the existence of factors in tumor 
microenvironments on a millimeter scale influencing 
the efficacy of antibody drug targeting. 
 
DISCUSSION
Unbiased detection of cancer metastasis and the 
biodistribution of tumor-targeting therapeutics at 
the single cell level would substantially accelerate 
pre-clinical cancer research. Towards this goal, 
we capitalized on a powerful whole-body clearing 
and imaging method combined with deep learning-
based analysis, enabling us to visualize and 
analyze cancer metastasis in intact transparent 
mouse bodies. The resulting DeepMACT workflow 
is a straightforward methodology for systemic 
analysis of micrometastases and therapeutic 
antibody drug distribution in whole mouse bodies 
at cellular resolution within days, a task that would 
otherwise take several months to years of human 
labor. Notably, DeepMACT can readily be applied in 
diverse labs without the need for highly specialized 
equipment as we provide detailed instructions on 
VDISCO whole body clearing and imaging, and 
make the algorithms, the training data, and the 
trained model publicly available (see methods). 
Thus, DeepMACT-based evaluation of whole 
mouse bodies instead of selected tissues/organs at 
the single cell level can foster the translation of new 
therapies into the clinic much more efficiently than 
traditional methods.
DeepMACT technology
Here we set out make use of recent technologies 
that are providing scalable and unbiased histological 
assessment of entire biological specimens. Most 
whole-body clearing and imaging studies have 
so far relied on visualization of endogenous 
fluorescent signal, which did not allow imaging 
and quantification in intact transparent mice5,26. To 
overcome this, here we adopted the vDISCO whole 
mouse transparency technology, as it amplifies the 
signal of cancer cells more than 100 times, ensuring 
reliable detection of single cells through intact bones 
and skin8. Because vDISCO employs nanobody 
enhancement of the endogenous fluorescent signal, 
currently up to 21 types of fluorescent proteins can 
be boosted with available nanobodies. In addition, 
conjugation of existing nanobodies with fluorescent 
dyes at diverse spectra, including those in the near 
infrared range would help to generate more options 
for multiplex experiments including imaging of more 
than one type of fluorescently labeled cell along 
with conjugated therapeutic antibodies. 
Secondly, we developed a highly efficient deep 
learning architecture based on U-net like CNNs 
exploiting 2D maximum-intensity projections with 
high SNR to reliably detect metastases in 3D. 
Deep learning-based detection not only serves 
the purpose of automation, but is also provides a 
very effective tool in finding metastases that would 
be easily overlooked by humans. In our data, a 
single human annotator missed around 29% of all 
metastases. This is in line with previous studies 
where human experts missed 1 in 4 breast cancer 
metastases in histopathology27, an issue that even 
increases substantially if humans work under time 
pressure28. Motivated by this, deep learning based 
approaches for cancer and metastasis detection 
recently gained substantial momentum for various 
imaging modalities, also beyond microscopy29-32.
Here we used an MDA-MB-231 cancer cell-based 
tumor model to train the algorithms. While training 
deep networks in general may require large training 
datasets to diversify their applications, the Unet-like 
architecture in the core of DeepMACT can be easily 
adopted to other cancer models33-36. In other words, 
DeepMACT learned to detect the characteristic 
shape and appearance of micrometastases against 
the background signal, and thus, is independent 
of the cancer cell model used. Therefore, it would 
require little effort to apply our algorithms to different 
types of tumor models. Also, adapting the algorithm 
to applications in which, for instance, shape and size 
differ substantially from MDA-MB-231 metastases, 
would not require training from scratch. Adjusting 
design parameters such as the size of subvolumes 
(see methods for details) allows the straightforward 
adaptation of the algorithm to new data with different 
SNR, metastasis sizes, or spatial resolution of the 
scan. Furthermore, building upon our pre-trained 
algorithms, which are freely available online, allows 
retraining the algorithm with substantially less 
training data.
To ensure high computational efficiency, our 
approach solves the three-dimensional task of 
detecting and segmenting the metastases by 
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exploiting two-dimensional representations of the 
data. This is important because 2D max-intensity-
projections increase SNR when there is little 
background noise owing to the high specificity of 
the labels in vDISCO clearing. 3D convolutions are 
exponentially more expensive in computing time 
than 2D convolutions, thus requiring more powerful 
computing resources and more data annotated in 
3D to train the algorithm. Importantly, annotating 
projections in 2D is substantially easier and faster 
than slice-by-slice 3D annotations. In addition, the 
exponentially more efficient nature of our approach 
allows training the entire algorithm on a standard 
workstation with an ordinary GPU within a few hours; 
applying the trained algorithm to a new dataset 
takes in the order of 15 minutes, highlighting the 
scalability and cost-efficiency of our pipeline. Thus, 
this architecture is designed to enable widespread 
adaptation of our approach by minimizing data 
annotation and computing requirements while 
allowing for easy adaptation for other experimental 
setups (such as different imaging modalities or 
tumor models).
DeepMACT detection of micrometastases and 
tumor-targeting drugs
Methods such as magnetic resonance imaging 
(MRI), computed tomography (CT), and 
bioluminescence imaging have been widely used 
to visualize cancer growth at the primary site and 
distal body regions37-42. While these methods 
provide crucial longitudinal information on the size 
of the primary tumor and large metastases, they 
typically can only resolve structures larger than 75 
µm, hence they do not have the resolution to detect 
smaller micrometastases consisting of fewer cells. 
Unbiased high-throughput mapping of tumor 
micrometastases at cellular resolution in entire 
rodent bodies can be a valuable tool to uncover 
the biology behind the dissemination of tumor cells. 
We show here that DeepMACT is an ideal tool 
for detecting and mapping cancer metastases in 
whole mouse bodies at the cellular level, allowing 
identification of the precise locations of single 
disseminated cancer cells. Complex analysis, e.g., 
of the size, location and density of micrometastases 
could be performed in a short time throughout the 
body, without dissecting any pre-defined region. 
In addition to detecting the micrometastases in 
the predicted organs such as the lungs and liver, 
we also identified numerous micrometastases 
throughout the torso. These may include cells that 
have metastasized to other organs, e.g. bones, 
peritoneum, bladder, intestines, as well as circulating 
tumor cells (or cells clusters) in the vasculature.
While precise assessment of antibody drug 
biodistribution is critical for evaluating its specificity 
and utility for tumor treatment, there have been no 
methods so far that can provide such information 
at the cellular level in the whole organism. Here, 
we applied DeepMACT to study not only the 
distribution of single tumor cells, but also of a 
therapeutic monoclonal antibody. We demonstrated 
that the “on” and “off” targeting of antibody drugs 
throughout the body can readily be assessed by 
DeepMACT. For example, we observed that not 
all micrometastases in the lungs were targeted 
by the anti-CA12 therapeutic antibody 6A10. 
Understanding why antibody-based therapeutics 
do not target all tumor cells would be important for 
developing more effective treatments. Towards this 
goal, we studied the potential mechanisms that could 
contribute to the lack of targeting. Vascular staining 
demonstrated that blood vessels were present in 
the immediate vicinity of all examined metastases in 
the lung, suggesting that insufficient vascularization 
is unlikely to be a common cause for the failure of 
antibody drug targeting. Interestingly, DeepMACT 
analysis found that micrometastases located in 
close proximity are more likely to be targeted. 
This suggests that the local microenvironment 
within metastatic niches plays an important role in 
determining the efficiency of antibody targeting, e.g. 
by altering antibody penetration, binding affinity and 
clearance. Furthermore, heterogeneity of antigen 
expression on the surface of tumor cells and 
internalization and degradation of antigen/antibody 
complexes might also affect therapeutic antibody 
targeting efficacy. 
In conclusion, DeepMACT is a powerful 
technology combining unbiased whole mouse 
body imaging with automated analysis. It enables 
visualization, quantification, and analysis of tumor 
micrometastases and antibody-based therapies at 
single cell resolution in intact mice, with an accuracy 
equivalent to that of human experts, but speeding 
up the workflow by orders of magnitude compared 
to traditional methods. Because this technology 
is time- and cost-efficient, scalable, and easily 
adoptable, it can be used to study metastasis and 
optimize antibody-based drug targeting in diverse 
tumor models.
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METHODS
Spontaneous metastasis model and injection of 
therapeutic antibody
Female NSG (NOD/SCID/IL2 receptor gamma 
chain knockout) mice were obtained from Jackson 
Laboratory and housed at the animal facility of the 
Helmholtz Center Munich. All animal experiments 
were conducted according to institutional guidelines 
of the Ludwig Maximilian University of Munich and 
Helmholtz Center Munich after approval of the Ethical 
Review Board of the Government of Upper Bavaria 
(Regierung von Oberbayern, Munich, Germany). 
MDA-MB-231 breast cancer cells transduced with a 
lentivirus expressing mCherry and enhanced Firefly 
luciferase43 were counted, filtered through a 100 µm 
filter and resuspended in RPMI 1640 medium. 2x106 
cells per mouse were injected transdermally in a 
volume of 50 µl into the 4th left mammary fat pad. 
Tumor growth was monitored by bioluminescence 
measurement (photons/second) of the whole body 
using an IVIS Lumina II Imaging System (Caliper 
Life Sciences) as described19. Briefly, mice were 
anesthetized with isoflurane, fixed in the imaging 
chamber and imaged 15 minutes after Luciferin 
injection (150 mg/kg; i.p.). Bioluminescence signal 
was quantified using the Living Image software 4.2 
(Caliper). 9 weeks after tumor cell injections, mice 
were randomly assigned to different experimental 
procedures including injection of a human carbonic 
anhydrase (CA) XII-specific antibody (6A10)24, 
boosting of endogenous mCherry fluorescence, 
immunolabeling and clearing, as described below. 
48 hours before perfusion mice were injected into 
the tail vein with 20 µg of 6A10 antibody conjugated 
with Alexa-568.
Perfusion and tissue processing
Mice were deeply anesthetized using a combination 
of midazolam, medetomidine and fentanyl (MMF) 
(1ml/100g of body mass for mice; i.p.) before 
intracardial perfusion with heparinized 0.01 M PBS 
(10 U/ml of Heparin, Ratiopharm; 100-125 mmHg 
pressure using a Leica Perfusion One system) for 
5-10 minutes at room temperature until the blood 
was washed out, followed by 4% paraformaldehyde 
(PFA) in 0.01 M PBS (pH 7.4) (Morphisto, 
11762.01000) for 10-20 minutes. The skin was 
carefully removed and the bodies were post fixed in 
4% PFA for 1 day at 4 °C and transferred to 0.01 M 
PBS. The vDISCO pipeline was started immediately 
or whole mouse bodies were stored in PBS at 4 
°C for up to 4 weeks or in PBS containing 0.05% 
sodium azide (Sigma, 71290) for up to 6 months.
uDISCO whole-body clearing 
The uDISCO protocol to clear whole body of mice 
was already described in details in ref (Pan et al., 
2016). In brief, a transcardial-circulatory system was 
established involving a peristaltic pump (ISMATEC, 
REGLO Digital MS-4/8 ISM 834; reference tubing, 
SC0266). Two channels from the pump were set for 
the circulation through the heart into the vasculature: 
the first channel pumped the clearing solution into 
the mouse body and the second channel collected 
the solution exiting the mouse body and recirculated 
the solution back to the original bottle. For the outflow 
tubing of the first channel, which injected the solution 
into the heart, the tip of a syringe (cut from a 1 ml 
syringe-Braun, 9166017V) was used to connect the 
perfusion needle (Leica, 39471024) to the tubing. 
Meanwhile, the inflow tubing of the second channel, 
which recirculated the clearing solutions, was fixed 
to the glass chamber containing the mouse body. 
The amount of solutions for circulation depended 
on the capacity of the clearing glass chamber. For 
example, if the maximum volume of glass chamber 
is 400 ml, 300 ml of volume of solution was used for 
circulation. 
All clearing steps were performed in a fume hood. 
Firstly, the mouse body was put in a glass chamber 
and the perfusion needle was inserted into the 
heart through the same hole that was used for 
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PFA perfusion. Then, after covering the chamber 
with aluminum foil the transcardial circulation was 
started with a pressure of 230 mmHg (60 rpm on the 
ISMATEC pump). The mouse bodies were perfused 
for 6 hours with the following gradient of tert-butanol: 
30 Vol%, 50 Vol%, 70 Vol%, 90 Vol% (in distilled 
water),100 Vol% twice, and finally with the refractive 
index matching solution BABB-D4 containing 4 
parts BABB (benzyl alcohol + benzyl benzoate 1:2, 
Sigma, 24122 and W213802), 1 part diphenyl ether 
(DPE) (Alfa Aesar, A15791) and 0.4% Vol vitamin 
E (DL-alpha-tocopherol, Alfa Aesar, A17039), for 
at least 6 hours until achieving transparency of 
the bodies. As the melting point of tert-butanol is 
between 23 to 26 °C, a heating mat set at 35-40 °C 
was used for the two rounds of 100% tert-butanol 
circulation to prevent the solution from solidifying. 
vDISCO whole-body immunostaining and 
clearing
The detailed protocol of vDISCO is described in 
ref (Cai et al, 2018). The following nanobodies and 
dyes were used for whole body immunostaining: 
Atto647N conjugated anti-RFP/mCherry 
nanobooster (Chromotek, rba647n-100), Atto594 
conjugated anti-RFP/mCherry nanobooster 
(Chromotek, rba594-100), Hoechst 33342 (Thermo 
Fisher Scientific, 21492H), Propidium iodide (PI, 
Sigma, P4864).
After PBS perfusion and PFA fixation, the animals 
were placed into a 300-ml glass chamber and 
the same transcardial-circulatory system with a 
peristaltic pump was established to perfuse the mice 
during decolorization and immunostaining steps. 
The animals were firstly perfused with decolorization 
solution for 2 days at room temperature to remove 
remaining heme and blood before immunostaining. 
The decolorization solution which is a 1:3 dilution 
of CUBIC reagent 1 (Susaki et al., 2014) in 0.01 M 
PBS was refreshed every 12 hours. CUBIC reagent 
1 was prepared as a mixture of 25 wt% N,N,N,N’-
tetrakis (2-hydroxypropyl) ethylenediamine 
(Sigma-Aldrich, 122262), 25 wt% urea (Carl Roth, 
3941.3) and15 wt% Triton X-100 in 0.1 M PBS, as 
described in the original publication. Before the 
immunostaining step, additional 0,22 µm syringe 
filters (Sartorius 16532) were attached to the tubing 
to prevent the potential accumulation of nanobody 
aggregates and ~230 mmHg high pressure 
pumping was maintained through the entire labeling 
process. Subsequently the animals were perfused 
for 5-6 days at room temperature with 300 ml of 
immunostaining solution containing 0.5% Triton 
X-100, 1.5% goat serum (Gibco, 16210072), 0.5 
mM of Methyl-beta-cyclodextrin (Sigma, 332615), 
0.2% trans-1-Acetyl-4-hydroxy-L-proline (Sigma, 
441562), 0.05% sodium azide (Sigma, 71290), 25 
µL of nano-booster (stock concentration 0.5 – 1 mg/
ml), 10 µg/ml Hoechst and/or 350 µL of propidium 
iodide (stock concentration 1mg/ml) in 0.01 M PBS. 
Then the mice were perfused with washing solution 
(1.5% goat serum, 0.5% Triton X-100, 0.05% of 
sodium azide in 0.01 M PBS) for 12 hours twice at 
room temperature and at the end with 0.01 M PBS 
for 12 hours twice at room temperature.
After the whole body immunolabeling, the whole 
mouse bodies were passively cleared using 
3DISCO. In short, mice were cleared at room 
temperature inside a glass chamber with gentle 
shaking under a fume hood. For dehydration, mice 
bodies were incubated in 250 ml of the gradient 
tetrahydrofuran THF (Sigma, 186562) in distilled 
water (6-12 hours for each step): 50 Vol% THF, 70 
Vol% THF, 80 Vol% THF, 100 Vol% THF and again 
100 Vol% THF; then mice were incubated for 1 hour 
in dichloromethane (Sigma, 270997), and finally in 
BABB. During all clearing steps, the glass chamber 
was sealed with parafilm and covered by aluminum 
foil. Further details on the vDISCO protocols are 
available at
 http://discotechnologies.org/vDISCO/.
Lectin vasculature labeling in lungs tissue 
sections 
The whole bodies of mice were perfused and 
collected as described above. After checking with 
epifluorescence stereomicroscopy (Zeiss AxioZoom 
EMS3/SyCoP3), the lung lobes with multiple 
metastases were dissected and sliced into 20 µm 
thick tissue sections by using a cryostat (Leica, 
CM3050S). The lung sections were washes 2 times 
with 0.01 M PBS and then incubated in Alexa 488 
conjugated Lectin (4 µg/ml, invitrogen, W11261) at 
4 °C overnight. The sections were then stained with 
Hoechst 33342 (10 µg/ml, Thermo Fisher Scientific, 
21492H) for 5 minutes at room temperature to 
visualize the nucleus. After washing 2 times with 
PBS, the slides were mounted with fluorescent 
mounting medium (Dako, 10097416) and were 
ready for confocal microscopy. 
mCherry nanoboosting in lung tissue sections
20 µm thick lung tissue sections were washed with 
0.01 M PBS 2 times before starting the boosting 
process. One hour incubation in blocking solution 
containing 1% Bovine Serum Albumin (Sigma, 
A7906), 2% goat serum (Gibco, 16210-072), 0.1% 
Triton X-100 and 0.05% Tween 20 (Bio-Rad, 161-
0781) in PBS, was performed at room temperature. 
Then the staining solution was prepared in 1% 
Bovine Serum Albumin and 0.5% Triton X-100 
in PBS. Atto647N conjugated anti-RFP/mCherry 
nanobooster was diluted 1:500 in the staining 
solution and the lungs sections were incubated 
overnight at 4°C. After the nanoboosting, the lungs 
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sections were washed 3 times with PBS for 5 
minutes with gentle shaking. After nuclear staining 
by Hoechst 33342 (10 µg/ml) and post wash with 
PBS as described before, the slides were mounted 
with fluorescence mounting medium and were ready 
for confocal microscopy.
Epifluorescence stereomicroscopy imaging 
Cleared whole mouse bodies were fixed in the 
original clearing chamber and were imaged with 
Zeiss AxioZoom EMS3/SyCoP3 fluorescence 
stereomicroscope using a 1x long working distance 
air objective lens (Plan Z 1x, 0.25 NA, Working 
distance (WD) = 56 mm). The magnification was set 
as 7x and imaging areas were selected manually to 
cover the entire mouse bodies. The images were 
taken with GFP, RFP and Cy5 filters and files were 
exported as RGB images.
Light-sheet microscopy imaging 
Single plane illumination (light-sheet) image stacks 
were acquired using an Ultramicroscope II (LaVision 
BioTec), allowing an axial resolution of 4 μm. For 
low magnification whole-body screening of tumor 
and antibody signals we used a 1x Olympus air 
objective (Olympus MV PLAPO 1x/0.25 NA [WD = 
65mm]) coupled to an Olympus MVX10 zoom body, 
which provides zoom-out and -in ranging from 0.63x 
up to 6.3x. Using 1x objective, we imaged a field 
of view of 2 x 2.5 cm, covering the entire width of 
the mouse body. Tile scans with 60% overlap along 
the longitudinal y-axis of the mouse body were 
obtained from ventral and dorsal surfaces up to 13 
mm in depth, covering the entire volume of the body 
using a z-step of 10 µm. Exposure time was 150 
ms, laser power was 3 to 4 mW (70% to 95% of 
the power level) and the light-sheet width was kept 
at maximum. After low magnification imaging of 
the whole body, individual organs (including lungs, 
liver, kidneys, brain, spleen, intestines and bones) 
were dissected and imaged individually using high 
magnification objectives (Olympus XLFLUOR 4x 
corrected/0.28 NA [WD = 10 mm] and Zeiss 20x Clr 
Plan-Neofluar/0.1 NA [WD 4 = mm]) coupled to an 
Olympus revolving zoom body unit (U-TVCAC) kept 
at 1x. High magnification tile scans were acquired 
using 20% overlap and the light-sheet width was 
reduced to obtain maximum illumination in the field 
of view keeping the same NA. For the data used 
for the comparison of signal profile plots of lung 
metastases taken in red and far-red channels and 
for the analysis of endogenous fluorescence signal 
depletion after the uDISCO protocol, we used the 
same MVX10 zoom body, coupled this time with a 
2x objective (Olympus MVPLAPO2XC/0.5 NA [WD 
= 6mm]) at zoom body magnification 6.3x and 2.5x 
respectively.
Confocal microscopy imaging 
For imaging the thick cleared specimens such as 
dissected tissues, pieces of organs or whole organs 
were placed on 35 mm glass bottom petri dishes 
(MatTek, P35G-0-14-C), then the samples were 
covered with one or two drops of the refractive 
index matching solution such as BABB or BABB-D4. 
Sealing of this mounting chamber was not necessary. 
The samples were imaged with an inverted laser-
scanning confocal microscopy system (Zeiss, LSM 
880) using a 40x oil immersion lens (Zeiss, EC Plan-
Neofluar 40x/1.30 Oil DIC M27) and a 25x water 
immersion long-working distance objective lens 
(Leica, NA 0.95, WD = 2.5mm), the latter one was 
mounted on a custom mounting thread. The z-step 
size was 1-2.50 μm. For imaging the lung tissue 
sections with lectin staining and with nanoboosters, 
the slides were imaged with the same inverted 
laser-scanning confocal microscopy system (Zeiss, 
LSM 880) using a 40x oil immersion lens (Zeiss, EC 
Plan-Neofluar 40x/1.30 Oil DIC M27). The z-step 
size was 2 µm. 
Reconstructions of whole-mouse body scans 
Epifluorescence (2D montage of whole mouse):
The collected epifluorescence images were 
stitched semi-automatically using Adobe Photoshop 
photomerge function (File\automate\photomerge). 
The different channels were stitched separately 
and merged in Adobe Photoshop to generate the 
composite images. 
Light-sheet microscopy (3D montage of whole 
mouse):
We acquired light-sheet microscope stacks 
using ImSpector (LaVision BioTec GmbH) as 
16-bit grayscale TIFF images for each channel 
separately. The stacks were first aligned and fused 
together with Vision4D (Arivis AG). Further image 
processing was done mostly in Fiji (ImageJ2): 
first, the autofluorescence channel (imaged in 488 
excitation) was equalized for a general outline of the 
mouse body. The organs were segmented manually 
by defining the regions of interests (ROIs). Data 
visualization was done with Amira (FEI Visualization 
Sciences Group), Imaris (Bitplane AG), Vision4D in 
both volumetric and maximum intensity projection 
color mapping.
General data processing
All data processing after image volume reconstruction 
was performed in Python using custom scripts based 
on publicly available standard packages comprising 
SciPy44, Seaborn45, and Pandas46. Deep Learning 
models were build using the PyTorch framework47. 
Since a single whole body scan is in the order of 
several terabytes due to its high resolution (the 
data used for training had a voxel size of (10µm)³), 
the volume was divided into 1176 subvolumes 
of (350px)³ (or (3.5mm)³) to enable efficient 
processing. Subvolumes were overlapping by 50px 
to ensure any given metastasis is fully captured by 
at least one subvolume to avoid artefacts of divided 
metastases at subvolume interfaces. Please note 
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that the size and overlap of subvolumes are design 
choices that allow easy adaptation to different data 
sets, e.g. with different SNR, metastasis sizes, or 
spatial resolution of the scan. Final analyses were 
conducted on the re-assembled full volume whereby 
reconcatenation ruled out any double-counting at 
previously overlapping subvolumes. 
Data annotation by human experts
To provide ground truth in the form of a commonly 
agreed upon reference annotation for training, as 
well as for evaluation of the algorithms developed, 
full body scans of two mice were manually annotated 
by a group of human experts. This manual process 
was augmented with a set of tools to reduce the total 
workload from an estimated total duration of several 
months down to 150 person-hours net annotation 
time.
Automatic pre-annotation with custom-made filter-
based detector
To avoid starting from scratch to annotate two 
volumes of several thousand z-slices, an automatic 
detection and segmentation method was applied to 
provide a basis for manual correction. Due to the 
insufficient performance of established methods 
(in this case: the 3D Object Detector for ImageJ48, 
we developed a custom-made filter based detector 
tailored to the specifics of this dataset. In brief, 
we handcrafted a spatial filter kernel optimized to 
detect the most common metastases and applied 
it with 3D convolutions to the dataset; subsequent 
binarization and connected-component analysis 
yielded seed points collocated with metastases. 
This allowed for further analyses of the immediate 
local neighborhood of these candidate regions; a 
local 3D segmentation was derived by selective 
region growing around these seed points based on 
the local signal intensity distribution up to a mean 
foreground signal limited to 4 standard deviations 
above the mean signal in the local surrounding. 
Finally, obvious false positives were filtered out. 
Together, this approach generated a first proposal 
for the data annotation that at least captured the 
most obvious metastases while producing an 
acceptable rate of false positives. As shown in 
the results section, the quality of this proposal 
was about twice as good as compared to the 3D 
Object Detector in ImageJ (35% instead of 18% in 
F1-score). Importantly, further fine-tuning of filters 
and parameters and any additional automated 
pre- or post-processing did not improve the results, 
indicating that a F1-score of 35% may be close to 
the performance limit of such approaches with fixed 
filter kernels and fixed decision rules for such kind 
of data.
Manual annotation correction by human experts
This first proposal served as a basis for human 
annotation. In general, three kinds of manual 
correction were needed to derive a good annotation: 
removal of false positives, addition of false negatives 
(previously missed metastases) and adjustment of 
the 3D segmentation of each metastasis. To avoid the 
need to perform this task individually for each of the 
350 layers of a (350px)³ data subvolume, a custom 
tool with an interactive graphical user interface was 
developed. Based on maximum intensity projections 
along each dimension, the tool allowed to review, 
adjust, add, and remove each potential metastasis 
in the subvolume with a few mouse clicks, drastically 
speeding up the annotation process from hours to 
minutes per subvolume. Different perspectives (X, Y, 
Z) and viewing modes (e.g., projections, orthogonal 
slices, adjusted contrasts, 3D renderings) for each 
individual metastasis allowed the annotator to take 
maximally informed decisions even in less obvious 
cases.
Refinement of annotation to commonly agreed upon 
ground truth
A small fraction (3%) of the entire data set was 
labeled several times by the annotators without 
their awareness to assess human labeling 
consistency. Since the difference in annotation 
for a given subvolume between two trials of a 
single annotator was about as big as between 
two independent annotators and quite substantial 
(the agreement between two trials of the same 
annotator or between annotators only reached an 
F1-score of 80-85%) we decided to invest additional 
time to refine the entire data set. First, all experts 
(3 graduate students with extensive experience 
in the field of imaging and tumor biology) jointly 
discussed examples of annotation differences to 
build a common understanding. Annotations of 
subvolumes with the biggest discrepancies were 
again reviewed and refined. Furthermore, this 
analysis revealed that the most prevalent source 
of annotation error was overlooked metastases 
(false negatives). Here, around 29% of metastases 
were missed in the human annotation, in line 
with previous studies27,28. To effectively identify all 
missed metastases in the entire data set, our deep 
learning algorithm (see next section) was trained 
on the status quo of the annotations and applied to 
the data set with high sensitivity. This yielded a long 
list of potential candidates. With the help of another 
custom-built, interactive graphical user interface, 
all potential candidates were manually reviewed 
by the annotators and either discarded or manually 
adjusted and added to the segmentation. A small set 
of potential metastases, for which human annotators 
could not take a conclusive decision even after 
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joint discussion, was recorded separately, but not 
added to the segmentation. These laborious steps 
ensured the generation of a high-quality ground 
truth for training the algorithm and, importantly, 
for evaluating its performance in comparison to 
a single human annotator. Here, this selectively 
iterative approach of refining annotations based on 
the input of several human experts was chosen due 
to the substantial amount of manual work involved 
with reviewing our high-resolution scans. Since a 
full review of one person takes about a month of 
full-time work, repeating this process several times 
would be desirable but too costly. In applications 
where several, independent full annotations are 
available, advanced mathematical frameworks for 
refining decisions from different experts to a single 
decision can be applied in order to avoid a bias 
towards individual decisions49,50.
Deep learning algorithm for metastasis detection 
and segmentation
Implementation details of the model architecture
Inspired by the established U-net architecture21, 
we designed a deep learning approach that is 
depicted in Figures 3A and briefly described in the 
results section. The architecture of the CNN at its 
core (Figure 3C) is characterized by an encoding 
downward path and a decoding upward path 
comprising a total of 7 levels, in which each level 
also has a lateral skip-connection that bypasses the 
deeper levels and feeds the output of the encoding 
unit directly to the corresponding decoding unit. 
Each encoding unit increases the number of feature 
channels per pixel with the help of two kernel-
based convolutions (kernel size: 3; padding: 1; 
dilation: 1; stride: 1) followed by batch normalization 
and a rectifying linear unit (ReLU). While the first 
convolutional step increases the number of feature 
channels, this number stays constant for the 
second convolutional step. Before being passed on 
to the next encoding stage, the spatial resolution is 
halved using max-pooling (kernel size: 2, stride: 2). 
Decoding units take two inputs: the output from the 
previous layer is spatially upsampled by a factor of 
two (bilinearly) and concatenated along the feature 
dimension with the output of the corresponding 
encoding unit, bypassing the deeper levels. A first 
convolutional step (same parameters as before) 
decreases the number of feature channels, which 
is again kept constant in the two subsequent 
convolutions. The 24-feature channel output of the 
last decoder is mapped to logits in the 2D space 
with a convolutional step without padding, batch 
normalization, or a rectifying linear unit.
Training, validation and test sets
Following established standards, model training 
and evaluation was based on k-fold cross-validation 
(k=5). Thus, the data set was split into mutually 
exclusive sets for training and validation (80%) and 
for testing (20%). This process was repeated k times, 
yielding a total of 5 mutually exclusive test sets that 
are collectively exhaustive. The network weights 
and all design choices and hyperparameters (such 
as batch size, learning rate, etc) were optimized 
solely with the training and validation set to avoid 
overfitting on the specifics of the test set. The data 
set was confined to subvolumes within the torso of 
the mouse body as subvolumes containing near-
zero values outside the body contain no useful 
information to train or test on. In contrast to all 
metastases in the entire body, the tumor tissues of 
the primary tumor and the auxiliary lymph node are 
several orders of magnitude larger (i.e., they follow 
very different statistics than all micrometastases) 
and were thus excluded. The signal from one 
subvolume was corrupted by a dirt particle and thus 
also excluded. In total, these exclusions made up 
less than 1% of the total scan volume. The split 
between the three subsets (training, validation, 
testing) of the data was done on a subvolume 
level (from which the three projections are created 
afterwards) to avoid information leak between 
different projections from the same subvolume.
 
Training and validation procedure
The model training was conducted in two steps. 
First, a large number of models spanning a broad 
set of different hyperparameters were trained for 
10 epochs using another (nested) k-fold cross-
validation (k=5) within the training and validation 
set. Second, the model with the best-performing 
set of hyperparameters (presented here) was 
trained for the remaining epochs. Thus, any 
hyperparameter choice was made without looking 
at the performance on the test set. The model was 
trained for 40 epochs of the entire training data set, 
using random vertical and horizontal flips of the data 
to augment its variance (further training epochs did 
not improve the predictive power). We used a batch 
size B of 4 but found that other batch sizes work 
similarly well. Each input was normalized by its local 
subvolume peak value, which was found to work 
better than normalization to the global volume peak 
value or non-linear normalizations. To calculate the 
gradients for network weight optimization (i.e., to 
train the model), we used weighted binary cross 
entropy as a loss function for a given prediction  
compared to the ground truth Y, giving more weight 
w for foreground (FG) pixels p versus background 
pixels (BG) to account for the class imbalance (i.e., 
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that metastases are very sparsely distributed in 
space): 
A small numerical offset = 10-4 was applied for 
numerical stability. We found equal weights or a 
slightly stronger bias to foreground to work almost 
equally well (here, we used w
FG
=2 and w
BG
=0.5), 
larger biases had negative effects. Additionally, we 
allowed the network to optimize the share of training 
data that contains at least some foreground by 
ignoring parts of training data in which no foreground 
is present. A share of 90% training data with at least 
some foreground optimized the performance on the 
validation set and was thus chosen. The network 
was trained using the Adam optimizer51; the initial 
learning rate was set to 10-4 and was gradually 
decreased by a factor of 10 to a minimum of 10-7 
every time the loss function reached a plateau 
for more than 2 epochs. A single training run over 
40 epochs takes only around 20-30 minutes on a 
normal workstation equipped with a NVIDIA Titan 
Xp GPU.
Testing and inference mode
As mentioned before, we applied k-fold cross-
validation. Thus, in each of the k=5 folds the model 
was tested on data that was not seen by the model 
during training and validation. Together, all 5 test 
sets span the entire data set. As depicted in Figure 
3A, the trained algorithm was used to generate 
probability masks for each of the three projection 
perspectives (P
XY
, P
YZ
, P
ZX
), in which the pixel value 
indicates the network’s confidence that this pixel 
is part of a metastasis in the given sub-volume s. 
Building the outer product of the three probability 
masks allows to recombine the three somewhat 
independent judgements of the network in 3D space: 
This 3D recombination  of the 2D probability maps 
yields a final predicted segmentation mask after 
binarization. By default, the confidence threshold 
was set to 50%; however, changing this parameter 
allows to manually adjust the trade-off between 
sensitivity and specificity, if desired (also see Figure 
S4). Please note that the F1-score for evaluation is 
not affected by this trade-off (i.e., a better detection 
rate at the cost of a higher false positive rate 
would not artificially increase the F1-score and 
vice versa). Subsequent connected-component 
analysis converts the output to an explicit list and 
segmentation of predicted metastases in 3D space.
Performance evaluation
The same performance evaluation procedure 
was used for the comparison shown in Figure 
3D, including the performance of a single human 
annotator. A standard test for detection tasks, the 
F1 score quantifies the accuracy of a model by 
combining precision (share of true positives among 
all positive predictions, including false positives) and 
recall (share of predicted positives among the sum 
of the true positive and false negative predictions). It 
is mathematically equivalent to the Sørensen–Dice 
coefficient (“Dice score”), which is the commonly 
used name for pixel-wise image segmentation 
problems. The F1 score is given as:
For all comparisons of detection and segmentation 
performance, the ground truth (refined by several 
human experts as described above) is used as a 
reference. We quantified the performance of the 
proposed deep learning algorithm based on its 
prediction of the test set. For a comparison, the 
segmentations as provided by established tools 
like the 3D Object Detector in ImageJ, our custom-
made detector as described above, as well as the 
annotation as provided by a single human annotator 
(before joint refinement) were quantified in the same 
manner. Overlapping segmentations for metastases 
were counted as true positive predictions, non-
overlapping predictions as false positives and 
metastases not detected by the prediction as 
false negatives. Predictions corresponding to the 
small set of cases unclear to the group of human 
experts (see above) were neither counted as true 
positive predictions nor as false negatives, i.e. they 
neither increased nor decreased the performance 
evaluation. All performance evaluations were 
conducted on the entirety of the test set as a whole. 
To quantify the inherent variance, the distribution 
of performance results was estimated with n=1000 
resampled test sets (of same size) using the 
bootstrapping approach.
The DeepMACT algorithms can be downloaded at: 
http://discotechnologies.org/DeepMACT. 
Quantifications and statistical analysis
Organ registration
For the full body light-sheet scans (e.g., Figure 4C,F) 
the outlines of selected organs of interest (all lung 
lobes, both kidneys, liver) were manually segmented 
as multi-point polygons in a stack of slices in 3D 
using Fiji. For each metastasis detected by our 
deep learning architecture we assessed whether its 
center of mass falls into the 3D segmentation of one 
of those organs using a custom Python script. Any 
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metastasis not registered to one of these organs is 
referred to as located in “the rest of the torso” in 
this manuscript. The 3D segmentation of the lungs 
was also used to compute the overall lung volume 
to assess the tumor density in Figure 4J, which we 
quantified as the share of the sum of the volume of 
all metastases registered to an organ of the entire 
organ volume. 
Metastasis characterization
The output of our deep learning architecture is a 
binary segmentation volume for all metastases. 
We developed a custom-made, highly efficient 
implementation of a connected component 
analysis (available online) to derive an explicit list 
of metastases fully characterized in 3D. Based on 
each metastasis 3D shape and voxel-based volume 
V, we computed its average diameter as
To quantify the number of cells in each metastasis, 
we measured the size of several isolated single cells 
(~1700 µm3) and estimated the total numbers in 
metastases based on volumetric interpolation. We 
confirmed the accuracy of the estimations by the 
number of nuclei (PI or Hoechst labeled) in selected 
micrometastases. The distance of each metastasis i 
to its nearest neighboring metastasis was measured 
in 3D space as the Euclidian distance between their 
center of masses CoM:
Drug targeting analysis
We assessed the 6A10 antibody targeting of a 
given metastasis by analyzing the distribution 
of the fluorescent signal strength within the 3D 
segmentation of each metastasis (ξ
m
) versus the 
distribution in its local surrounding (250 µm around 
the metastasis) ξ
s
. For each signal distribution, the 
number of voxels within the metastasis segmentation 
n
m
 or in its local surrounding n
s
 can be seen as the 
number of observations of the underlying true (but 
unknown) distributions. The degree of targeting was 
estimated by quantifying the ratio of mean signal 
strength within the segmentation to the mean signal 
strength in its surrounding (e.g., in Figure 5K). We 
refer to this as antibody signal ratio. A ratio larger 
than 1 means that the antibody signal strength 
within then 3D segmentation of the metastasis is 
higher than around it (see dashed line in Figure 
5K). Whether or not a metastasis was deemed 
“targeted” was assessed with a version of the t-test 
to determine whether mean of the observed signal 
distribution in the metastasis ξ
m
 was significantly at 
least Δ=50% (ratio of 1.5) above the mean of the 
observed signal distribution in the local surrounding 
ξ
s
. Importantly, a t-test is valid for the signals despite 
their highly non-normal underlying distribution 
as the number of observations far exceeds the 
requirements of the central limit theorem (i.e., 
while the signals are not normally distributed, the 
estimation of their means is normally distributed due 
the high number of observations). This was verified 
manually. However, due to a typically much larger 
number of observations in the local surrounding 
ξ
s
 than for the metastasis itself ξ
m
, the statistical 
test was not performed with a Student’s t-test but 
with the Welch’s t-test that corrects the degrees of 
freedom for an unequal number of observations for 
both distributions:
Analysis of fluorescence signal profiles from light-
sheet images:
We considered the fluorescence signal profiles from 
each channel: excitation 470 nm, 561 nm and 647 
nm. These profiles were plotted in the same z-stack 
and normalized as percentage over the maximum 
peak. To compare the reduction of the background 
and the improvement of the signal over background 
ratio (SBR) in far-red and near far-red channels, 
we analyzed lung metastases expressing mCherry 
imaged with excitation 545/561 nm, lung metastases 
labeled with anti-mCherry nanobody conjugated with 
Atto594 imaged with excitation 590 nm, and lung 
metastases labeled with anti-mCherry nanobody 
conjugated with Atto647N imaged with excitation 
640 nm (n=9 tumors per each experimental group 
which consisted of 3 animals per each imaging 
modality). The signal profile was measured from 
a defined straight line covering the tumors and 
surrounding tissue background and all the values 
of the plot from a representative animal per each 
experimental group were shown in a representative 
line chart (Figure S1D). Finally, the normalized 
plots represented in Figure S1E were calculated by 
normalizing the plots of lung metastases obtained 
as described above over the average signal intensity 
of the respective surrounding background. 
Quantification of metastasis diameter and distance 
between metastases and vessels
Metastasis diameters were verified manually. For 
quantifying the distance between metastases and 
vessels, ten points on the border of each metastasis 
were randomly selected and the shortest distance 
from these points to the closest vessel wall were 
measured. The presented distance between each 
metastasis and nearest vessels was quantified by 
averaging these ten measurements. In Figure 6B, 
20
50 metastases were quantified to generate the 
distribution map and each bullet point represent one 
single metastasis.
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MOVIE LEGENDS
Movie S1 
3D reconstruction of an intact mouse torso scanned 
by light-sheet microscopy. The left side shows the 
segmented view, in which the torso is represented 
in gray, the lungs in yellow and the heart in green. 
The right side shows the original 2D data from 
the light-sheet microscopy. Various macro- and 
micro-metastases (magenta) are visualized in high 
contrast over the background. 
Movie S2 
3D visualization of some micrometastases in the 
lungs showing the single cell resolution obtained 
by light-sheet microscopy. The tumors are shown in 
magenta and PI nuclear labeling in green.
Movie S3 
3D animation of whole mouse body scanned by light-
sheet microscopy at the cellular level. The outline of 
the mouse (scan of the unlabeled autofluorescence 
channel at 488 nm excitation) shown in gray, some 
segmented organs (lungs, kidney, liver and brain) 
in blue, the tumors in magenta, and the tumor & 
therapeutic antibody 6A10 co-localization in white. 
The first part of the animation shows tumor macro- 
and micrometastasis throughout the body, and 
the second part shows the biodistribution of the 
therapeutic antibody 6A10 along with tumor macro- 
and micrometastases. 
Movie S4
3D animation of the lungs demonstrating the details 
of the therapeutic antibody binding. Micrometastases 
are shown in magenta and the co-localization of 
micrometastases and therapeutic antibody in white. 
While most of the micrometastases are targeted 
by the therapeutic antibody (white), a fraction was 
not (the ones remaining magenta throughout the 
movie). 
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3. Discussion 
Aiming to provide practical tools for systems biology studies, we developed 
u/vDISCO whole-body tissue clearing methods which achieved complete light-sheet 
fluorescent scanning of intact rodent bodies for the first time. Novel findings of 
anatomic structures and global distribution map of disease related pathologies 
revealed by u/vDISCO indicate the importance of unbiased whole-body screening 
without sectioning. Comparing with other whole-body clearing methods, uDISCO and 
vDISCO provided a time and labor efficient solution for studying the structure or cell 
subtypes labeled by endogenously expressed fluorescent proteins with cellular level 
light-sheet microscopy and systemic analysis through entire organisms.  
 
3.1 Combining transcardial circulation and organic solvents achieved robust 
whole-body tissue clearing  
In terms of the experimental setting, uDISCO creatively established a constant 
transcardial circulation system which improved the clearing efficiency and thereby 
helped to preserve the fluorescent signal. In addition, the continuous transcardial 
perfusion was utilized to build a high pressure driven nanobody delivery system and 
led to the complete deep tissue immunolabeling in vDISCO. In fact, most whole-body 
tissue clearing methods appeared after uDISCO utilized the transcardial perfusion 
system. For instance, by using a mixture of tert-butonal and PEG400 as clearing 
solutions and by combing with decalcification and decolorization, PEGASOS 
achieved 2-photon imaging of tdTomato labeled neurons through transparent spinal 
cord by circulating the clearing solutions at 37 °C (Jing et al., 2018).  
 
On the other hand, another key step of uDISCO was screening fluorescent protein 
compatible organic solvents which could provide better preservation of fluorescent 
signal. In this study, we utilized tert-butonal as dehydration solution instead of THF 
used in 3DISCO and added DPE which has high RI while less prone to oxidation for 
RI matching. However, more attempts of screening new candidates which could 
provide even better signal preservation are still on the way. And it is worth noting that 
some promising approaches have already been achieved. For example, Inspired by 
the fact that maintaining the pH in alkaline range helps to stabilize the fluorescent 
proteins (Schwarz et al., 2015), Zhu et al. utilized a mixture a tert-butonal and 
Quadrol to achieve better signal preservation (Li et al., 2018). Applying the same 
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concept to THF, the FDISCO overcomes the fast fluorescence quenching and 
preserves the fluorescent signal of GFP and tdTomato even better than uDISCO (Qi 
et al., 2019). Park et al. recently developed a protein preservation strategy by 
generating the intramolecular epoxide linkages which maintains the protein 
fluorescence and tissue architecture from harsh chemical treatment (Park et al., 
2018). All these existing and upcoming approaches could be utilized as good 
candidates to improve whole-body tissue clearing.  
 
3.2 Applying far red dye conjugated nanobodies for deep tissue 
immunolabeling 
GFP has been widely used to label cell populations or biological structures in multiple 
transgenic animal lines. However, the excitation and emission wavelengths of GFP is 
in the blue/green spectrum which generate severe light scattering and 
autofluorescence (Piatkevich et al., 2017). As a result, core of the heme rich tissue 
such as liver could hardly be imaged with blue wavelengths even after tissue clearing 
(Cai et al., 2019). In fact, engineered fluorescent proteins which can be excited by 
light with far red or infrared wavelength have been used for non-invasive deep-tissue 
imaging in mammals (Chu et al., 2014; Hong et al., 2017). This indicates that these 
far red or infrared fluorescent proteins should be considered for generating 
transgenic mouse lines and imaging in far red spectrum helps to achieve better laser 
penetration and imaging quality.  
 
On the other hand, whole mount antibody immunolabeling has been used to study 
neuronal projections and to map the brain activities (Belle et al., 2017; Renier et al., 
2016). However, the antibody labeling efficiency varies not only between different 
antibodies or suppliers but also between different batches even from the same 
producer. This makes the variation of suitable antibodies time and labor consuming. 
Attempts have been made to increase the penetration of conventional antibodies for 
whole mount immunostaining. For instance, SWITCH achieved homogenous 
immunolabeling by blocking the initial binding between antibody and antigen, thereby 
improved the deep tissue staining quality (Ku et al., 2016). We reasoned that 
nanobody, which is the variable domain of heavy chain antibodies (VHH), has unique 
advantage for deep-tissue labeling because of their small size (12–15 kDa) 
comparing to conventional antibodies (~150 kDa). Indeed, vDISCO utilized far red 
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dye conjugated nanobodies to enhance the fluorescent signal intensity while shifting 
the imaging laser wavelength to far red spectrum which significantly minimized the 
tissue autofluorescence and improved the imaging quality through intact transparent 
bone and skin.  
 
Last but not least, tissue shrinkage mediated by organic solvent clearing is 
particularly suitable for imaging cleared samples originally with large scale. One 
major hurdle for large sample imaging is the limitation of microscopy system, 
especially the working distance of objectives. In general, the working distance of high 
NA (Numerical Aperture) long working distance objectives is around 10 mm, which is 
far from overcoming the thickness of an adult mouse (2-3 cm). By reducing the size 
of biological samples up to 30% from each dimension, an entire body of adult mouse 
can be fit into the commercially available LSFM system and imaged with its entirety 
from one side firstly and then the other side. In contrast, although the subcellular 
level or even molecular level resolution imaging achieved by expansion microscopy 
should be highly appreciated (Chen et al., 2016; Gao et al., 2019), the size of 
biological samples could be imaged by expansion microscopy limits its application in 
large scale tracing and quantifications. Taken together, enhanced fluorescent 
imaging quality complemented with shrinkage light-sheet microscopy makes uDISCO 
and vDISCO a practical and powerful platform for whole-body mapping at cellular 
level. 
 
3.3 Evaluating risks for BMSCs transplantation 
Although BMSCs transplantation has been widely used as an effective therapeutic 
approach, the potential risks need be considered. Firstly, pulmonary complications 
were reported after hematopoietic stem cell transplantation including pulmonary 
veno-occlusive disease and cytolytic thrombi (Diab et al., 2016). In fact, in Research 
Article 1, we detected the clusters of BMSCs in the vasculature in lungs (data not 
shown). Although whether these stem cell clusters will form thrombosis in lungs 
needs to be further evaluated, strategy of systemic administrations of BMSCs should 
be improved. Indeed, Kelkela et al. compared intravenous vs. intra-arterial 
administration of BMSCs and found the intra-arterial transplantation significantly 
reduced the accumulation of BMSCs in lungs (Kerkela et al., 2013), therefore could 
potentially decrease the risk to form pulmonary veno-occlusion.. As a practical 
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cellular mapping methodology, uDISCO and vDISCO whole-body clearing could be 
readily used to clarify the distribution of intra-arterial injected BMSCs as well as the 
fate and clearance pathways of transplanted BMSCs which still remains elusive 
(Leibacher and Henschler, 2016).  
 
3.4 Systemic inflammatory response triggered by tissue damage 
Whether inflammation is beneficial or harmful for CNS regeneration is still 
controversial (Gadani et al., 2015). Negative effect of inflammation upon proliferation 
of neural stem/progenitor cells  has been observed which results in reduced numbers 
of newborn neurons and ineffective repair of the damaged circuitry (Ekdahl et al., 
2003; Monje et al., 2003). Other studies showed that peripheral leukocytes which 
infiltrated into the lesion site enhanced the proliferation of progenitor cells and 
thereby lead to higher neuronal survival rates (Ziv et al., 2006). The protective or 
detrimental effects of inflammation is highly dependent on different cell types (e.g. 
neutrophils vs. leukocytes). To manipulate inflammation as a potential therapeutic 
approach for CNS injuries requires comprehensive understanding of disease-specific 
immune cell populations and the dynamic changes of their functions at different 
stages of the injury. Apart from the whole-body mapping tools we developed, high-
through-put transcriptome and proteomics analysis will also play important roles from 
this perspective (Jordao et al., 2019). 
 
On the other hand, discovering novel infiltration routes of peripheral immune cells 
and clarifying their roles in CNS disease will provide potential therapeutic target to 
block the invasion of harmful cell types. Here, we identified vascular connections 
between skull bone marrow and brain meninges which were filled with trafficking 
neutrophils after stroke as an additional immune cell infiltration route. Considering 
that skull bone marrow is close to brain in distance, it could be considered as 
administration targets or source of beneficial immune cells for brain diseases therapy. 
However, better understanding of the cellular content of skull bone marrow and 
molecular signaling pathways involving immune cells recruitment from these 
connections is needed. It is also worth noting that trans-cortical vessels (TCVs) in the 
long bones were recently discovered by using simpleCLEAR tissue clearing method 
(Grüneboom et al., 2019). Taking together with the skull-meningeal vascular 
connections revealed by vDISCO, this further suggests that tissue clearing has 
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unique advantage to study the fragile anatomic structures which may largely be 
destroyed or distorted during dissection.  
 
In addition, in Research Article 2, we evaluated the immune response after spinal 
cord injury (SCI). It is not surprising that CD68 positive immune cells increased 
significantly at the lesion core (Wang et al., 2015). However, since CD68 expressed 
both in activated microglia and macrophages (Chiu et al., 2009), we could not 
distinguish the invasion peripheral immune cells from the local microglia. A potential 
strategy to overcome this hurdle could be using double transgenic mouse lines such 
as CCR2 line crossed with Tmem119 line. Since Tmem119 is a microglia marker 
more specific than widely used CX3CR1 transgenic line (Bennett et al., 2016), it 
would help to study the interaction or communication between local microglia and 
peripheral immune cells. Interestingly, comparing with naïve mice without any injury, 
we detected CD68 positive immune cells accumulated in the spinal meninges in the 
mice with sham surgery which only hurts the muscle tissue but not the vertebra. This 
finding indicates that injury in periphery might in turn affect the CNS. Therefore, 
systemic analysis through the entire organism is needed for investigating diseases 
with global impact. 
 
3.5 Deep learning based methodology facilitates cancer related studies 
Although progress has been made in cancer therapy and 5-year relative survival rate 
of patients has been significantly improved (Howlader N, 2017), cancer is still the 
biggest killer in 12 major European countries (SanjayTanday, 2016). Searching 
potential molecular targets as well as evaluating therapeutic efficacy of tumor-specific 
drugs requires novel technology with improved detection and quantification of 
pathologies in cancer animal models and in human biopsies. As a practical 
methodology improvement, tissue clearing has been used in cancer studies to 
achieve the intact volumetric information of the tumors (Tanaka et al., 2017; Zhao et 
al., 2017). Furthermore, as briefly mentioned above, Kubota et al. apply CUBIC 
whole-body clearing to the cancer mouse model and quantified the metastasis in 
lungs using a threshold-based algorithm (Kubota et al., 2017). However, it is 
challenging to apply threshold-based algorithm to quantify the whole-body because 
the background signal varies from different tissue. For instance, lung tissue usually 
has low level background while muscle tissue creates high level background. 
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Applying the universal filter normally results in either low detection rate of metastasis 
or high false positive signal (see Research Article 3, Figure 3 D).  
 
In fact, the emerging robust artificial intelligence based tools have shown great 
values in clinical diagnose of various diseases and automated experiments in 
biomedical research (Yu et al., 2018). In cancer study, deep learning has been used 
to improve the accuracy of histopathological diagnosis (Litjens et al., 2016) and to 
detect the breast cancer metastases in the lymph nodes (Ehteshami Bejnordi et al., 
2017). Here, we developed a deep learning based algorithm which achieved the 
automated detection and quantification of cancer metastasis through the whole 
mouse bodies with cellular resolution. The result DeepMACT pipeline reaches the 
similar detection accuracy with human operator while outperformed threshold-based 
algorithm. After training, DeepMACT is able to quantify a whole-body data set over 
300 times faster than a human annotator. Overall, DeepMACT provides a time 
efficient and high-through put methodology for cancer metastasis studies.  
 
3.6 Potential mechanisms of therapeutic antibody targeting 
Systemic evaluation of bio-distribution as well as better understanding of the 
mechanisms related to targeting efficacy of therapeutic antibodies is important for 
cancer immunotherapy development. It is known that a variety of factors could affect 
the molecule movement from blood to organ parenchyma such as antibody size, 
concentration,  polarity and membrane permeability (Tabrizi et al., 2010). In tumors, 
the abnormal endothelial cells of tumor vessels lead to disrupted vasculature and 
unstable blood supply (Carmeliet and Jain, 2000; McDonald and Baluk, 2002). This 
would further hinder the delivery of therapeutic antibody (Jain, 2012). However, in 
this study, we found that all the metastasis in lungs were next to blood vessels 
suggesting that the insufficient blood supply might not be the major reason of 
antibody off-targeting. One possibility is that the metastasis in lungs are relatively 
small comparing with the primary tumors (~100 µm vs. 5 mm) and antibody can 
already reach the target cancer cells by passive diffusion. In fact, we barely found 
vessel structure in the center of lung metastasis indicating that the size of these 
metastasis did not reach the threshold to angiogenesis (Hillen and Griffioen, 2007). 
 
 145 
 
On the other hand, the expression level of antigen, which is CAXII, might directly 
influence the binding of 6A10 antibody. We evaluated the presence of CAXII mRNA 
by using fluorescence in situ hybridization (FISH) and found the heterogeneity of 
CAXII expression even within the same metastasis (data not shown). However, better 
membrane staining to distinguish each tumor cells as well as CAXII immunostaining 
is needed to study the co-localization of CAXII and 6A10 antibody. Last but not least, 
we found that the metastasis targeted by 6A10 antibody in lungs seems to be 
clustered, suggesting the microenvironment of the metastatic niches might play an 
important role of antibody targeting. Considering the recent work from Lee et al. that 
the hepatocytes may change the microenvironment of liver and make it the primary 
metastatic organ for various types of cancer (Lee et al., 2019), whether specific cells 
subtypes or cellular factors involves in the therapeutic antibody targeting remains 
unknown and requires further investigation. 
 
3.7 Limitations of current whole-body tissue clearing 
Although u/vDISCO whole-body tissue clearing are robust techniques for life science 
studies at systems level, they are developed for endpoint experiments of fixed rodent 
samples and not applicable for longitudinal analysis. To achieve large scale 
longitudinal analysis, natural transparency of the organism is quite important for in 
vivo deep tissue imaging. For instance, multiple model organisms such as 
Caenorhabditis elegans (Venkatachalam et al., 2016) and zebrafish (Barbosa et al., 
2016) are widely used for in vivo neuronal structure and activity investigations 
because their larva are naturally transparent. Furthermore, genetic modifications had 
been approached to knockout the skin pigmentation and to make the adult transgenic 
zebrafish transparent (Antinucci and Hindges, 2016). Although we are still far from 
generating a living transparent mouse line, understanding the genetic and physical 
basis of biological transparency will contribute to this perspective in the future 
(Johnsen, 2001).  
 
On the other hand, approaches involving bio-compatible reagents or solutions had 
also been applied to reach in vivo tissue transparency. For instance, by using a 
solution composed with fructose, polyethylene glycol-400 and thiazone, Shi et al. 
achieved a switchable skin window to study the blood flow distribution in the footpad 
of a living mouse (Shi et al., 2017). Zhao et al. utilized another reagent containing 
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collagenase, EDTA disodium and glycerol to image the mouse cortex through 
transparent skull in vivo (Zhao et al., 2018). Although these technical approaches are 
not sufficient to render an entire living mouse optically transparent, they already 
helped to achieve non-invasive in vivo deep tissue imaging for specific studies. 
Taken together, combining genetic, physical and chemical approaches will provide 
the possibility to achieve biocompatible whole-body tissue clearing for longitudinal 
studies. 
 
 
In conclusion, as presented above, we developed uDISCO and vDISCO whole-body 
tissue clearing methods which brings the systems biology studies to the next level. 
Applying these techniques, we identified novel anatomic structures between skull 
bone marrow and brain meninges and analyzed the bio-distribution of stem cells, 
cancer metastasis and therapeutic antibody through the entire mouse bodies. As 
practical and time efficient methodologies, uDISCO and vDISCO will facilitate studies 
in various biological and biomedical research fields. Technical revolutions from other 
fields including the development of large scale high resolution light-sheet microscope, 
solutions for large data storage and computer cluster operation, as well as AI or deep 
learning based automated algorithm will further boost the applications of u/vDISCO 
whole-body tissue clearing in the future. 
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